¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/9/3 ¤W¤È 09:26:05
²Ä 3383 ½g¦^À³
|
¬õ¹Ð¤j ¶R·sªÑ(¥xªÑ)¡A ½æªÑ( ¬ü°êADR) ? ¦p¦óª±ªk ? ¶R·sªÑ Á«ÂªÑ+ ¥[¤âÄò¶O + ¶R½æ¶O¥Î ¯à°Q¨ì¬Æ»ò«K©y ®Çªù¨«¹D ¥¼¥²¤ß·Q¨Æ¦¨
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/9/3 ¤W¤È 07:25:54
²Ä 3382 ½g¦^À³
|
³ÌªñADR¤U¶^¡A§Ú·Qì¦]¬O¥D¤O¤§«e¤w¸g ¦b¥xªÑÀ£§C¦Y³f¤F¡A²³æ»¡¡A¶R·sªÑ¡A½æ ªѡA®M²{¤F¡A¤§«e§C»ù¶R¥xªÑ·Ç³ÆADR ÁÈ»ù®tªº®£©È¬OºC¤F¤@¨B¡AªÑ²¼¥«³õ¯u¬O¡A ¸ÞÃÔ¦hÅÜ¡A¦ý¬O¹Lµ{¤£«n¡Aµ²§½¤~«n¡A ÁÙ¬O´Á«Ý004ªºªí²{¡A¤~¬O¯u§ë¸ê |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/9/3 ¤W¤È 06:47:04
²Ä 3381 ½g¦^À³
|
¥xÁÞ¤jªº¨£¸Ñ10000%¦P·N¡C
1.ASLAN004 1bÁ{§Éµ²ªG¡A¥u·|Åã¥Ü©MDupilumab¬Û¦üªº¤@¶g¤@°wÀø®Ä¡A ¾¯¶qASLAN004¡A200mg¤ñDupilumab ªº300mg ¡C
2.ASLAN004 2bÁ{§É¡A¤~·|¥X²{ ¥|¶g¤@°w¡A16¶g ¡AÁ`¾¯¶q¥i¯à¤p©ó1600mgªºÁ{§É«ü¼Ðµ²ªG¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2020/9/2 ¤U¤È 11:53:31
²Ä 3380 ½g¦^À³
|
¤Úµá¯S±j½Õªø´Á§ë¸êªº«n ¨M©w§ë¸ê¬Y®a¥ø·~¡A¤£¬O¦]¬°³o®a¤½¥q¥Ø«eªí²{¨}¦n¡A¦Ó¬O¬Ý¦n¥¦·|Ä~Äò¦³¦nªí²{¡F¦pªG§A¤£Ä@«ù¦³¤@ÀɪѲ¼10¦~¡A¨º³Ì¦n³s10¤ÀÄÁ³£¤£n«ù¦³
³Ì«áÁȳ̦hªº¤£¬O¦~©³´Á¤¤¼Æ¾Ú¦n§âASLN ADR«ùªÑ½æ±¼ªºªÑªF ³Ì«áÁȳ̦hªº¬O¼õ¨ì¤G´Á¼Æ¾Ú¥X¨Ó³Q¤jªº¥Í§Þ¤½¥q¨ÖÁʪºªÑªF
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/9/2 ¤U¤È 10:27:11
²Ä 3379 ½g¦^À³
|
¥xÆW¨È·à±dÂà´«ADR¤§«á¤@¤U¦h¤F¨º»ò¦hªÑ²¼n½æ ²{¦b«ù¦³ªº¤H´N·|¥ý½æ±¼¤@½ë¤F ! »ù®æÀ³¸Ó·|©¹1¶ô¥ª¥k¾aªñ ! ¤£¥Î´Á«Ý²{¦b·|º¦ ! nº¦¥i¯ànµ¥¨ì¨ä¤¤¼Æ¾Úµoªí¤F ! «e´£¬O¼Æ¾Ú«GÄR ! ¦pªG¤£¦n´NGG¤F ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2020/9/2 ¤U¤È 10:21:26
²Ä 3378 ½g¦^À³
|
ADR ¶^10%¦³¤Hª¾¹D«ç¤\¤F¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/9/1 ¤U¤È 08:42:03
²Ä 3377 ½g¦^À³
|
ÁÉ¿ÕµáSarilumab¬OAnit-iL6
¦b¤µ¦~¤T¤ë¤]¸òµÛRoach TCZ§@°w¹ïCOVID-19 ¶i¦æ·s«aªÍª¢¬ÛÃöÁ{§É
Sarilumab Clinical trails clinicaltrials.gov/ct2/show/NCT04327388
¤T´ÁÁ{§Éµ²ªG¤]¬O¨S¦³¹F¼Ð¡A¥H¤U¬°¬ÛÃö·s»D³sµ²
www.pharmatimes.com/news/kevzara_fails_in_phiii_covid-19_trial_1347570
¥H¤U¬°¤¤°ê¤¤¤å·s»Dµuºô§}
reurl.cc/k0L8YG
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/9/1 ¤U¤È 06:20:35
²Ä 3376 ½g¦^À³
|
Tralokinumab ªº¤T´ÁÁ{§É¥Dn«ü¼Ð IGA,0/1 ¶È¬ù20%,¬°¹ï·Ó²Õ¬ù10%ªº2¿.
¡X¡XDupilumab ¤T´Á¦P¥Dn«ü¼Ð©M¹ï·Ó²Õ¤ñ¬°3.8~4.5¿, 36% /8%=4.5
¦]¬°Tralokinumab §@¥Î¦bIL-13 ADÁ³±Û¡A¨ÏIL-13µLªk©MIL-13R£\1±µ¦X¡A¦ÓªýÂ_IL-13 °T¸¹¶Ç»¼¡C
¦ýµLªkªýÂ_IL-4ªº°T¸¹¶Ç»¼¡A©Ò¥H©M¹ï·Ó²Õªº¥Dn«ü¼Ð¶È¤G¿¡A¶ÈDupilumab ªº50% ¤ô凖¡C
ASLAN044 ¦PDUPILUMAB MOA¸ô®|¡A¬GÀø®Ä±N¬Û·íDupilumabÀu©óTralokinumab 2¿¡C ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K LEOºË·Ç2021¦~¬ü°ê±À¥XÀã¯l(²§¦ì©Ê¥Ö½§ª¢)AD ÃĪ«tralokinumab
Richard StainesRichard Staines 2020¦~7¤ë1¤é
LEO Pharma¦b¦VFDA´£¥æ¥Ó½Ð«á¡A¥¿·Ç³Æ¦b©ú¦~±À¥X¨äÀã¯lÃĪ«tralokinumab¡A¦]¬°¥¦¥¿·Ç³Æ»PÁɿյ᪺Ävª§¹ï¤âDupixentÄvª§¡C
³o®a¤¦³Á»sÃĤ½¥q¦b¤@¥÷Án©ú¤¤ªí¥Ü¡AFDA¤w§åã¤F¼Ð·Çªº¤QÓ¤ë¼f¬d¡A¨Ã±N¨M©w¤é´Á©w¦b2021¦~²Ä¤G©u«×¡C
ÁÉ¿Õµá¦b³oºØ³QºÙ¬°¯SÀ³©Ê¥Öª¢ªº¯e¯f¤¤©~©ó»â¥ý¦a¦ì¡A¨äµù®gÃĪ«Dupixent¡]dupilumab¡^¤w¦¨¬°³o®aªk°ê¤½¥qªº¥Dn¦¬¤J¨Ó·½¡C
¥¦¨C©u«×¬°³o®aªk°ê¤½¥q±a¨Óªñ¤@¦Ê¸U¼Ú¤¸ªº¦¬¤J¡A¨Ã¥B¦b2017¦~º¦¸Àò±oFDAÀã¯l§åã«á¡A¾P°âÃB¤´¦b§Ö³t¼Wªø¡C
ÁöµMª½±µ¤ñ¸û¤£¦PªºÁ{§É¸ÕÅ礣¬O¤@ºØ¦n¤èªk¡A¦ý¥i¥Î¼Æ¾Ú±o¥Xªº¦@ÃѬODupixent¬O§ó¦nªºÃĪ«¡A§¨Ó¤½¥qªº3´ÁÄvª§ªÌlebrikizumab¤]¥i¯à´£¨Ñ¿E¯PªºÄvª§¡C
½÷·ç¤½¥qÁÙ¦b¶}µoªü¥¬¦è´À¥§¡A¾¨ºÞ¥Ø«e¬°¤îªº¸ÕÅç¼Æ¾Ú¤¤¾á¤ß¥¦ªº°Æ§@¥Î¡A¦ý¬Ý°_¨Ó¥¦¥i¯à¬O¦³®Äªº¡A¥i¥H³Qµø¬°¹ï±wªÌ¤Í¦nªºÃÄ¡C
»PDupixent¤@¼Ë¡Atralokinumab¬O¤@ºØ§¹¥þ¤H·½ªº³æ§J¶©§ÜÅé¡A¥i¤¤©M¥Õ²ÓM¤¶¯À13¡]IL-13¡^²ÓM¦]¤l¡A«áªÌ¬O¯SÀ³©Ê¥Öª¢ª¢¯gªºÃöÁäÅX°Ê¦]¯À¡C
¸Ó¤å¥ó°ò©óECZTRA 1¡B2©MECZTRA 3²Ä¤T¶¥¬q¬ã¨sªº¼Æ¾Ú¡A¼Ú·ùºÊºÞ¾÷ºc¦b¤WӤ봣¥æ¤å¥ó«á¤]¤w¶}©l¹ï¨ä¶i¦æ¼f¬d¡C
ECZTRA 1©M2¦b¤¤««×¯e¯fªº¦¨¦~¤H¤¤´ú¸Õ¤Ftriokinumab§@¬°¦w¼¢¾¯ªº³æ¤@Àøªk¡A¦ÓECZTRA 3¦b¤¤««×¯e¯fªº¦¨¦~¤H¤¤µû¦ô¤F»P§½³¡¥Ö½èÃþ©T¾J¦X¥Îªº¦w¥þ©Ê©M¦³®Ä©Ê¡C
Tralokinumab¥Ñªü´µ§Q±d¡]AstraZeneca¡^ªºMedImmune¥Íª«»s¾¯³¡ªù¶}µo¡ALEO¦b2016¦~¤ä¥I¤F1.15»õ¬ü¤¸¥HÀò±o¥Ö½§¯f¾AÀ³¯gªºÅv§Q¡A¨Ã¥i¯à¤ä¥I¶W¹L10»õ¬ü¤¸ªº¨½µ{¸O¶O¥Î¡C
AZ«O¯d¤F¦±§´¯]³æ§Ü¦bý³Ý©M©I§l¹D¾AÀ³¯g¤¤ªºÅv§Q¡A¦ý¸ÓÃĪ«¦b2017¦~ªº¤T¶µ¤j«¬ý³Ý¸ÕÅ礤§¡§i¥¢±Ñ¡C
pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/
LEO eyeing 2021 US launch for eczema drug tralokinumab
Richard StainesRichard StainesJuly 10, 2020
LEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the FDA, as it bids to take on Sanofi¡¦s class rival Dupixent.
The Danish pharma said in a statement that the FDA has granted a standard ten-month review, setting a decision date in the second quarter of 2021.
Sanofi has taken a leadership position in the disease also known as atopic dermatitis with Dupixent (dupilumab), an injected drug which has become a major source of revenue for the French firm.
It brings in nearly half a million euros every quarter for the French firm and sales are still growing rapidly after a first FDA approval in eczema in 2017.
While it¡¦s not good form to directly compare different clinical trials, the consensus from the data available is that Dupixent is the better drug, and that Eli Lilly¡¦s phase 3 contender lebrikizumab may also provide stiff competition.
Pfizer is also developing abrocitinib, which looks like it may be effective, and can be taken as a patient-friendly pill, although there are concerns about its side-effects in trial data seen so far.
Like Dupixent tralokinumab is a fully human monoclonal antibody that neutralises the interleukin-13 (IL-13) cytokine that is a key driver of inflammation in atopic dermatitis.
The filing is based on data from ECZTRA 1, 2 and ECZTRA 3 phase 3 studies, and regulators in the EU have also begun their review following a filing last month.
ECZTRA 1 and 2 tested tralokinumab as a monotherapy against placebo in adults with moderate-to-severe disease, while ECZTRA 3 assessed safety and efficacy in combination with topical corticosteroid in adults with moderate-to-severe disease.
Tralokinumab was developed by AstraZeneca¡¦s MedImmune biologics division, and LEO paid $115 million for rights in dermatology indications in 2016 and could pay more than a billion dollars in milestones.
AZ retained rights to tralokinumab in asthma and respiratory indications, but the drug failed in three large asthma trials in 2017. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/9/1 ¤U¤È 03:30:13
²Ä 3375 ½g¦^À³
|
FDA³Ìªñ«Å¥¬¡A±N¦b10¤ë22¤é»P¥~³¡¿Ô¸ß©eû·|°Q½×¦³Ãö¦¹Á|¥H¤Î¤@¯ë¬Ì]§å㪺°Q½×¡C A discussion about such a move, as well as in general vaccine approval, will be discussed with an outside advisory committee on Oct. 22, the FDA recently announced.
---------------------------------- ½÷·çCEO ¦b¤ëªì·t¥Ü,8¤ë©³¥i§¹¦¨3¸U¤HCOVID-19 ¬Ì]¤T´ÁÁ{§É¤Hû©Û¶Ò.
¥«³õ¤H¥«¦ôp9¤ë¤¤µo§GÁ{§É¬ÛÃö.¤Q¤ë¦VFDA¥Ó½Ð¥[³t¼f®Öºò«æ¨Ï¥ÎÅv ----------------------------------------- www.genetinfo.com/international-news/item/41237.html
«aª¬¯f¬r§ó·s¡GFDA¤Þµo¤F¦³Ãö¡§ºòÀH«Xù´µ¡A¤¤°ê¡¨¬Ì]ªº·sÅG½× ¦w©g²ú¡]Anjalee Khemlani¡^ °ª¯Å°OªÌ ¡A ¶®ªê°]¸g•2020¦~9¤ë1¤é
¨³³t¶}µo«aª¬¯f¬r¬Ì]¥¿¦b¤Þ°_½Ã¥Í±M®aªºÃöª`¡A¥L̾á¤ßCOVID-19¦M¾÷À³¹ï±N¶i¤@¨B¤À¤Æ¡A¨Ã¨ü¨ì¬FªvÀ£¤Oªº¯}Ãa¡C
¤W¶g¥½¡AFDA±Mû´µ¸¦ªâ¡P«¢®¦¡]Stephen Hahn¡^¦b±µ¨ü^°ê¡mª÷¿Ä®É³ø¡n±Ä³X®Éĵ§i±M®a¡AºÙºÊºÞ¾÷ºc¥i¥H¦b¤T´Á¸ÕÅ秹¦¨¤§«e§åã¬Ì]¡C
³´¤J¿E¯Pªº³s¥ô¤§¾Ôªºð¯Ç¼w¡P¯S®Ô´¶¡]Donald Trump¡^Á`²Î¤w°ª«×«µø¦b¦~©³¤§«e³¡¸pªº¬Ì]Ô¿ï¤H¡C
¡§¥ÑÃÙ§U°Ó¡]¬Ì]¶}µo°Ó¡^¥Ó½Ð±ÂÅv©Î§åã¡A§Ú̱N¹ï¥L̪º¥Ó½Ð¶i¦æµô¨M¡C¦pªG¥L̦b²Ä¤T¶¥¬qµ²§ô¤§«e³o¼Ë°µ¡A§ÚÌ¥i¯à·|»{¬°¦X¾A¡C§ÚÌ¥i¯à·|µo²{¤£¦X¾A¡A§Ú̱N¤U©w¨M¤ß¡A¡¨«¢®¦¹ï^°ê¡mª÷¿Ä®É³ø¡nªí¥Ü¡C
FDA³Ìªñ«Å¥¬¡A±N¦b10¤ë22¤é»P¥~³¡¿Ô¸ß©eû·|°Q½×¦³Ãö¦¹Á|¥H¤Î¤@¯ë¬Ì]§å㪺°Q½×¡C
Coronavirus update: FDA sparks new debate over ¡¦following Russia, China¡¦ in vaccine push Anjalee Khemlani Senior Reporter , Yahoo Finance•September 1, 2020
The rapid push toward a coronavirus vaccine is feeding concerns among health experts, who fear the COVID-19 crisis response will be further polarized and undermined by political pressures.
Over the weekend, FDA Commissioner Stephen Hahn alarmed experts when, in an interview with the Financial Times, he suggested the regulatory body could approve a vaccine before Phase 3 trials are complete.
President Donald Trump, who is locked in a fierce reelection battle, has placed a high priority on a vaccine candidate being deployed by year¡¦s end.
¡§It is up to the sponsor [vaccine developer] to apply for authorization or approval, and we make an adjudication of their application. If they do that before the end of Phase Three, we may find that appropriate. We may find that inappropriate, we will make a determination,¡¨ Hahn told FT.
A discussion about such a move, as well as in general vaccine approval, will be discussed with an outside advisory committee on Oct. 22, the FDA recently announced.
finance.yahoo.com/news/coronavirus-update-fda-sparks-new-debate-over-vaccine-push-164533822.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/31 ¤W¤È 08:04:34
²Ä 3374 ½g¦^À³
|
¤t´¶²r¬IÀ£¡IFDA§½ªø¡GÄ@¶¹L¥¿±`µ{§Ç¡@ºÉ§Ö®Öã¬Ì]
2020-08-30 22:54 Áp¦X³ø / ½sĶ³¯³§Ê¡þ§Y®É³ø¾É
¬ü°êÁ`²Î¤t´¶23¤é¦b¥Õ®c¬Ì±¡Â²³ø·|ij¤W²âÅ¥«¢®¦µo¨¥¡C¬üÁpªÀ¬ü°êÁ`²Î¤t´¶23¤é¦b¥Õ®c¬Ì±¡Â²³ø·|ij¤W²âÅ¥«¢®¦µo¨¥¡C¬üÁpªÀ ¬ü°êÁ`²Î¤t´¶23¤é¦b¥Õ®c¬Ì±¡Â²³ø·|ij¤W²âÅ¥«¢®¦µo¨¥¡C¬üÁpªÀ
—B Y —I „H —H
¬ü°êÁp¨¹¹«~º[ÃĪ«ºÞ²z§½¡]FDA¡^§½ªø«¢®¦30¤éªí¥Ü¡AÄ@·N¶¹L¥¿±`µ{§ÇºÉ§Ö®Öã·s«a¬Ì]¡C¥un©xûÌ»{¬°¯q³B¤j©ó·ÀI¡AFDA·Ç³Æ¦n§å㥼§¹¦¨²Ä¤T¶¥¬qÁ{§É¹êÅ窺¬Ì]¡A¦ý¤Ï»é¥[§Ö®Öã¬O¬°¤F´£®¶¤t´¶¿ï±¡ªº«ü±±¡C
¥L¦bª÷¿Ä®É³ø30¤é¥Z¥Xªº±M³X¤º®e¤¤»¡¡G¡u¥Ó½Ð±ÂÅv©Î¬O§åã¥Ñ¬Ì]¶}µo°Ó¨M©w¡A§Ú̹ï¥L̪º¥Ó½Ð°µ¥Xµô¨M¡AY¥L̦b²Ä¤T¶¥¬qµ²§ô«e´£¥X¥Ó½Ð¡A§ÚÌ¥i¯à·|»{¬°¾A·í©Î¤£¾A·í¡A§Ú̱N°µ¥X¨M©w¡C¡v
«¢®¦ªº¨M©w¥i¯à¬O¬ü°ê¤½½Ã¥v¤W³Ì«n»P³Ì±Ó·Pªº¨Mµ¦¤§¤@¡A¦]¬°¸õ¹L²Ä¤T¶¥¬qÁ{§É¹êÅ窺¬Ì]¨Ã¤£¦w¥þ¡C
«¢®¦«ü¥X¡A¦b²Ä¤T¶¥¬qÁ{§É¹êÅçµ²§ô¤§«e¡A¦³¤@ºØ¦w¥þªº¤èªk¯à´£¨Ñ¬Ì]¡A¥i¯à¬O³z¹Lºò«æ±ÂÅv¨Ñ¬Y¨Ç¸sÅé¨Ï¥Î¡A¦ý¤£¬O¥þ±§åã¡C
¦ý«¢®¦°íºÙ¦Û¤v¤£·|«æµÛ§åã¬Ì]¨Ó¨ú®®¬ü°êÁ`²Î¤t´¶¡A¦]¦³³ø¾ÉºÙ¤t´¶§Æ±æ¯à¦b11¤ë¤j¿ï«e´£¨Ñ¬Ì]¡AÀ°¦£©Ô°ª³Ó¿ï¾÷²v¡C
ª÷¿Ä®É³ø23¤é´¿³ø¾É«ü¥X¡A¤t´¶¦Ò¼{¥[³t§åã^°êÃļtªü´µ¯S±¶§Q±d»P¤û¬z¤j¾ÇÁp¦X¬ãµoªº·s«a¬Ì]¦b¬ü°ê¨Ï¥Î¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/31 ¤W¤È 07:58:07
²Ä 3373 ½g¦^À³
|
·s«a¬Ì]Á{§É10¤ë´¦¾å ²o°ÊªÑ¥«¤d»õ¬ü¤¸¸êª÷
2020-08-31 00:20 ¸gÀÙ¤é³ø / ½sĶªL«³ºa¡þºî¦X¥~¹q –«¬Ì]
—B Y —I „H —H
Ãļt²Ä¤@ªi¤j³W¼Ò·s«a¬Ì]ªº¤HÅéÁ{§É¸ÕÅçµ²ªG¡A³Ì§Ö±N©ó10¤ë¥XÄl¡A¦¨®Ä¤£¶È§ñÃö¥þ¤HÃþ°·±d¡A¤]±N²o°ÊªÑ¥«§ë¸ê¤H¹O1,000»õ¬ü¤¸ªº¸êª÷¡C¤ÀªR®v»{¬°¡AYµ²ªG¨}¦n¡Aµu½u§ë¸ê¤H¥i¯à·|Àò§Q¤Fµ²¡B¸¨³U¬°¦w¡Aªø´Á±N¨ú¨M©óÀò§å㪺¬Ì]¼Æ¡B¤Î¥Á²³ªº±µºØ±¡ªp¡C
¤Ú¶©©P¥Z³ø¾É¡A·s«a¬Ì]¬ÛÃö®ø®§³£·|¤ÞµoªÑ»ù¤j´T¾_Àú¡A¦]©Ò¯A§Q¯qÃe¤j¡F§B®¦´µ©Z¤½¥q¡]Bernstein¡^¤ÀªR®v»\º¸ªí¥Ü¡A¥ú¬O©ú¦~¤@¦~¡A¦UÃļt¾P°âªº·s«a¬Ì]»ùÈ¥i¯à°ª¹F200»õ¬ü¤¸¡C¬ü°ê¤W©Pªí¥Ü¡A¤w°w¹ï¤TºØÔ¿ï¬Ì]¡A¥Í²£¦n´X¤Q¸U¾¯¡AÀò§åã«á«K¥i§ë¤J¥«³õ¡C
¥Ø«e·s«a¬Ì]ªº¬ãµoÄvÁÉ¥Rº¡¤£½T©w©Ê¡A¦ì©~»â¥ýªÌ¬°²ö¼w¯Ç¡]Moderna¡^¡B½÷·ç¡]Pfizer¡^¡BBioNTech¡BNovavax©Î¼b¥Íµ¥¤½¥q¡A¦ý¦óªÌªº¬Ì]®ÄªG»P¦w¥þ©Ê³Ì¨Î¡A¤´¤£²M·¡¡C³Ì·s¤@ªi½u¯Á¥i±æ10¤ë¯B²{¡A©¡®É½÷·ç»PBioNTech¹w´Á³£±N¤½¥¬¯A¤Î3¸U¤Hªº¬Ì]¸ÕÅç¼Æ¾Ú¡A²ö¼w¯Ç¤§«á¤£¤[¤]±N¤½¥¬¸ê®Æ¡C
¤ÀªR®vªí¥Ü¡A¸ÕÅç¼Æ¾Ú±N¨M©w³o¨Ç¤½¥qªºªÑ»ù¨«¶Õ¡F¬ü°ê¹«~º[ÃĪ«ºÞ²z§½¡]FDA¡^»¡¡A¬Ì]ªº³\¥i¼Ð·Ç¬OÁ{§É¹êÅ禳®Ä²v¦b50%¥H¤W¡A³oÓ«ü¼Ð¤]±N¦¨¬°§ë¸ê¤Hªº¹w³]¼Ð·Ç¡CY¼Æ¾Ú¨}¦n¡Aµu½u§ë¸ê¤H¥i¯à¥ýÀò§Q¤Fµ²¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2020/8/30 ¤U¤È 10:51:44
²Ä 3372 ½g¦^À³
|
9/4-0930,°O±o¥h°Ñ¥[¨È·à±d¦b¥x³Ì«á¤@¦¸ªÑªF·|,Dressing with yellow and stay in right rear |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/29 ¤W¤È 08:52:51
²Ä 3371 ½g¦^À³
|
¨È·àÂ÷¥x ³Ì«á¤@¤éªº«ùªÑ®t²§ª¬ªp(¶È¤@¤é¥æ©ö)
«ùªÑÁ`¤H¼Æ¤W¶g3176¤H,³Ì«á¤@¤é 2745¤H´î¤Ö 431¤H ¤@.1-50±i«ùªÑ®t²§,´î¤Ö1730±i/´î¤Ö422¤H ----¥»¶g«ùªÑ±i14253/2570¤H(§t112¤H¹sªÑ), ¡X-¤W¶g«ùªÑ15983±i/2992¤H¡]§t115¤H¹sªÑ¡^ .
----¥»¶g50±i¥H¤W«ùªÑ«ùÄò¼W¥[,¼W¥[1730±i
¤G¡B.¥»¶g¥~¸ê¶R¶W¼W¥[:1108±i
¶°«O¤áªÑÅv¤À´²ªí(¤W¶g) ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~08¤ë21¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 115 10,846 0.00 2 1,000-5,000 2,123 4,254,331 2.23 3 5,001-10,000 361 2,974,529 1.56 4 10,001-15,000 130 1,713,304 0.90 5 15,001-20,000 115 2,194,000 1.15 6 20,001-30,000 89 2,349,549 1.23 7 30,001-40,000 30 1,114,952 0.58 8 40,001-50,000 29 1,375,000 0.72 9 50,001-100,000 71 5,516,368 2.90 10 100,001-200,000 45 6,687,483 3.52 11 200,001-400,000 19 5,231,850 2.75 12 400,001-600,000 14 6,741,974 3.54 13 600,001-800,000 2 1,465,000 0.77 14 800,001-1,000,000 7 6,233,155 3.28 15 1,000,001¥H¤W 26 142,092,629 74.80 ¦X¡@p 3,176 189,954,970 100.00 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/29 ¤W¤È 07:16:02
²Ä 3370 ½g¦^À³
|
¥xÆW¨È·àÂd»Oªº³Ì«á«ùªÑµ²ºc
¶°«O¤áªÑÅv¤À´²ªí ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~08¤ë28¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 112 10,416 0.00 2 1,000-5,000 1,815 3,617,849 1.90 3 5,001-10,000 288 2,389,529 1.25 4 10,001-15,000 106 1,404,058 0.73 5 15,001-20,000 105 2,012,587 1.05 6 20,001-30,000 81 2,144,000 1.12 7 30,001-40,000 31 1,156,952 0.60 8 40,001-50,000 32 1,521,000 0.80 9 50,001-100,000 62 4,894,368 2.57 10 100,001-200,000 43 6,453,483 3.39 11 200,001-400,000 21 5,834,970 3.07 12 400,001-600,000 14 6,849,974 3.60 13 600,001-800,000 1 750,000 0.39 14 800,001-1,000,000 5 4,555,155 2.39 15 1,000,001¥H¤W 29 146,360,629 77.05 ¦X¡@p 2,745 189,954,970 100.00 »¡©ú¡G 1. ¿Ä¸ê¿Ä¨é±M¤á¡BÃÒ¥æ©Òɨ鹺¼·±M¤á¡Bɨé¾á«O«~±M¤á¡A»P´Á¥æ©Ò¼ÐªºÃÒ¨éú¥æ½æ¥X¶RÅv«OÃÒª÷±M¤á¡B¼ÐªºÃÒ¨é¼i¬ù¥æ³Î±M¤áµ¥¦U±M¤á³¡¤À¡A¥H¸Óµ¥±M¤á©Ò¸üªÑ¼Æpºâ¡C 2. ¦XpªÑ¼Æ¥]§t¹sªÑ«Ý»â¦^©ÎÃÒ¨é¤ä¥I¾Ì³æ¤§ªÑ¼Æ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/28 ¤U¤È 09:16:05
²Ä 3369 ½g¦^À³
|
¤@¦~¨Ó ªÑ»ù¥«È¤w¤jº¦50»õ¬ü¤¸ finance.yahoo.com/quote/1801.HK/
Innovent©M§¨Ó«Å¥¬ÂX¤jTYVYTR¡]Sintilimabª`®g¾¯¡^³\¥i¨óij ¬ü³qªÀPR Newswire¡E2020¦~8¤ë18¤é ¤¤°êĬ¦{©M¦L²Ä¦w¯Ç¦{¡A2020¦~8¤ë18¤é¡A¬ü°ê/¯Ã¯Sºô/-Innovent Biologics¡AInc¡C¡]¡§ Innovent¡¨¡^¡]»´ä¥æ©ö©ÒªÑ²¼¥N½X¡G01801¡^¡A³o¬O¤@®a¥@¬É¤@¬yªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo¡A¥Í²£©M°Ó«~¤Æ¥Î©óªvÀøªº°ª½è¶qÃĪ«Eli Lilly and Company¡]¡§ Lilly¡¨¡ANYSE¡GLLY¡^¤µ¤Ñ«Å¥¬ÂX¤j¨ä°w¹ïTYVYTR¡]sintilimabª`®g²G¡^¡]¤@ºØ§ÜPD-1³æ§J¶©§ÜÅé§K¬Ì¨t²Î¡^ªº¾Ô²¤Áp·ù-¥ÑInnovent©M§¨Ó¦b¤¤°ê¦@¦P¶}µoªº¸~½FÂå¾Ç¡C
Innovent©M§¨Ó¡]Lilly¡^¦b¸g¹L¦Ü¤Ö¨â¨t¨t²Î¤ÆÀøªº½Æµo©ÎÃøªv©Ê¸g¨åÀN©_ª÷²O¤Ú½FÀò±o¥«³õ§åã«á¡A©ó2019¦~¶}©l¦b¤¤°ê°Ó·~¤ÆTYVYT¡C TYVYT¬O°ß¤@³Q¦C¤J¡m¤¤°ê°ê®aÃĪ«¥Ø¿ý¡n¡]NRDL¡^ªºPD-1§í»s¾¯¡A¨Ã³Q¯Ç¤J¡m 2019¦~¤¤°ê²O¤Ú´c©Ê¸~½FÁ{§É¸~½F¾Ç·|«ü«n¡n¡C
Innovent©M§¨Ó¤½¥q¥Ø«e¦b¤¤°ê±NTYVYT°Ó·~¤Æ¡C®Ú¾ÚÂX®i³\¥i¨óijªº±ø´Ú¡A§¨Ó±NÀò±oTYVYT¦b¤¤°ê¥H¥~¦a°Ïªº¿W®a³\¥i¡A¨Öp¹º¦b¬ü°ê©M¨ä¥L¥«³õ¶i¦æTYVYTªºµù¥U¡C§@¬°¦^³ø¡A
Innovent±NÀò±o2»õ¬ü¤¸ªº¹w¥I´Ú¡A¨Ã¦³¸ê®æÀò±o°ª¹F8.25»õ¬ü¤¸ªº¼ç¦b¶}µo©M°Ó·~¨½µ{¸O¡A¥H¤Î²b¾P°âÃBªº¨â¦ì¼Æ¤À¼h¯S³\Åv¨Ï¥Î¶O¡C
¨â®a¤½¥qÁÙ±N«O¯d±NTYVYT»P¨ä¥LÃĪ«Áp¦X¨Ï¥Î§@¬°¨ä¦Û¨Á{§Ép¹ºªº¤@³¡¤ÀªºÅv§Q¡C
Innovent¥Ø«e¥¿¦b¨Ï¥ÎTYVYT¶i¦æ20¦h¶µÁ{§É¬ã¨s¡A¥Hµû¦ô¨ä¦b¦hºØÀù¯g¾AÀ³¯g¤¤ªº¦w¥þ©Ê©M¦³®Ä©Ê¡A¥]¬A»P§¨Ó¤½¥qªºALIMTAR¡]°ö¬ü¦±¶ë¡^©M¹`ÃþÃĪ«Áp¦X¥Î©ó«DÅ쪬«D¤p²ÓMªº¤@½uªvÀøªÍÀù¡A¨Ã¥¿¦b¿n·¥¦a¦b¤¤°ê¥H¥~¶}µoTYVYT¡C¥»¤ëªì¡A¨â®a¤½¥q¦bIASLC 2020¦~ªÍÀù¥@¬ÉµêÀÀÁ`²Î¬ã°Q·|¥@¬É·|ij¤Wµo¥¬¤FORIENT-11¥O¤H¹ª»Rªº¤¤´Á¤ÀªR¼Æ¾Ú¡C ORIENT-11¬O¤@¶µÀH¾÷¡AÂùª¼¡A3´ÁÁ{§É¸ÕÅç¡Aµû¦ô¤FTYVYT©Î¦w¼¢¾¯Áp¦XAlimtaR©M¹`Ãþ¤Æ¾ÇÀøªk§@¬°¤@½uªvÀø±ß´Á©Î½Æµo©Ê«DÅ쪬NSCLCªº¤@½uªvÀø¡A¦Ó¤£·|¨ÏEGFR¬ðÅÜ©ÎALK«±Æ±Ó·P¡C®Ú¾Ú¿W¥ß¼Æ¾ÚºÊ±±©eû·|¶i¦æªº¤¤´Á¤ÀªR¡A»P¦w¼¢¾¯Áp¦XAlimta©M¹`Ãþ¤Æ¾ÇÀøªk¦X¥Î¡ATYVYT»PAlimta©M¹`Ãþ¤Æ¾ÇÀøªk¦X¥ÎªºµL¶i®i¥Í¦s²v¦b²Îp¾Ç¤W¦³ÅãµÛ§ïµ½¡A²Å¦X¹w©wªºÀø®Ä¼Ð·Ç¡C°w¹ï¸Ó¾AÀ³¯gªº¸É¥R·sÃĥӽС]sNDA¡^¥¿¦b¤¤°ê¶i¦æºÊºÞ¼f¬d¡C¨â®a¤½¥q´Á«ÝµÛ±N¨Ó¦V¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½©M¨ä¥LºÊºÞ¾÷ºc´£¥æ¦³Ãö¦¹«ü¥Ü©M¨ä¥L«ü¥Üªº§÷®Æ¡C
¡§§ÚÌ«Ü°ª¿³»P§¨Ó¤½¥q¦¨¥\«Ø¥ß¤¤°êTYVYT¦X§@Ãö«Y¡A²{¦b±N¤¤°ê¥H¥~ªº¥«³õ¥]¬A¶i¨Ó¡C³o¶µ¨óij¤]¼Ð»xµÛ±NInnoventªº³Ð·s²£«~±À¦V¥þ²y¥«³õªº°í¹êªº²Ä¤@¨B¡C¡¨ Innoventªº³Ð©l¤H¡A¸³¨Æªøݺ®u°õ¦æ©x¡C ¡§§Ú̦³«H¤ß±N§¨Óªº¥þ²y°Ó·~±Mªø»PTYVYTªºÁ{§É¯S¼x¬Ûµ²¦X¡A±N¶i¤@¨B¥[§Ö§Ú̪º¨Ï©R¡A¨Ï¥þ²y±wªÌ¨ü¯q¡C¡¨
§¨Ó¸~½F¾ÇÁ`µô¦w©g¡PÃh¯S»¡¡G¡§Â§¨Ó¸~½F¾ÇP¤O©ó¬°Àù¯g±wªÌ©MÅ@²zÀù¯gªº¤H´£¨Ñ§ïÅܥͩRªºÃĪ«©M¤ä«ù¡C¡¨ ¡§§ÚÌ»PInnoventªºÁp·ù¦¨¥\¦a±NTYVYT±À¦V¤F¤¤°ê¥«³õ¡C³q¹LÂX¤j¦X§@½d³ò¡A§Ú̧Ʊæ¨ÏTYVYT¯à°÷¬°¥þ²y±wªÌ©Ò¥Î¡C§Ú̬۫HTYVYT¥i¥H¬°¥@¬É¦U¦aªºÀù¯g±wªÌ±a¨Ó¥¨¤j»ùÈ¡A¨Ã¥B§Ú̱NÄ~Äò¬ã¨s¨ä¦b¦UºØ¸~½FÃþ«¬¤¤ªº¼ç¤O¡C¡¨
¦¹¶µ¥æ©ö¶·¿í¦uºD¨Ò¦¨¥æ±ø¥ó¡A¥]¬A®Ú¾Ú¡m«¢¯S¡Ð´µ¬ì¯S¡Ðù}¿Õ¤Ï¦«©Ô´µ§ï¶iªk¡nªº§åã¡C
Ãö©óTYVYTR¡]¨¯¸¦³æ§Üª`®g²G¡^
TYVYTR¡]sintilimabª`®g¾¯¡^¬O¤@ºØ³Ð·sÃĪ«¡A¨ã¦³¥ÑInnovent©M§¨Ó¦b¤¤°ê¦@¦P¶}µoªº¥þ²y½è¶q¼Ð·Ç¡C TYVYT¤wÀò±oNMPAªº¤W¥«³\¥i¡A¥Î©óªvÀø¦Ü¤Ö¨â¨t¨t²Î¤ÆÀø«á´_µo©ÎÃøªvªº¸g¨åÀN©_ª÷²O¤Ú½F¡A¨Ã³Q¯Ç¤J2019¦~¤¤°ê²O¤Ú´c©Ê¸~½FÁ{§É¸~½F¾Ç·|«ü«n¡C TYVYT¬O°ß¤@ªºPD-1§í»s¾¯¡A¤w³Q¦C¤J2019¦~11¤ëªº·sNRDL¥Ø¿ý¤¤¡C
Innovent and Lilly Announce Expansion of TYVYTR (Sintilimab Injection) Licensing Agreement PR Newswire PR Newswire¡EAugust 18, 2020 SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (Lilly, NYSE:LLY) today announced an expansion of their strategic alliance for TYVYTR (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China.
In 2019, Innovent and Lilly began commercializing TYVYT in China after being granted marketing approval for relapsed or refractory classic Hodgkin¡¦s lymphoma after at least two lines of systemic chemotherapy. TYVYT is the only PD-1 inhibitor to be included in China¡¦s National Reimbursement Drug List (NRDL) and is included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies.
Innovent and Lilly currently co-commercialize TYVYT in China. Under the terms of the expanded license agreement, Lilly will obtain an exclusive license for TYVYT for geographies outside of China and plans to pursue registration of TYVYT in the U.S. and other markets. In return, Innovent will receive an upfront payment of $200 million and will be eligible for up to $825 million in potential development and commercial milestones, as well as tiered double-digit royalties on net sales. Both companies will also retain the right to study TYVYT in combination with other medicines as part of their own clinical programs.
Innovent is currently conducting more than 20 clinical studies with TYVYT to evaluate its safety and efficacy in a wide variety of cancer indications, including in combination with Lilly¡¦s ALIMTAR (pemetrexed) and platinum as first-line therapy in non-squamous non-small cell lung cancer, and is actively pursuing the development of TYVYT outside of China. Earlier this month, the two companies released encouraging interim analysis data from ORIENT-11 at the IASLC World Conference on Lung Cancer 2020 Virtual Presidential Symposium. ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating TYVYT or placebo in combination with AlimtaR and platinum chemotherapy as a first-line treatment for advanced or recurrent non-squamous NSCLC without sensitizing EGFR mutations or ALK rearrangements. Based on the interim analysis conducted by the Independent Data Monitoring Committee, TYVYT in combination with Alimta and platinum chemotherapy demonstrated a statistically significant improvement in progression-free survival compared with placebo in combination with Alimta and platinum chemotherapy, which met the pre-defined efficacy criteria. A supplemental New Drug Application (sNDA) for this indication is under regulatory review in China. The companies look forward to future submissions with the U.S. Food and Drug Administration and other regulatory agencies for this and other indications.
We are thrilled to expand on our successful China TYVYT collaboration with Lilly to now include markets outside of China. This agreement also marked the first solid step toward getting Innovent¡¦s innovative portfolio into the global market, said Michael Yu, Ph.D., Founder, Chairman and CEO of Innovent. We are confident that pairing Lilly¡¦s global commercial expertise with TYVYT¡¦s clinical profile will further accelerate our mission, benefitting patients globally.
Lilly Oncology is dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them, said Anne White, president of Lilly Oncology. Our alliance with Innovent successfully brought TYVYT to market in China. Through this expansion of our collaboration, we hope to make TYVYT accessible to patients globally. We believe TYVYT could deliver significant value to people living with cancer around the world and we intend to continue to study its potential across tumor types.
This transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
About TYVYTR (Sintilimab Injection)
TYVYTR (sintilimab injection) is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China. TYVYT has been granted marketing approval by the NMPA for the treatment of relapsed or refractory classic Hodgkin¡¦s lymphoma after at least two lines of systemic chemotherapy and was included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. TYVYT is the only PD-1 inhibitor that has been included in the new Catalogue of the NRDL in November 2019.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/28 ¤U¤È 04:15:14
²Ä 3368 ½g¦^À³
|
2019¦~12¤ë REGNªºCEO«Å¥¬¡A¹w´Ádupilumab ³Ì°ª¥i¾P°â110»õ¬ü¤¸¡A¨äªÑ»ùªñ¥b¦~¤Wº¦300»õ¬ü¤¸.
¤ôº¦²î°ª,ASLAN004 , ©MDupilumab ªº¥¼¨ÓÀø®Ä¬Û·í¡A¦~Àøµ{¶O¥Î¦ô20,000¬ü¤¸¡A¶ÈDupilumab31,200¬ü¤¸ªº 64%. Dupilumab 2¶g¥´¤@°w¡AASLAN004 ¹w´Á4¶g¥´¤@°w¡C
®Ú¾ÚEylea vs Lucentis ¾P°â¥«³õÂX¥R¼Ò¦¡ ¡AASLAN004 ¥¼¨Ó¤W¥«²Ä¥|~¤¦~ ¾P°â±N¶W¶VDupilumab.¶W¶V100»õ¬ü¤¸.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/28 ¤U¤È 04:03:17
²Ä 3367 ½g¦^À³
|
2019¦~¡A5¤ë31¤é¡A©MCSL ñ¬ù¶RÂ_ ASLN004 ¥þ²yµo®i¡B¥Í²£¡B°Ó·~¤Æ«e¡A ¨Ì¥«³õ»{¦PDupilumab ³Ì°ª¾P°â³Ì°ª¥i¹F50»õ¬ü¤¸ .¬°°ò¦¡Añq 31.2»õ¬ü¤¸³Ì°ª¾P°â¬°°ò¦ªº±ÂÅv¦X¬ù ¡]¦U¤@¥bÅv§Q :7.8»õ¬ü¤¸ ùµ{ª÷¡Ï5%~10%¾P°â¤À¼í¡^
2017 ¦~ Q3¶}©l¾P°â¡A¥b¦~½æ¥X2.27»õ¬ü¤¸ 2018¦~¥þ¦~ ¾P°â9.22»õ¬ü¤¸ 2019¦~Q1 ¾P°â3.73»õ¤¸¬ü¤¸
¾P°â¹êÁZ Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA ROW ¤pp 2020 Q1 679.0 176.2 855.2 Q2 770.4 176.6 945.0
2019 Q1 303.0 70.7 373.7 Q2 454.7 102.6 557.3 Q3 508.3 124.8 633.1 Q4 605.2 146.3 751.5 ¤pp 1,871.2 444.4 2,315.6
2018 Q1 117.2 14.2 131.4 Q2 180.9 28.3 209.2 Q3 219.6 43.0 262.6 Q4 258.6 60.2 318.8 ¤pp 776.3 145.7 922.0
2017 Q1 ******* Q2 ******* Q3 88.5 0.5 89.0 Q4 136.9 2.0 138.9 ¤pp 225.4 2.5 227.9 2017/03/28 FDA®Öã¤W¥«
investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2020-financial-and-operating |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/28 ¤U¤È 03:46:46
²Ä 3366 ½g¦^À³
|
Dupilumnab AD ·§©À©ÊÁ{§É¹êÅçµ²ªG¡A½T»{MOA¦b 2013¦~3¤ë3¤é¤½¥¬¡C
¦ÓASLAN004 AD·§©À©Ê¡]1b)Á{§É¹êÅçµ²ªG¡A¹w©w2021¦~3¤ë31¤é°µ§¹¡C
ÁÉ¿Õµá©MRegeneron³ø§i¯SÀ³©Ê¥Öª¢¤¤IL-4R£\§ÜÅéDupilumabªº¶§©Ê·§©ÀÅçÃҼƾÚ
²Ó¸` Ãþ§O¡G§ÜÅé µoªí©ó2013¦~3¤ë3¤é¬P´Á¤é21:41 ÂIÀ»¼Æ¡G1408
¦b¬ü°ê¥Ö½§¬ì¾Ç¾Ç·|²Ä71©¡¦~·|±ß·|¤W¤¶²Ð¤F¶¥¬q1b¼Æ¾Ú
ªk°ê¤Ú¾¤©M¬ü°ê¯Ã¬ù¦{¶ð¨½´°2013¦~3¤ë2¤é¡AÁÉ¿Õµá¡]ªx¼ÚÃÒ¨é¥æ©ö©Ò¡GSAN¡A¯Ã¬ùÃÒ¨é¥æ©ö©Ò¡GSNY¡^©M¦A¥Í¤¸»sÃĤ½¥q¡]REGN¡^¤µ¤Ñ«Å¥¬¡A¨Ó¦Û¨â¶µ¨Ï¥Îdupilumab¶i¦æªº1b´ÁÁ{§É¸ÕÅ窺¶×Á`¼Æ¾Ú¡]REGN668 / SAR231893¡^ ¡^¡A¦bÁÚªü±K¬ü°ê¥Ö½§¬ì¾Ç°|¡]AAD¡^²Ä71©¡¦~·|¤W¡A´£¥X¤F¤@ºØ°w¹ï¥Õ¤¶¯À4¨üÅé£\¨È°ò¡]IL-4R£\¡^ªº¡A°ª¿Ë©M©Ê¡A¥Ö¤Uµ¹ÃĪº¬ã¨s©Ê¥þ¤H§ÜÅé¡C ¡C
1b´Á¬ã¨sªº¥Dn¥Øªº¬Oµû¦ôdupilumabªº¦w¥þ©Ê¡C¨ä¥L±´¯Á©Ê²×ÂI¥]¬AÃÄ¥N°Ê¤O¾Ç¡A¥Íª«¼Ð»xª«©M¥\®Ä°Ñ¼Æ¡C¥\®Ä¼Æ¾Úªí©ú¡A¨C¶g¥|¦¸¥Ö¤Uª`®gdupilumab¨C¶g150²@§J¡]mg¡^©Î300mg¶i¦æªvÀø¡A¥iÅãµÛ§ïµ½¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡]AD¡^±wªÌªº¯gª¬©MÅé¼x¡A³o¨Ç±wªÌªº¯f±¡¥¼±o¨ì¾A·í±±¨î§½³¡¥ÎÃÄ¡C¨ãÅé¦Ó¨¥¡A»P¦w¼¢¾¯¬Û¤ñ¡A±q°ò½u¨ì²Ä4¶g¡A±µ¨üdupilumabªvÀøªº±wªÌªºÅéªí±¿n¡]BSA¡^µû¤À¡A¬ã¨sªÌÁ`Åéµû¦ô¡]IGA¡^µû¤À©MÀã¯l±¿nÄY«©Ê«ü¼Æ¡]EASI¡^§¡¦³ÅãµÛ§ïµ½¡]p <0.05 vs.¦w¼¢¾¯©Ò¦³±¹¬I©M¾¯¶q¡^¡C 300mg¾¯¶q²ÕªºBSA¡AIGA©MEASIµû¤À¦b²Ä8©P«O«ù¤FÅãµÛ§ïµ½¡]»P¦w¼¢¾¯¬Û¤ñ¡Ap <0.05¡^¡C¤@¶µÅTÀ³ªÌ¤ÀªRÅã¥Ü¡A¦b²Ä4¶g¡A±µ¨ü150mg¾¯¶qªvÀøªº±wªÌ¤¤¦³54.5¢Hªº±wªÌ©M±µ¨ü300mg¾¯¶qªvÀøªº±wªÌ¤¤¦³71.4¢HªºEASI±o¤À°§C¤F50¢H©Î§ó°ª¡A¦Ó¦w¼¢¾¯¬°18.8¢H¡]p <0.05¡^ ¡C³Ì±`¨£ªº¤£¨}¨Æ¥ó¬O»ó«|ª¢¡]¦w¼¢¾¯¬°19.6¢H¡A¦Ó¦w¼¢¾¯¬°12.5¢H¡^©MÀYµh¡]¦w¼¢¾¯¬°11.8¢H¡A¦Ó6.3¢H¡^¡C
Á{§É¬ã¨s°Æ±Ð±Â®J¨½§J¡P¨¯´¶´Ë¡]Eric Simpson¡^³Õ¤h»¡¡G¡§¾¨ºÞ¦³²{¦³Àøªk¡A¤¤««×¯SÀ³©Ê¥Öª¢±wªÌ¤¤¤´¦³«Ü¤j¤@³¡¤ÀÄ~Äò¾D¨ü¥Ö½§µoª¢©M¹x©T©Êæ±Äoªº§xÂZ¡A³oÄY«¼vÅT¤F¥L̪º¥Í¬¡½è¶q¡C¡¨ ¡A¬ü°ê«X°Ç©£¦{ªi¯SÄõ¥««X°Ç©£°·±d»P¬ì¾Ç¤j¾Ç¡A¥H¤Î¸Ó¬ã¨sªºº®u¬ã¨sû¡C ¡§³oºØ¨ã¦³·s¿o§@¥Î¾÷¨îªº¥Íª«Àøªkªº¦´Áµ²ªG¹ï¨º¨ÇªvÀø³o¨Ç±wªÌ¨Ãȱo¶i¤@¨BÁ{§É¬ã¨sªº¤H¨Ó»¡¬O¥O¤H¹ª»Rªº¡C¡¨
¡§³q¹LªýÂ_IL-4R£\¡Adupilumab¥i½Õ¸`IL-4©MIL-13³~®|ªº«H¸¹¶Ç¾É¡A³o»P¹L±Ó©Ê¯e¯fªº¯f²z¥Í²z¦³Ãö¡A¡¨Âå¾Ç³Õ¤h¡Aº®uÂå¾Ç³Õ¤h³ìªv¡PD¡P´¬ì´¶¬¥´µ»¡Regeneronªº¬ì¾Ç©x©MRegeneron¹êÅç«ÇªºÁ`µô¡C ¡§§ÚÌ´Á«Ý¤µ¦~±ß¨Ç®ÉÔ±q¤@¶µ¬°´Á12¶gªº¯SÀ³©Ê¥Öª¢ªº2a´ÁÁ{§É¸ÕÅ礤´£¨Ñ§ó¦hªº¼Æ¾Ú¡A¥H¤Î¦b±w¦³¯SÀ³©Ê¥Öª¢ªº±wªÌ¤¤¶}©l¨Ï¥Îdupilumab¶i¦æªº§ó¤jªº2b´ÁÁ{§É¸ÕÅç¡C¡¨
¤µ¤Ñ¦bAAD·|ijªº³Ì·sÁ{§É¸ÕÅç·|ij¤W¤¶²Ðªº1b´Á¸ÕÅç¥]¬A67¦W±wªÌ¡A³o¨Ç±wªÌÀH¾÷¤À°t¤F¤TºØ¤£¦P¾¯¶qªºdupilumab¡]75mg¡An = 8¡F 150mg¡An = 22¡F 300mg¡An = 21¡^©M¦w¼¢¾¯¡]n = 16¡^¡C 1b´Á¬ã¨sªº¥Dn¥Øªº¬Oµû¦ôdupilumabªº¦w¥þ©Ê¡C¨ä¥L²×ÂI¥]¬AÃÄ¥N°Ê¤O¾Ç¡A¥Íª«¼Ð»xª«©M¥\®Ä°Ñ¼Æ¡C¦b¬°´Á4¶gªºªvÀø´Á«á¡A¹ï¬ã¨s¤¤ªº±wªÌ¦AÀH³X4¶g¡A¦@p8¶g¡C
Ãö©óIL-4R©MIL-4 / IL-13³q¸ô ¯SÀ³©Ê¥Öª¢©M¬Y¨ÇÃþ«¬ªºý³Ýªº¯S¼x¬O»¤¾É¯S©wÃþ«¬ªº§K¬Ì¤ÏÀ³¡A³oºØ§K¬Ì¤ÏÀ³¥ÑºÙ¬°2«¬»²§UT²ÓM©ÎTh2²ÓMªº§K¬Ì²ÓM¨È¸sÅX°Ê¡C IL-4©MIL-13¬O±Ò°Ê©Mºû«ù¦¹Th2§K¬ÌÀ³µª©Ò»ÝªºÃöÁä²ÓM¦]¤l¡C IL-4©MIL-13«H¸¹§¡³q¹L¨âÓ¤£¦PªºIL-4¨üÅé¡]I©MII«¬¡^µo¥Í¡A¥¦Ì³£¥]§t¤@Ó¦@¦PªºIL-4R£\¨È°ò¡C
Ãö©óDupilumab¡]SAR231893 / REGN668¡^ Dupilumab¬O°w¹ïIL-4R£\ªº§¹¥þ¤HÃþ³æ§J¶©§ÜÅé¡A³q¹L¥Ö¤Uª`®gµ¹ÃÄ¡C³q¹LªýÂ_IL-4R¡A£\dupilumab¥i¥H½Õ¸`IL-4©MIL-13ªº«H¸¹¶Ç¾É¡A±q¦ÓÅX°ÊTh2§K¬ÌÀ³µª¡C Dupilumab¬O¨Ï¥ÎRegeneronªº¶}³Ð©ÊVelocImmuneR§Þ³N³Ð«Øªº¡A¥Ø«e¥¿¦b»PÁÉ¿Õµá¦@¦P¶}µo¡C Dupilumab¥Ø«e¥¿¦b²§¦ì©Ê¥Öª¢©Mý³Ý¤¤¶i¦æ¬ã¨s¡C
Ãö©ó¯SÀ³©Ê¥Öª¢ ¯SÀ³©Ê¥Öª¢¡]AD¡^¬O¤@ºØºC©Êªº¡A§K¬Ì¤¶¾Éªº¥Ö½§ª¢¯g¡A¨ä¯S¼x¦b©ó¬õ´³¡]¬õ¸~¡^©w¸q¤£²M¡A¦³¤ô¸~¡]¸~µÈ¡^¡A«æ©Ê´Á¬y²\©MºC©Ê´Á¥Ö½§¼W«p¡]aÄö¼ËÅÜ¡^¡CºC©Ê©M/©Î½Æµo©Ê¯fÅÜ¡A¥H¤Îæ±Äo¡]ITC
Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
Details Category: Antibodies Published on Sunday, 03 March 2013 21:41 Hits: 1408
Phase 1b Data Presented at Late Breaking Session of 71st Annual Meeting of the American Academy of Dermatolog
PARIS, France and TARRYTOWN, NY, USA I March 2, 2013 I Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other exploratory endpoints included pharmacokinetic, biomarker, and efficacy parameters. The efficacy data showed that treatment with four weekly subcutaneous injections of dupilumab at either 150 milligrams (mg) or 300mg per week, significantly improved the signs and symptoms of patients with moderate-to-severe atopic dermatitis (AD) whose disease was not adequately controlled with topical medications. Specifically, patients treated with dupilumab had significant improvements in body surface area (BSA) score, Investigator Global Assessment (IGA) score, and Eczema Area Severity Index (EASI) from baseline to week 4 compared to placebo (p<0.05 vs. placebo for all measures and doses). The significant improvements in BSA, IGA, and EASI scores were maintained at week 8 in the 300mg dose group (p<0.05 vs. placebo). A responder analysis demonstrated that at week 4, 54.5% of patients treated with the 150mg dose and 71.4% of patients treated with the 300mg dose achieved a reduction in EASI score of 50% or greater compared to 18.8% with placebo (p<0.05). The most common adverse events (AEs) were nasopharyngitis (19.6% vs 12.5% for placebo) and headache (11.8% vs 6.3% for placebo).
Despite existing therapies, a significant proportion of patients with moderate-to-severe atopic dermatitis continue to suffer from inflamed skin and intractable itch, which significantly impacts their quality of life, said Dr. Eric Simpson, Associate Professor, Director of Clinical Studies, Oregon Health and Science University, Portland, Oregon, USA, and Principal Investigator of the study. The early phase results with this biologic therapy, which has a novel mechanism of action, are encouraging to those of us who treat these patients and warrant further clinical investigation.
Through blockade of IL-4R alpha, dupilumab modulates signaling of both the IL-4 and IL-13 pathway, which have been implicated in the pathophysiology of allergic disease, said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. We look forward to presenting additional data from a 12-week, Phase 2a trial in atopic dermatitis, as well as starting a larger Phase 2b trial with dupilumab in patients with atopic dermatitis, later this year.
Presented today in a late-breaking clinical trials session at the AAD meeting, the Phase 1b trials included 67 patients randomized to three different doses of dupilumab (75mg, n=8; 150mg, n=22; 300mg, n=21) and placebo (n=16). The primary objective of the Phase 1b studies was to assess the safety profile of dupilumab. Other endpoints included pharmacokinetic, biomarker, and efficacy parameters. Following the 4-week treatment period, patients in the studies were followed for an additional 4 weeks for a total of 8 weeks.
About IL-4R and the IL-4/IL-13 Pathway Atopic dermatitis and some types of asthma are characterized by the induction of a specific type of an immune response that is driven by a subset of immune cells called Type 2 helper T cells, or Th2 cells. IL-4 and IL-13 are key cytokines that are required for the initiation and maintenance of this Th2 immune response. Both IL-4 and IL-13 signaling occurs through two different IL-4 receptors (Type I and II), which both contain a common IL-4R alpha subunit.
About Dupilumab (SAR231893/REGN668) Dupilumab is a fully human monoclonal antibody directed against IL-4R alpha and is administered via subcutaneous injection. By blocking IL-4R alpha dupilumab modulates signaling of both IL-4 and IL-13, drivers of a Th2 immune response. Dupilumab was created using Regeneron¡¦s pioneering VelocImmuneR technology and is being co-developed with Sanofi. Dupilumab is currently being studied in both atopic dermatitis and asthma.
About Atopic Dermatitis Atopic dermatitis (AD) is a chronic, immune-mediated, inflammation of the skin that is characterized by poorly defined erythema (redness) with edema (swelling), weeping in the acute stage, and skin thickening (lichenification) in the chronic stage. Chronic and/or relapsing lesions, along with pruritus (itching) and scratching are the hallmarks of the disease. The prevalence of AD is estimated to be between 1% and 3% of adults. For many patients, topical therapies are not effective for keeping the disease under control and the only approved systemic therapies to treat AD are prednisone and cyclosporine (in Europe). Moderate-to-severe atopic dermatitis can negatively impact patients¡¦ lives and is associated with a high burden to society both in terms of direct costs of medical care and prescription drugs, as well as loss of productivity. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/28 ¤U¤È 03:37:31
²Ä 3365 ½g¦^À³
|
ASLAN004 MOA ½T»{& °ê»Ú±ÂÅv-----¤½§i
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ
§Ç¸¹ 1 µo¨¥¤é´Á 108/03/29 µo¨¥®É¶¡ 17:14:34 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ ¸³¨Æªøº[°õ¦æªø µo¨¥¤H¹q¸Ü 0227583333 ¥D¦® ¨È·à±d-KY«Å¥¬§¹¦¨²§¦ì©Ê¥Ö½§ª¢·sÃÄASLAN004²Ä¤@³¡¤À³æ¤@ ¾¯¶q»¼¼W¸ÕÅç
²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 108/03/29 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/03/29 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ:¨È·à±d-KY§¹¦¨ASLAN004²Ä¤@³¡¤À¤§³æ¤@¾¯¶q»¼¼W¸ÕÅç(SAD)¡A¦¹³¡¤À«Y¥HÀR ¯ßª`®g¤§¤è¦¡¹ï°·±d¨ü¸ÕªÌ¶i¦æ¦P¯Åº¨£ªvÀø©Ê§ÜÅéASLAN004¤§ÃĪ«´ú¸Õ¡C ³o¶µ²Ä¤@´Á³æ¤@¾¯¶q»¼¼W¸ÕÅç¦b·s¥[©Y¤@³BÁ{§É¸ÕÅ礤¤ß¶i¦æ¡A¨äÅã¥ÜASLAN004¥HÀR¯ß ª`®g¤§µ¹ÃĤ覡¦b©Ò¦³¾¯¶q¤U¬Ò®i²{¨}¦n¤§¦w¥þ©Ê»P@¨ü©Ê¡A¸ÕÅ礤¥¼¦³¥X²{¤£¨}¨Æ¥ó ¦Ó¾ÉPªvÀø¤¤Â_ªº±¡ªpµo¥Í¡C°w¹ï¤U´å¤¶½è©Ò¶i¦æ¤§¤ÀªRÅã¥Ü¦bµ¹ÃĪº¤@¤p®É¤º¡A¥]¬A ¦b¹L±Ó©Êµoª¢¤ÏÀ³¤¤§êºt«n¨¤¦â¤§¤¶½è¡§ÁC»Ä¤ÆSTAT6 (pSTAT6)¡¨§Y¨ü¨ì§¹¥þ§í¨î¡C ¦¹§í¨î®ÄªG¥i«ùÄòªø¹F29¤Ñ¡AÅã¥Ü¨C¤ëµ¹ÃĤ@¦¸¥i±æ¬°¥i¦æªºµ¹ÃĤ覡¡C ¥Ø«e¥¿¦b¶i¦æ¤¤ªº²Ä¤G³¡¤À³æ¤@¾¯¶q»¼¼W¸ÕÅç±N°w¹ï¥Ö¤Uª`®g¤§µ¹ÃĤ覡¶i¦æÁ{§É´ú ¸Õ¡C¨È·à±d-KY±N©ó3¤ë27¤é§¹¦¨³Ì«á¤@¦ì¨ü¸ÕªÌ¤§ÃĪ«´ú¸Õ¡A¨Ã©ó¤¤ë¥÷¨ú±o²Ä¤G³¡¤À ¸ÕÅ礧¼Æ¾Úµ²ªG¡C¨È·à±d-KY¹wp¦b2019¦~¤U¥b¦~®i¶}°w¹ï¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢±w ªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GASLAN004 ¤G¡B¥Î³~¡GASLAN004¬°¥þ¤H·½³æ®è§ÜÅé¡AÂê©wIL-13¨üÅé£\1¦¸³æ¦ì (IL-13R£\1)¡C ASLAN004¹wp¾A¥Î©ó²§¦ì©Ê¥Ö½§ª¢»P®ð³Ý¡CASLAN004-001Á{§É¸ÕÅ礧°Ñ»PªÌ¬°¦ÛÄ@°Ñ¥[ ¤§°·±d¨ü¸ÕªÌ¡C
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¡B·sÃĬdÅçµn°O¨Ñ
§Ç¸¹ 1 µo¨¥¤é´Á 108/06/04 µo¨¥®É¶¡ 19:35:48 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ ¸³¨Æªøº[°õ¦æªø µo¨¥¤H¹q¸Ü 0227583333 ¥D¦® ¨È·à±d-KY«Å¥¬§¹¦¨ASLAN004²§¦ì©Ê¥Ö½§ª¢¤@´ÁÁ{§É¸ÕÅç
²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 108/06/04 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/06/04 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¨È·à±d¶¶§Q§¹¦¨ASLAN004³æ¤@¾¯¶q»¼¼W¸ÕÅç(SAD) ¨Ã¤½¥¬ASLAN004¥H¥Ö¤Uª`®gµ¹ÃÄ ¤è¦¡¤§²Ä¤G³¡¤À¸ÕÅç¼Æ¾Ú¡C¦¹¸ÕÅç°w¹ï°·±d¨ü¸ÕªÌ¶i¦æ¦P¯Åº¨£ªvÀø©Ê§ÜÅé ASLAN004¤§ÃĪ«´ú¸Õ¡A³æ¤@¾¯¶q»¼¼W¸ÕÅ礧³Ì«áµ²ªGÅã¥ÜASLAN004@¨ü©Ê¨}¦n¡A ¥i§¹¥þ§í¨î¤U´å¤¶½è¡A¥ÎÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C ¨È·à±d-KY©ó2019¦~3¤ë¤½¥¬²Ä¤@³¡¤À¸ÕÅçASLAN004¥HÀR¯ßª`®g¤è¦¡µ¹ÃĤ§¼Æ¾Úµ²ªG¡C ²Ä¤G³¡¤À¸ÕÅç¼Æ¾ÚÅã¥ÜASLAN004¥H¥Ö¤Uª`®gµ¹ÃĦb©Ò¦³¾¯¶q¤U¬Ò®i²{¨}¦n@¨ü©Ê¡A ¨ÃµL¥X²{¥ô¦óÄY«¤£¨}¨Æ¥ó¦Ó¾ÉPªvÀø¤¤Â_ªº±¡ªpµo¥Í¡A¶È¦³¤@¦W¨ü¸ÕªÌ¥X²{ »´·Lª`®g³¡¦ì·kÄo¡A¦ý¯gª¬¦b24¤p®É¤º§Y¸Ñ°£¡C°w¹ï¤U´å¤¶½è©Ò¶i¦æ¤§¤ÀªRÅã¥Ü¡A ¦bµ¹ÃĪº¤@¤p®É¤º¡A¥]¬A¦b¹L±Ó©Êµoª¢¤ÏÀ³¤¤§êºt«n¨¤¦â¤§¤¶½è ¡§ÁC»Ä¤ÆSTAT6 (pSTAT6)¡¨§Y¨ü¨ì§¹¥þ§í¨î¡A¥B¤@ÃĪ«°Ê¤O¦±½u¹Ï (pharmacokinetic profile)Åã¥ÜASLAN004ªºµ¹ÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C ¯S§Oȱoª`·Nªº¬O¡A¸ÕÅç¼Æ¾Ú«ü¥XASLAN004§¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«× (trough level)¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq¯Å¡C ³o¶µ¼Æ¾Ú¦b¨È·à±d-KY©ó2019¦~5¤ë31¤é«Å¥¬»PCSL×q¦X¬ù¨ú±oASLAN004¥þ²y¬ãµo¡B »s³y»P°Ó«~¤ÆÅv§Q«á¤½¥¬¡A¨È·à±d-KY¤U¤@¨B±N©ó2019¦~¤U¥b¦~±Ò°Ê°w¹ï¤¤«×¦Ü««× ²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C 6.¦]À³±¹¬I:µL
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ
§Ç¸¹ 1 µo¨¥¤é´Á 108/05/31 µo¨¥®É¶¡ 14:30:34 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ ¸³¨Æªøº[°õ¦æªø µo¨¥¤H¹q¸Ü 0227583333 ¥D¦® ¨È·à±d-KY¦VCSL¨ú±oASLAN004¥þ²y°Ó«~¤Æ©Ò¦³Åv
²Å¦X±ø´Ú ¡@²Ä 10 ´Ú ¨Æ¹êµo¥Í¤é 108/05/31 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/05/31 2.«´¬ù©Î©Ó¿Õ¬Û¹ï¤H:CSL Limited 3.»P¤½¥qÃö«Y:µL 4.«´¬ù©Î©Ó¿Õ°_¨´¤é´Á¡]©Î¸Ñ°£¤é´Á¡^:108/05/31 5.¥Dn¤º®e¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497) »PCSL (CSL Limited)×q±ÂÅv¦X¬ù¡A ¨ú±oASLAN004©ó©Ò¦³¾AÀ³¯g¤§¥þ²y¶}µo¡B»s³y»P°Ó«~¤ÆÅv§Q¡A×q¦X¬ù ±N¨ú¥NÂù¤èì¥ý©ó2014¦~5¤ëñq¤§¦X¬ù¡C 6.¨î±ø´Ú¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ¨ÌÂù¤èñq¤§«O±K¦X¬ù¡AÂù¤è¹ï©ó¨ãÅ騽µ{¸O´Ú¤ÎÅv§Qª÷¬Ò¨ã¦³«O±K¸q°È¡A¸Ó¦X¬ù ¹ï©ó¥¼¨ÓÀ禬°^Äm¡A¨Ì¤½¶}¸ê°TÆ[´ú¯¸¨C¤ëÀ禬¤§¤½§i°T®§¤Î·|p®v¬d®Ö©Î®Ö¾\¤§¦U ´Á°]°È³ø§i¤½§i°T®§¬°¥D¡C 7.¹ï¤½¥q°]°È¡B·~°È¤§¼vÅT¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ¨È·à±d-KY±N©óASLAN004¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥ICSLºµ§´Ú¶µ3,000¸U¬üª÷¡CCSL±N¥i¦¬¨ú ³Ì°ª¹F9,500¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F6.55»õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB ¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü10%¤§Åv§Qª÷¡C ®Ú¾Úì¦X¬ù¤º®e¡A¨È·à±d-KYÀ³ºÉ¬ãµoASLAN004¦Ü·§©À©ÊÅçÃÒ(proof-of-concept) §¹¦¨¤§¸q°È¨Ã´M§ä°õ¦æ¤T´ÁÁ{§É¸ÕÅç¤Î°Ó«~¤Æ¤§¦X§@¹Ù¦ñ¡C CSL±N¥i¦¬¨ú¥]¬AÂà¥X±ÂÅv¦X¬ù¦b¤º©Ò¦³ ASLAN004 ¦¬¤J¤§ 40%¦Ü50%¡C 8.¨ãÅé¥Øªº¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ÂX¤j¹ï²£«~¤§°Ó·~±±¨îÅv§Q¨Ã«O¯d§ó¦h²£«~²Õ¦X»ùÈ¡C
----------------------
资°T¤£¹ïºÙ:
¤@¯ëÀù¯gMOA½T»{¡A须n2bÁ{§ÉÅçÃÒ©M¹ï·Ó组¥Dn«ü¼Ð¤ñ¸û PÈ<0.05¡C
¤¤-««×AD¼Ð¹v¡A¥Ñ©ó«D¼Ð¹v¹ï·Ó组ªº预«á«ü¼ÐESAI¥±`°´T·±20%¥ª¥k¡A¦Ó¼Ð¹vªºESAI¥§¡°´T¡ADupilumab¦b70%¥ª¥k¡A¬°¹ï·Ó组3.5¿¡A¦]¦¹nµý©úMOA·§©À©ÊÁ{§É¡A´£«e¨ì1b 50¤H¥H内¡C
¨È·àASLAN004¡AM0A«á¬q©Mdupilumab¬Û¦P¡Aªý断II«¬¨üÅéªý组¦¨¡A¦P®É¥i§í¨îÂù¼Ð¹vIL-4/IL-13°T¸¹¶Ç»¼¡C
¦]¦¹´£«e¦b1A¡A°·±d¤H42¤HªºÁ{§É¡A¥i´úªº§¹¥þ§í¨î¤U´å¤¶½èpSTAT6,¨Óµý©ú¤wªý断II«¬¨üÅé组¦¨¡C¦Ó½T»{MOA¡C
2019/05/31²Ä¤@¦¸°ê»Ú±ÂÅv¦¨¥\¡C 谮¦b°ªÂI¾P°â31.2»õ¬ü¤¸¡C(¨ÌDupilumab预´Á50»õ¬ü¤¸¾P°â°ªÂIx64%(q»ù§é¦©)
¨È狮±d©MCSL¦@¦P¶}µo¡A¦U±oÀò§Q ¡K¡K±ÂÅvª÷7.8»õ¬ü¤¸+¾P°â¤À¼í¡K¡K¡K §é现ȦU±o10»õ¬ü¤¸¡C¦Xp20»õ¬ü¤¸¡C
随Dupilumab ¾P°â°ªÂI´£°ª¨ì110»õ¬ü¤¸¡C ASLAN004销°â°ªÂI¡A¦ô110¡Ñ64%=70»õ¬ü¤¸¡C ¨È·à³Q¨ÖÁÊ»ùÈ´£°ª¨ìAD21»õ¬ü¤¸+4e¬ü¤¸2b+7e¬ü¤¸ý³Ý/COPD¡C
资°T¤£¹ïºÙ¡A»ùÈ«D¤Z¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/28 ¤U¤È 03:11:23
²Ä 3364 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j2019»PCSLñ¸pªº004·s¦X¬ù ¡A¬O§_À³¸Ó¬OCSL尙¤£ª¾004¥H½T»{MOAªº ±¡ªp¤Uñ¸pªº¡A§_«hÁȤj¿úªº¾÷·|«ç»ò·| «ý¤â¬ÛÅý¡A¹ï·Óªº®É¶¡¡A¤]¬O¤½¥q«Å¥¬»PCSL ñq·s¦X¬ù¦b«e¡A¤½¥¬004½T»{MOA¦b«á¡A³o¬O ¤½¥q¥¼¨Ó¬O§_¯à°÷ÁȤj¿ú«D±`«nªºÃöÁä®É¨è ©M°µªk |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/26 ¤U¤È 07:22:24
²Ä 3363 ½g¦^À³
|
ÂIF-¨È·à ,¦³¤£¦P°Q½×°Ï
¥¼¤W¥«ÂdªÑ²¼¤½¥q¦WºÙ ¼ÐÃD ¦^À³ ³Ì·s¦^ÂÐ ¯d¨¥¤é´Á §@ªÌ §Ú¬O§V¤O¸Ñª¼ªº·sÃĤ½¥q,¦ýê©óªk¥O§Ú¥²¶·Â÷¶}¥xÆW¤F 3362 20/08/26 18:45 17/07/26 14:22 ©t¨àÃÄ F-¨È·à ´«ADR¿ëªk 98 20/08/26 18:42 20/07/17 20:15 ¤Ñ©R F-¨È·à ¶W¶V100»õ¬ü¤¸¾P°â¼ç¤O 14 20/08/26 07:54 20/08/21 13:58 ¤Ñ©R F-¨È·à 70»õ¬ü¤¸¾P°â¼ç¤O 39 20/08/24 09:36 20/07/22 07:38 ¤Ñ©R F-¨È·à 21»õ¬ü¤¸§é²{¼çÈ 45 20/08/22 09:21 20/07/16 06:43 ¤Ñ©R F-¨È·à MOA(¾÷Âà) 37 20/08/21 08:05 20/07/18 10:35 ¤Ñ©R F-¨È·à AD/ý³Ý ³Ì¨ÎÀøªk¼ç¤O 102 20/08/14 05:50 20/01/06 11:37 ¤Ñ©R F-¨È·à ADRÂà´«±ÂÅv®Ñ 6 20/07/30 14:54 20/07/30 08:46 ·¤p¶³ F-¨È·à ±¾µP¤W¥« 1 17/07/25 22:47 17/05/19 10:17 AA
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G±áÄf10141758 |
µoªí®É¶¡:2020/8/26 ¤U¤È 06:45:35
²Ä 3362 ½g¦^À³
|
«ç¤@°±µP«á¤j®a³£ÅܦwÀR¤F¡H¤j¤j̳£¤£¨£¤F. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2020/8/24 ¤U¤È 04:13:08
²Ä 3361 ½g¦^À³
|
finance.yahoo.com/quote/ASLN/holders/
¥Dn«ù¦³¤H & ³»¯Å¾÷ºc«ù¦³¤H
«ç»ò¬O³»¯Åªº%¤j©ó¥Dn¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/24 ¤U¤È 04:07:04
²Ä 3360 ½g¦^À³
|
¦³¨S¦³§Æ±æÀ³¸Ó¬Ý1´Á¤½¥¬ªº¼Æ¾Úµ²ªG ¡A´N¤j·§¥i¬Ý¥XºÝÙ¤F¡A§Æ±æ¤j®a¦h¬O ³Ì«áªºÄ¹®a¤jÁȦ¬³õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/24 ¤U¤È 03:51:06
²Ä 3359 ½g¦^À³
|
¬ÝÀ´¼v¤ù¤ßÀY¤~·|¦w¡I
1.&2 ¬O¬Û³qªº¡A¤@©wn°Ñ³z/®©³z/¬Ý¨£¥Õ ¤~¦³¾÷·|©ê¨ì±ÂÅv/¨ÖÁÊ.¡I¦Ó𣎴³Q¬~±¼¡I
1.ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/24 ¤U¤È 03:37:05
²Ä 3358 ½g¦^À³
|
www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw ¥~¸ê¤µ¤é¶R¶W 1,108±i
6¤ë12¤é¥H¨Ó²Öp¬ù¶R¶W4500±i.
¦U¦ì¤j¤j¦A¨Ón¶R¥u¯à¶RASLN ADR |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2020/8/24 ¤U¤È 02:49:31
²Ä 3357 ½g¦^À³
|
¤U¦nÂ÷¤â~~~¦Ñ·à¤ÍÌ,§Ú̱q68¶ô¬Ý¨ì³Ì§C3.14,³Ì«á¦b¥xÆW¤U¥«¦ÓÂà¾ÔADR«÷³Õ³Ì«áªº¾÷·|~¨ä¹ê¤ß¸Ì±¬O¤£¦wªº,¦A«¨Ó¤@¦¸ªº¸Ü,¹çÄ@¦b30¶ô®É´N°±·l¥X³õ,¦ý¹L©¹¤£¯à«¨Ó,¥u¯à§Æ±æ¦~©³¦p¶i«×¸Ñª¼´Á¤¤¼Æ¾Ú,ºò±µ§¹¦¨2A,Åý»ùȦ^¨ì68¶ô,Åý½Ñ¦h·à¤Í¥·l©ÎÁÈ¿ú,¤£¹LÂàADR«á´N¬O¤j¤áªº¤Ñ¤U,½ä½ä¬Ý¦~©³¼Æ¾Ú©Ò±a¨Óªº·Q¹³ªÅ¶¡¤F~~~
¥H¤W°Ñ¦Ò...
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2020/8/24 ¤U¤È 02:33:34
²Ä 3356 ½g¦^À³
|
¥»¸ê®Æ¥Ñ¡@ (¤WÂd¤½¥q) ¨È·à±d-KY¡@¤½¥q´£¨Ñ §Ç¸¹ 1 µo¨¥¤é´Á 109/08/24 µo¨¥®É¶¡ 14:27:21 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü +65 6222 4235 ¥D¦® ¤½§i¥»¤½¥q²§¦ì©Ê¥Ö½§ª¢·sÃÄASLAN004«ì´_¨ü¸ÕªÌ©Û¶Ò ²Å¦X±ø´Ú ²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 109/08/24 »¡©ú 1.¨Æ¹êµo¥Í¤é:109/08/24 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¦]À³·s¥[©Y³v¨B¸Ñ«Ê¡A¥»¤½¥q¤µ¤é«Å¥¬«ì´_ASLAN004°w¹ï¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢¶i ¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº¦h¾¯¶q»¼¼WÃĪ«¸ÕÅç(MAD)¤§¨ü¸ÕªÌ©Û¶Ò¡C
6.¦]À³±¹¬I: (1)¨ü¨ì·s¥[©Y¬F©²¬°§í¨î·s«¬«aª¬¯f¬r(COVID-19)ÂX´²¦Ó¹ê¬Iªº¸T¥O¼vÅT¡A¨È·à±d- KY©ó2020¦~4¤ë13¤é¼È°±¤F¨ü¸Õ¯f±wªº©Û¶Ò¡C¦Óªñ´Á·s¥[©Y¶}©l³v¨B¸Ñ«Ê¡A¨È·à±d-KY ¦b·s¥[©Y©Ò¦³¸g¹L¿zÀ˦w¥þªºªº¸ÕÅç¦aÂI«ì´_¤F²Ä¤G¾¯¶q±Ú¸s¨ü¸Õ¯f±wªº©Û¶Ò¡C (2)¬°¤F¥[³t¨ü¸ÕªÌªº©Û¶Ò¡A¨È·à±d-KY©ó¿D¬w»P¬ü°ê¶}³]ÃB¥~ªº¸ÕÅç¦aÂI¥ç¦P¨B·Ç³Æ ¤¤¡C (3)¥»¤½¥q¹wp±N¦b2020¦~²Ä¥|©u¤½¥¬¥þ³¡3Ó¾¯¶q±Ú¸sªº´Á¤¤¸Ñª¼¼Æ¾Ú¡C
7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë¸ê ¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C¤Wz¤½§i½Ð¸Ô¥»¤½¥q·s»D½Z¡C aslanpharma.com/news/
¥H¤W¸ê®Æ§¡¥Ñ¦U¤½¥q¨Ìµo¨¥·í®É©ÒÄÝ¥«³õ§O¤§³W©w¥Ó³ø«á¡A¥Ñ¥»¨t²Î¹ï¥~¤½§G¡A¸ê®Æ¦p¦³µê°°¤£¹ê¡A§¡¥Ñ¸Ó¤½¥qt³d.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gtimchan51610148760 |
µoªí®É¶¡:2020/8/24 ¤U¤È 02:09:01
²Ä 3355 ½g¦^À³
|
·í®É68¶ô¤W¥« ¤£ª¾¹D¦³¨S¦³©â¨ì«áÁÙ¯d¨ì²{¦bªº¤H !
¤½§i¥»¤½¥q¿ì²zªÑ²¼ªì¦¸¤WÂd²{ª÷¼W¸ê¦¬¨¬ªÑ´Úº[¼W¸ê°ò·Ç¤é 1.¨Æ¹êµo¥Í¤é:106/05/25 2.µo¥Í½t¥Ñ:¨Ì¾Ú¡uµo¦æ¤H¶Ò¶°»Pµo¦æ¦³»ùÃÒ¨é³B²z·Ç«h¡v²Ä9±ø²Ä1¶µ²Ä2´Ú³W©w¿ì²z¡C 3.¦]À³±¹¬I:µL¡C 4.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¥»¤½¥q¿ì²zªÑ²¼ªì¦¸¤WÂd«e²{ª÷¼W¸êµo¦æ´¶³qªÑ14,458,000ªÑ¡AÄv»ù©ç½æ³Ì§C©Ó¾P»ù®æ¬°¨CªÑ·s»O¹ô64¤¸¡A¨Ì§ë¼Ð»ù®æ°ªªÌÀu¥ý±o¼Ð¡A¨C¤@±o¼Ð¤HÀ³¨Ì¨ä±o¼Ð»ù®æ»{ÁÊ¡A¦U±o¼Ð³æ¤§»ù®æ¤Î¨ä¼Æ¶q¥[Åv¥§¡»ù®æ·s»O¹ô68.92¤¸¡F¤½¶}¥ÓÁÊ©Ó¾P»ù®æ¬°¨CªÑ·s»O¹ô68.92¤¸¡FÁ`p·s»O¹ô992,290,510¤¸¤Î¬üª÷139,666.57¤¸·~¤w¥þ¼Æ¦¬¨¬¡C(2)²{ª÷¼W¸ê°ò·Ç¤é¡G106¦~5¤ë25¤é¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸>
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/24 ¤W¤È 07:25:35
²Ä 3354 ½g¦^À³
|
«e15¤j¶R½æ¶W¤¤:
¥~¸ê¶R¶W ¥ÃÂת÷ÃÒ¨é(¥~¸ê) 1600±i½L«á¥æ©ö¡A¥¼¯Ç¤J²Îp ¥ÃÂת÷ÃÒ¨é(¥~¸ê) 805 ¬üªLÃÒ¨é 806 ¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¦Xp¶R¶W 3211±i
¨È·à±d-KY(6497) ¥D¤O¶i¥X©ú²Ó ³æ¦ì¡G±i¡@³Ì«á§ó·s¤é¡G2020/08/21 ¡@¦Û³]°Ï¶¡¡G ±q¡@¦~ 6¤ë14 ¤é ¡ã ¦~8 ¤ë 21¤é ¶R¶W ///½æ¶W ¶R¶W¨é°Ó ¶R¶i ½æ¥X ¶R¶W ¦û¦¨¥æ¤ñ« ///½æ¶W¨é°Ó ¶R¶i ½æ¥X ½æ¶W ¦û¦¨¥æ¤ñ« ´I¨¹-¥xªF 1,665 427 1,238 3.74% ///¦X®w-¥x¤¤ 91 549 458 1.38% »O»È 1,063 95 968 2.92%¡C /// °ê²¼ 10 421 411 1.24% ¥x·sÃÒ¨é 1,303 387 916 2.77% ///´I¨¹-°ª¶¯ 43 362 319 0.96% ¥ÃÂת÷ÃÒ¨é 1,030 205 825 2.49% ///¤¸¤j-Â×ì 275 593 318 0.96% ¬üªL 819 13 806 2.43% ///µØ«n¥Ã©÷-´°«n 11 272 261 0.79% ³Í°ò-¦Ë¬ì 669 83 586 1.77% ///³Í°ò-¹ü¤Æ 99 338 239 0.72% ¦X®wÃÒ¨é 634 66 568 1.71% ///³Í°ò-]®ß 0 187 187 0.56% ¥ÃÂת÷-¤º´ò 530 38 492 1.49%/// ¤¸¤j-Âí¥_ 65 252 187 0.56% ¤¤°ê«H°U 614 197 417 1.26% ///³Í°ò-¤¤¤s 10 183 173 0.52% ´I¨¹-·s¦ËµØ«H 425 23 402 1.21%/// ¦X®w-·s¦Ë 12 180 168 0.51% ¤é²±-«H¸q 460 83 377 1.14%/// ¤¤°ê«H°U-·s¦Ë 171 309 138 0.42% ¤¸¤j-¦èªù 297 3 294 0.89%/// ²Î¤@-¦Ë«n 0 137 137 0.41% ¸s¯qª÷¹©-ªF´ò 290 7 283 0.85%/// ¤¸¤j-¥j«F 106 240 134 0.4% ¤¸¤j-³Õ·R 382 112 270 0.82%/// ´I¨¹-¶§©ú 28 149 121 0.37% ³Í°ò-¥xªF 275 31 244 0.74%/// ¤¸¤j-®ç¿³ 14 131 117 0.35% ¦Xp¶R¶W±i¼Æ 8,686 ¦Xp½æ¶W±i¼Æ 3,368 ¥§¡¶R¶W¦¨¥» 4.84 ¥§¡½æ¶W¦¨¥» 5.75 ¡iµù1¡j¤Wz¶R½æ¶WӪѶȴ£¨Ñ±Æ§Ç«áªº«e15¦W¨é°Ó¡A¥B¥¼p¤J¦ÛÀç°Ó³¡¥÷¡C ¡iµù2¡j¦Xp¶R¶W©Î½æ¶W¡A¬°¤Wz®a¼Æ¦Xp¡C ¡iµù3¡j¥§¡¶R¶W©Î½æ¶W¦¨¥»¡A¬°¤Wz®a¼Æ¦Xp¶R½æ¶Wª÷ÃB/¤Wz®a¼Æ¦Xp¶R½æ¶W±i¼Æ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/24 ¤W¤È 06:34:39
²Ä 3353 ½g¦^À³
|
6¤ë12¤é vs 8¤ë21¤é «ùªÑµ²ºc (¤»¤ë¤¤¦¯¨È·à¤½§i¥i¯à¤U¥««°T)
6¤ë12¤é «ùªÑÁ`¤H¼Æ4951¤H 8¤ë21¤é«ùªÑÁ`¤H¼Æ3176¤H,´î¤Ö 1773¤H, 1773/4951=35.8%
(1)¤@.1-50±i«ùªÑ®t²§,´î¤Ö9045±i/´î¤Ö1790¤H,
¡X¡X6¤ë12¤é«ùªÑ 25,028±i/4782¤H
¡X¡X8¤ë21¤é«ùªÑ15,983±i/2992¤H¡]§t115¤H¹sªÑ¡^
. (a) 1-10±i«ùªÑ»P8¤ë21¤é¤ñ´î¤Ö4577±i,´î¤Ö1585¤H
¡X¡X6¤ë12¤é«ùªÑ 11,805±i/4069¤H
¡X¡X8¤ë21¤é«ùªÑ7,228±i/2484¤H (b)11~50±i »P8¤ë21¤ê¤ñ«ùªÑ´î¤Ö4468±i/´î¤Ö205¤H
(2)----8¤ë21¤ê 50±i¥H¤W«ùªÑ«ùÄò¼W¥[,¼W¥[9045±i
(a)1000±i¥H¤W ¼W¥[ 1¤H¡A¼W¥[2079±i (b)800~1000±i ¼W¥[4¤H¡A¼W¥[3569±i (c)100~200±i ¼W¥[11¤H¡A¼W¥[1767±i
¶°«O¤áªÑÅv¤À´²ªí ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~08¤ë21¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 115 10,846 0.00 2 1,000-5,000 2,123 4,254,331 2.23 3 5,001-10,000 361 2,974,529 1.56 4 10,001-15,000 130 1,713,304 0.90 5 15,001-20,000 115 2,194,000 1.15 6 20,001-30,000 89 2,349,549 1.23 7 30,001-40,000 30 1,114,952 0.58 8 40,001-50,000 29 1,375,000 0.72 9 50,001-100,000 71 5,516,368 2.90 10 100,001-200,000 45 6,687,483 3.52 11 200,001-400,000 19 5,231,850 2.75 12 400,001-600,000 14 6,741,974 3.54 13 600,001-800,000 2 1,465,000 0.77 14 800,001-1,000,000 7 6,233,155 3.28 15 1,000,001¥H¤W 26 142,092,629 74.80 ¦X¡@p 3,176 189,954,970 100.00
¶°«O¤áªÑÅv¤À´²ªí ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~06¤ë12¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 108 14,670 0.00 2 1,000-5,000 3,488 7,101,234 3.73 3 5,001-10,000 581 4,704,698 2.47 4 10,001-15,000 210 2,747,416 1.44 5 15,001-20,000 167 3,132,000 1.64 6 20,001-30,000 130 3,337,549 1.75 7 30,001-40,000 55 1,990,952 1.04 8 40,001-50,000 43 2,003,000 1.05 9 50,001-100,000 76 5,390,368 2.83 10 100,001-200,000 34 4,920,483 2.59 11 200,001-400,000 16 4,309,849 2.26 12 400,001-600,000 13 6,285,967 3.30 13 600,001-800,000 2 1,330,000 0.70 14 800,001-1,000,000 3 2,673,155 1.40 15 1,000,001¥H¤W 25 140,013,629 73.70 ¦X¡@p 4,951 189,954,970 100.00
»¡©ú¡G 1. ¿Ä¸ê¿Ä¨é±M¤á¡BÃÒ¥æ©Òɨ鹺¼·±M¤á¡Bɨé¾á«O«~±M¤á¡A»P´Á¥æ©Ò¼ÐªºÃÒ¨éú¥æ½æ¥X¶RÅv«OÃÒª÷±M¤á¡B¼ÐªºÃÒ¨é¼i¬ù¥æ³Î±M¤áµ¥¦U±M¤á³¡¤À¡A¥H¸Óµ¥±M¤á©Ò¸üªÑ¼Æpºâ¡C 2. ¦XpªÑ¼Æ¥]§t¹sªÑ«Ý»â¦^©ÎÃÒ¨é¤ä¥I¾Ì³æ¤§ªÑ¼Æ¡C 3. ¥»¾ú¥vÀɮ׸ê®Æ¦Û97¦~7¤ë¥÷°_«Ø¸m¡A¸ê®Æ«O¦s´Á¶¡¬°¤@¦~¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/24 ¤W¤È 05:00:16
²Ä 3352 ½g¦^À³
|
¨È·à±d6497 ¦b¥xÆWÂd¥x³Ì«á¥æ©ö¤é, ´N³Ñ¤µ¤Ñ¡I
¤µ¤Ñ¹L«á¡A¤½¶}¥æ©ö©Ò¥u¦b¬ü°ê¯Ç´µ¹F§J¡I ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ASLAN004 ·§©À©ÊÁ{§É´Á¤¤¸Ñª¼¡A°t¦X¤½¶}¶Ò¸ê¡A¦ôp¦b10¤ë©³~11¤ë©³¤§¶¡¡A
¹êÅç²Õ 200mg/400mg/600mg ¦U6¤H,¤pp18¤H ¹ï·Ó²Õ 200mg/400mg/600mg ¦U2¤H,¤pp6¤H ¦Xp 24¤H ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥t¥~¶}©l ³Ì¨Î¾¯¶qÂX¥R¹êÅç
¦ôp200mgx¨C¶g¤@°wx8¶g (¹wp2021¦~3¤ë31¤é§¹¦¨)
¹êÅç²Õ 200mg 12¤H ¹ï·Ó²Õ 200mg 6¤H ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦U¹w«á«ü¼Ð¡A½Ð°Ñ¦Òdupilumab ¨C¶g¤@°wªºÁ{§Éµ²ªG¡I
Dupilumab ¦U´ÁÁ{§É¼Æ¾Ú¡C
1. Dupilumab ¦´Á¥|Ó AD Á{§É 4¶g/12¶g , 2014/07/10
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
www.nejm.org/doi/10.1056/NEJMoa1314768
2. Dupilumab 2a/2b Á{§É ,2018/SEP
journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx
3.Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/22 ¤W¤È 09:02:42
²Ä 3351 ½g¦^À³
|
°ê»Ú·sÃıÂÅv¦X¬ù §é²{Ȳʺâªk
±ÂÅv¦X¬ù = ±ÂÅvª÷¡]ñ¬ùª÷¡Ï¶¥¬qùµ{ª÷¡Õ¦U¶¥Á{§É¡Ï¨ú±oÃĵý¡Ö¡Ï¾P°âùµ{ª÷¡^¡Ï¾P°â¤À¼í ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ASLAN004 ¥¼¨Ó±ÂÅv¦X¬ù¡A §é²{Ȳʦô¥i¥Î ±ÂÅvª÷x150%¤½¦¡¨Ó¦ôºâ ¦Ó¨È·à±o¨ä¤¤2/3, CSL ±o1/3
Y±ÂÅvª÷35»õ¬ü¤¸¡Ï¾P°â¤À¼í(Áô§t70»õ¬ü¤¸³Ì°ª¾P°â) §é²{È¥i¥Î35x150%=52.5»õ¬ü¤¸pºâ.
¡X¡X¨È·à¬ù¤À±o2/3, 52.5x2/3=35»õ¬ü¤¸ ¡X¡XCSL¬ù¤À±o1/3.52.5x1/3=17.5»õ¬ü¤¸
Y±ÂÅvª÷55»õ¬ü¤¸¡Ï¾P°â¤À¼í(Áô§t110»õ¬ü¤¸³Ì°ª¾P°â) §é²{È¥i¥Î55x150%=82.5»õ¬ü¤¸pºâ.
¡X¡X¨È·à¬ù¤À±o2/3, 82.5x2/3=55»õ¬ü¤¸ ¡X¡XCSL¬ù¤À±o1/3.82.5x1/3=27.5»õ¬ü¤¸
¡X¡X¡X¡X¡X¡X¡X¡X- 2015¦~ Áú°êHanmi±ÂÅvªvÀø ¿}§¿¯f ªø®Ä GLP-1µ¹ªk°êÁÉ¿Õµá ¬°¨Ò
±ÂÅvª÷42»õ¬ü¤¸¡Ï >10% 2¦ì¼Æ ªº¾P°â¤À¼í¡X¡X-Áô§t84»õ¬ü¤¸ªº³Ì°ª¾P°â
ªÑ»ù¥«È¼W¥[62»õ¬ü¤¸ ¦bñ¬ù«e«á¡C
62/42=148% ¡X¡X¡X-³oÓ¥²±µªñ¦X¬ùªº§é²{È
42x150%=63»õ¬ü¤¸
84»õ³Ì°ª¾P°â¹w¦ô
±ÂÅv¦X¬ù=42»õñ¬ùª÷¡Ï¾P°â¤À¼í
§é²{»ùȦô=±ÂÅvª÷ 42x150%=42x150%=63»õ¬ü¤¸.
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X www.marketwatch.com/investing/stock/128940?countrycode=kr Hanmi Pharmaceutical Co. Ltd.
2015¦~11¤ë ªÑ»ù¤jº¦¦Ü682,954Áú¤¸¡]¥«È8.148¥üÁú¤¸,x0.028515=2323 »õ¥x¹ô/71.66»õ¬ü¤¸) 2015¦~¤¸¤ë ªÑ»ù 88,067Áú¤¸(¥«È 1.05¥üÁú¤¸x0.028515=300»õ¥x¹ô/9.25»õ¬ü¤¸)
ñ¬ù«á¤jº¦ 62»õ¬ü¤¸
¥Ø«e292,500Áú¤¸ ,¥«È 3.49¥üÁú¤¸¡]
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/8/21 ¤W¤È 11:56:48²Ä 36 ½g¦^À³ ASLAN004 ¥¼¨Ó ±ÂÅv ±N¬D¾Ô ³o2015¦~11¤ë °O¿ý¡G
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ±ÂÅvª÷42»õ¬ü¤¸¡Ï >10% 2¦ì¼Æ ªº¾P°â¤À¼í¡X¡X-Áô§t84»õ¬ü¤¸ªº³Ì°ª¾P°â
§ó·s2-ÁÉ¿Õµá¡Aº~¦Ì¥H°ª¹F42»õ¬ü¤¸ªº»ù®æñ¤U¿}§¿¯f³\¥i¨óij
* Hanmi¹w¥I4»õ¼Ú¤¸¡A³Ì¦h35»õ¨½µ{¸O
*ÁÉ¿ÕµáÀò±oªø®ÄGLP-1ÃĪ«ªº¿W®a³\¥i
*³oµ§¥æ©ö³Qµø¬°¹ïÁÉ¿Õµá²{¦³¦X§@¹Ù¦ñ¦èÄõ¤½¥q¤£§Q¡]¼W¥[¤F¤ÀªR®vªºµû½×¡A§ó·s¤FªÑ»ù¤ÏÀ³¡^
°¨¸¦¨È´µ¡P¥¬©Ô»X¯S¡]Matthias Blamont¡^
¸ô³z¤Ú¾¤11¤ë5¤é-ÁÉ¿Õµá¤w»Pº~¦Ì»sÃĤ½¥q¡]Hanmi Pharmaceutical¡^ñ¸p¤F¤@¶µ³\¥i¨óij¡A¥H¶}µo¹êÅç©Êªº¡Aªø®Äªº¿}§¿¯fÀøªk¡A³o®aªk°ê»sÃÄ°Ó©P¥|ªí¥Ü¡A¦¹Á|¦®¦b«®¶¨ä¿}§¿¯f³¡ªù¡C
Á`³¡¦ì©óÁú°êªºHanmi±NÀò±o4»õ¼Ú¤¸¡]4.34»õ¬ü¤¸¡^ªº¹w¥I´Ú¡A¨Ã¦³¸ê®æÀò±o°ª¹F35»õ¼Ú¤¸ªº¶}µo¡Aµù¥U©M¾P°â¨½µ{¸O¡A¥H¤Î²b¾P°âÃBªº¨â¦ì¼Æ¯S³\Åv¨Ï¥Î¶O¡C
§@¬°¦^³ø¡AÁÉ¿Õµá±NÀò±o¥þ²y¿W®a³\¥i¡A¥H¶}µo©M°Ó·~¤ÆHanmiªº©Ò¿×GLP-1¿}§¿¯fªvÀøÃĪ«¡C Hanmi±N«O¯d¦bÁú°ê©M¤¤°ê¦@¦P¾P°â³o¨Ç²£«~ªº¿W®a¿ï¾ÜÅv¡C
³o¶µ¥æ©ö¼Ð»xµÛÁÉ¿Õµá¦b¨ä³Ì«nªº¿}§¿¯f·~°È³´¤J§x¹Ò¤§»Ú¡A¹ï·s§Þ³Nªº¥¨¤j½äª`¡C
NEWSNOVEMBER 5, 2015 / 7:32 PM / 5 YEARS AGO
UPDATE 2-Sanofi, Hanmi seal diabetes licence deal for up to $4.2 bln 3 MIN READ * Hanmi gets 400 mln euros upfront, up to 3.5 bln milestones
* Sanofi wins exclusive licence to long-acting GLP-1 drugs
* Deal seen as negative for existing Sanofi partner Zealand (Adds analyst¡¦s comment, updates share price reaction)
By Matthias Blamont
PARIS, Nov 5 (Reuters) - Sanofi has signed a licence deal with Hanmi Pharmaceutical to develop experimental, long-acting diabetes treatments, the French drugmaker said on Thursday, in a move to revive its diabetes division.
South Korea-based Hanmi will receive an upfront payment of 400 million euros ($434 million) and is eligible for up to 3.5 billion euros in development, registration and sales milestones, as well as double-digit royalties on net sales.
In return Sanofi will get an exclusive worldwide licence to develop and commercialise Hanmi¡¦s so-called GLP-1 diabetes treatments. Hanmi will retain an exclusive option to co-commercialise the products in Korea and China.
The deal marks a sizeable bet by Sanofi on a new technology at a time when its all-important diabetes business is struggling.
www.reuters.com/article/sanofi-hanmi-diabetes/update-2-sanofi-hanmi-seal-diabetes-licence-deal-for-up-to-4-2-bln-idUSL8N1303GH20151105#zfxFkCQGu0cDA9Z7.97 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/22 ¤W¤È 07:56:08
²Ä 3350 ½g¦^À³
|
¨È·àÂ÷¥x˼Ƥ@¤éªº«ùªÑª¬ªp
«ùªÑÁ`¤H¼Æ3176¤H,¤ñ¤W¶g 3543¤H´î¤Ö 367¤H
¤@.1-50±i«ùªÑ®t²§,´î¤Ö1582±i/368¤H ----¤W¶g«ùªÑ17565±i/3360¤H(§t112¤H¹sªÑ), ¡X-¥»¶g«ùªÑ15983±i/2992¤H¡]§t115¤H¹sªÑ¡^ .
----¥»¶g50±i¥H¤W«ùªÑ«ùÄò¼W¥[,¼W¥[1582±i
¤G¡B.¥»¶g¥~¸ê¶R¶W¼W¥[:1065±i
¶°«O¤áªÑÅv¤À´²ªí ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~08¤ë21¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 115 10,846 0.00 2 1,000-5,000 2,123 4,254,331 2.23 3 5,001-10,000 361 2,974,529 1.56 4 10,001-15,000 130 1,713,304 0.90 5 15,001-20,000 115 2,194,000 1.15 6 20,001-30,000 89 2,349,549 1.23 7 30,001-40,000 30 1,114,952 0.58 8 40,001-50,000 29 1,375,000 0.72 9 50,001-100,000 71 5,516,368 2.90 10 100,001-200,000 45 6,687,483 3.52 11 200,001-400,000 19 5,231,850 2.75 12 400,001-600,000 14 6,741,974 3.54 13 600,001-800,000 2 1,465,000 0.77 14 800,001-1,000,000 7 6,233,155 3.28 15 1,000,001¥H¤W 26 142,092,629 74.80 ¦X¡@p 3,176 189,954,970 100.00
¶°«O¤áªÑÅv¤À´²ªí ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~08¤ë14¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 112 10,959 0.00 2 1,000-5,000 2,426 4,884,828 2.57 3 5,001-10,000 395 3,247,529 1.70 4 10,001-15,000 150 1,965,106 1.03 5 15,001-20,000 112 2,139,000 1.12 6 20,001-30,000 99 2,578,549 1.35 7 30,001-40,000 36 1,341,547 0.70 8 40,001-50,000 30 1,401,000 0.73 9 50,001-100,000 72 5,398,368 2.84 10 100,001-200,000 42 6,316,483 3.32 11 200,001-400,000 22 5,955,850 3.13 12 400,001-600,000 14 6,837,967 3.59 13 600,001-800,000 2 1,465,000 0.77 14 800,001-1,000,000 6 5,427,155 2.85 15 1,000,001¥H¤W 25 140,985,629 74.22 ¦X¡@p 3,543 189,954,970 100.00
¨È·à±d-KY(6497) ¥D¤O¶i¥X©ú²Ó ªñ5¤ê ¶R¡þ½æ¶W«e15¤j¨é°Ó
³æ¦ì¡G±i¡@³Ì«á§ó·s¤é¡G2020/08/21 ¡@¦Û³]°Ï¶¡¡G ±q¡@2020¦~ 8¤ë 17 ¤é ¡ã 2020 ¦~ 8 ¤ë21 ¤é ¶R¶W ½æ¶W ¶R¶W¨é°Ó ¶R¶i ½æ¥X ¶R¶W ¦û¦¨¥æ¤ñ« ///½æ¶W¨é°Ó ¶R¶i ½æ¥X ½æ¶W ¦û¦¨¥æ¤ñ« ¥ÃÂת÷ÃÒ¨é 819 0 819 18.29% ///³Í°ò-´_¿³ 8 345 337 7.52% ¤¸¤j-³Õ·R 350 0 350 7.81% ///¥x·sÃÒ¨é 15 126 111 2.48% ¬üªL 246 0 246 5.49% ///´I¨¹-°ª¶¯ 0 103 103 2.3% ¥ÃÂת÷-¤º´ò 221 16 205 4.58%¡C ///¤¸¤j-«n®r 0 72 72 1.61% ¤¸¤j-¤¤Ãc 165 0 165 3.68% ///¤¸¤j-Âù©M 0 72 72 1.61% ²Î¤@-¤º´ò 365 225 140 3.13% ///¤¤°ê«H°U-¤å¤ß 34 98 64 1.43% ¥É¤s-¤hªL 98 1 97 2.17% ///²Î¤@-¹ü¤Æ 0 62 62 1.38% ¸s¯qª÷¹©-®ü¤s 100 11 89 1.99% ///´I¨¹-ùªF 50 112 62 1.38% ¤é²±-Â×ì 82 0 82 1.83% ///µØ«n¥Ã©÷-¥ÁÅv 0 60 60 1.34% ·s¥ú 105 23 82 1.83% ///¸s¯qª÷¹©-¥_°ª¶¯ 0 57 57 1.27% ´I¨¹-ªO¾ô 80 5 75 1.67% ///µØ«n¥Ã©÷-ªê§À 0 56 56 1.25% ´I¨¹-¥xªF 90 16 74 1.65% ///³Í°ò-¤¤¤s 0 44 44 0.98% ¸s¯qª÷¹©-©yÄõ 50 0 50 1.12% ///¤¸¤j-«n§ë 0 44 44 0.98% ¤¸¤j-«eª÷ 50 5 45 1% ////»O»È-»O¤¤ 5 45 40 0.89% ¤¸¤j-¦¨¥\ 43 0 43 0.96% ///¶§«H 0 40 40 0.89% ¦Xp¶R¶W±i¼Æ 2,562 ///¦Xp½æ¶W±i¼Æ 1,224 ¥§¡¶R¶W¦¨¥» 5.56 ¥§¡½æ¶W¦¨¥» 5.60 ¡iµù1¡j¤Wz¶R½æ¶WӪѶȴ£¨Ñ±Æ§Ç«áªº«e15¦W¨é°Ó¡A¥B¥¼p¤J¦ÛÀç°Ó³¡¥÷¡C ¡iµù2¡j¦Xp¶R¶W©Î½æ¶W¡A¬°¤Wz®a¼Æ¦Xp¡C ¡iµù3¡j¥§¡¶R¶W©Î½æ¶W¦¨¥»¡A¬°¤Wz®a¼Æ¦Xp¶R½æ¶Wª÷ÃB/¤Wz®a¼Æ¦Xp¶R½æ¶W±i¼Æ¡C fubon-ebrokerdj.fbs.com.tw/z/zc/zco/zco_6497_2.djhtm |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/21 ¤W¤È 08:32:12
²Ä 3349 ½g¦^À³
|
finance.yahoo.com/quote/TSLA/
Tesla, Inc. (TSLA) ªÑ»ù:2000¬ü¤¸/ªÑ ¥«»ù:3730»õ¬ü¤¸
²bÈ66»õ¬ü¤¸(2019/12/31)
ªÑ»ù²bȤñ3730/66=56¿
ir.tesla.com/static-files/07bfcb70-aba1-4a27-af09-4f101678320c |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/21 ¤W¤È 06:07:31
²Ä 3348 ½g¦^À³
|
REGNªÑ»ù¡A2016¦~«á¤@¸ô®¶Àú©¹¤U¨ì2019¦~9¤ë1¤é¡A291¬ü¤¸¡A¥«È291»õ¬ü¤¸¡A¦ý¸g¹L¤£¨ì¤@¦~¡A¦^¨ì¥Ø«e630¬ü¤¸/ªÑ¡A¥«È³Ð2015¦~/08¤ë¨Ó¾ú¥v·s°ª¡A¨Ó¨ì630»õ¬ü¤¸¡C
ªÑ»ù领¥ý5¦~¡A¦b2015¦~8¤ë¤ÏÀ³2020¦~À禬/Àò§Q¡C
û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/8/20 ¤W¤È 11:48:01²Ä 3337 ½g¦^À³ REGN ªÑ»ù&¾ú¥v¨Æ¥ó
2011¦~ 1¤ë3 ¤é,ªÑ»ù34¬ü¤¸/ªÑ»ù¥«È¬ù34»õ¬ü¤¸
11¤ë1¤é,ªÑ»ù56¬ü¤¸/ªÑ»ù¥«È¬ù56»õ¬ü¤¸-----a
11¤ë©³ Eylea FDA ®Öã¤W¥«.
(Lucentis 2011¦~¾P°â20~24»õ¬ü¤¸/¦~, Eylea ¥H 16,000¬ü¤¸/¦~Àøµ{¶O¤W¥«,¬°Lucentis 24,000 ¬ü¤¸/¦~Àøµ{¶Oªº66%.
¦X²z¥«³õ¹w¦ô Eylea , 30»õ¬ü¤¸*66.6%=20»õ¬ü¤¸³Ì°ª¾P°â.-----a
--------------------------------------- 2012¦~ 1¤ë3¤é ,ªÑ»ù65 ¬ü¤¸/ªÑ/ªÑ»ù¥«È¬ù65»õ¬ü¤¸ -----b
ªÑ»ù¥«È/³Ì°ª¾P°â, b/a=65/20=3.25¿
4¤ë23¤é,ªÑ»ù140¬ü¤¸/ªÑ»ù¥«È¬ù140»õ¬ü¤¸
2013¦~ 5¤ë13¤é,ªÑ»ù266¬ü¤¸/ªÑ//¥«È¬ù266»õ¬ü¤¸ ,(¤½¥¬/Eylea 2012¦~ À禬8»õ¬ü¤¸) 9¤ë30¤é,ªÑ»ù308¬ü¤¸/ªÑ/¥«È¬ù308»õ¬ü¤¸ ,(¤½¥¬2013¦~Q3À禬)----¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸)
2014¦~ 7¤ë dupilumab 2b Á{§Éµ²ªG¥¿¦V 2014¦~10¤ë6¤éªÑ»ù343¬ü¤¸/ªÑ/¥«È¬ù343»õ¬ü¤¸ 11¤ë dupilumab ÀòBTD(¬ð¯}©ÊÀøªk)-----¤ÀªR®v¦ôdupilumab ¥¼¨Ó³Ì°ª¾P°â50»õ¬ü¤¸
12¤ë29¤éªÑ»ù427¬ü¤¸/ªÑ/¥«È¬ù427»õ¬ü¤¸
2015¦~8¤ë10¤é579¬ü¤¸/ªÑ/¥«È¬ù579»õ¬ü¤¸
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(REGN----Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35// 2012¡V24.00//8.70**B/A=36%**32.7 ¡]Eylea 2011,11¤ë FDA ®Öã¤W¥«) 2013¡V39.53//20.43**B/A=51%**50.96¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/21 ¤W¤È 05:53:13
²Ä 3347 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
Ë¼Æ²Ä 2 Ó¥æ©ö¤ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/20 ¤U¤È 08:17:50
²Ä 3346 ½g¦^À³
|
¤½¥q¤jªÑªF¦pªGÁÙª`·N´î¸ê«áÅv¯q ªº°ÝÃD¡A ´Nªí¥Ü¹ï¤½¥q¥¼¨ÓÁÙ¬O¦³´Á«Ý¡A ¤£¬O¶Wµu½uªº |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/8/20 ¤U¤È 04:48:26
²Ä 3345 ½g¦^À³
|
¤£·|¦³´£²¼¤H¼Æ¤£°÷ªº°ÝÃD ì«h¤W¨Ì¨È·à±d¤jªÑªF«ùªÑ¨ä¹ê´N¬O¥LÌ»¡¤Fºâ §Ṳ́pªÑªF¥u¬O¦b§ëªí¹F¤ßÁnªº ¹L»P¤£¹L³£¬Ý¤jªÑªFªº
¸Ü»¡®Ú¥»¤£¥ÎºÞ²{¦bº¦°±ÁÙ¶^°± ¦pªG³£¥´ºâ¸ò¨ì¨º´µ¹F§J¥h ´N¬O±Mª`¦b¨È·à±d«áÄòªºªí²{ §Ú¤]¿ï¾Ü¬Û«H¤½¥q ½ß³£½ß¤F¡A·íµMnª±¨ì³Ì«á |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/20 ¤U¤È 02:29:14
²Ä 3344 ½g¦^À³
|
½Ð°Ý¤½¥qn¶i¦æªºµ{§Ç»ÝnªÑªF§ë²¼ªí¨Mªº´£®×¡A·|¤£·|¦³°Ñ»P¤H¼Æ¤£°÷ªº°ÝÃD¡A¦pªG¦³¡A¦Ó¥B§ë²¼¤H¼Æ¤£°÷®É¡A«ç»ò¸Ñ¨M |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/20 ¤U¤È 01:44:40
²Ä 3343 ½g¦^À³
|
ªÑ»ù¤µ¤é¶^°±¡A¨ì²{¦bÁÙ¨S¨M©wn¤£n¸ò¥h¬ü°ê¶Ü¡Hª±³o´X¤Ñªºµu½u¡AÁȪº¨ì¿ú¶Ü¡HºÃ°Ý |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/20 ¤U¤È 01:36:45
²Ä 3342 ½g¦^À³
|
¤À¤l:³Q¨ÖÁÊ»ù¤£¨ü¼vÅT/¤À¥À : Á`¼â¦æªÑ¥÷𣎴ÅÜ
°²³]¤µ¤Ñ ³Q¨ÖÁÊ21»õ¬ü¤¸ ªÑ²¼µo¦æ¶q 189,955 ±i
21x29.5/18.955x10=326¤¸¥x¹ô/ªÑ
326x5/29.5=55¬ü¤¸/ªÑ¡X-ADR
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥H¤WªÑªFÅv¯q¬Ò¤£ÅÜ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/20 ¤U¤È 01:16:57
²Ä 3341 ½g¦^À³
|
¬Ý¤£¤ÓÀ´¡A¬OªÑ»ù·|ÅÜ«K©yªº·N«ä¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/20 ¤U¤È 12:19:17
²Ä 3340 ½g¦^À³
|
2020¦~²Ä¤G¦¸ªÑªFÁ{®É·|¤â¥U
²Ä¥|®× ®×¥Ñ: ÀÀ´î¤~¤Ö¥»¤½¥qÃB©w¸ê¥»®×----conditional approval »¡©ú:
3.ªÑªF¹ï©ó¨äªÑ¥÷¤§Åv§Q¨Ã¤£¨ü¨ì¨CªÑ±ÃB»ù®æ§ïÅܤ§¼vÅT.
(ªÑ®ßÁ`µo¦æ¶q¤£ÅÜ ,¥Ø«e¤vµo¦æ189,955±i(¤dªÑ))
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/20 ¤U¤È 12:04:59
²Ä 3339 ½g¦^À³
|
ªÑ²¼±ÃB´î¬° 0.01¬ü¤¸¡A µo¦æªÑ¼Æ¤£ÅÜ 189,955±i(¤dªÑ)¡C
CEO «ÜÁo©ú, ¡I
¸Ô¨£ ¤½¶}¸ê°T¯¸ , 9¤ë5¤é Á{®ÉªÑªF·|¡A¸ê®Æ
doc.twse.com.tw/server-java/t57sb01?step=1&colorchg=1&co_id=6497&year=109&mtype=F& |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G·P°Ê£®10141081 |
µoªí®É¶¡:2020/8/20 ¤W¤È 11:51:39
²Ä 3338 ½g¦^À³
|
¤½¥q²×©ó¤½§i«áÄòn¶i¦æªºµ{§Ç¤F ¤»Ó¤½§i¦³¤TÓ¬OÃö©ó¸ê¥»ÃB©M´î¸êªº°ÝÃD,ªí¥Ü³o«Ü«n ¤§«e¦³¤HÁ|¤F¤@¨Ç²z¥Ñ»¡¤½¥q°õ¦æªø¤£¬O¶Ì¥Ê,µ´¹ï¤£·|´î¸ê ²{¦b¨Æ¹ê³Ó©ó¶¯ÅG,½Ö¤~¬O¶Ì¥Ê
ÁÙ¬O¨º¤@¥y¦Ñ¸Ü ¦Û¤vn·Q²M·¡²{¦bªº«ùªÑ¨ì©³¦³¤°»ò·N¸q ÁÙ¦³¥¼¨Ó§A¦pªG¦³¾÷·|°Ñ»P¼W¸êªº¸Ü,ÁÙ¥i¥H¦A§ë¤J¦h¤Ö¿ú ¤£n¥u¬Ý¨ì»PADRªº»ù®t,¤]¤£n¥u¬Ý¨ì³Ìªñ¥~¸êªº¶R¶i ¦]¬°³o¨Ç³£¬O·|Åܤƪº,¦ý¬O·|p¤W²bȬOt¼Æ¬O³Ì¯u¹êªº ¥¼¨Óªºµo®i¦³¨S¦³¾÷·|±q¤£¦nÅܦn,·íµM¬O¦³,¥u¬O¾÷²v¨Ã¤£²M·¡ ¦Ó³oºØÅܤƷ|«Ü¤jªº±¡ªp´Nªí¥Ü½ä©Ê«Ü¤j ¦Ó§A¥´ºâ½ä¦h¤j,¦pªG³Ì²×¥i¯àÂk¹sªº¸Ü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/20 ¤W¤È 11:48:01
²Ä 3337 ½g¦^À³
|
REGN ªÑ»ù&¾ú¥v¨Æ¥ó
2011¦~ 1¤ë3 ¤é,ªÑ»ù34¬ü¤¸/ªÑ»ù¥«È¬ù34»õ¬ü¤¸
11¤ë1¤é,ªÑ»ù56¬ü¤¸/ªÑ»ù¥«È¬ù56»õ¬ü¤¸-----a
11¤ë©³ Eylea FDA ®Öã¤W¥«.
(Lucentis 2011¦~¾P°â20~24»õ¬ü¤¸/¦~, Eylea ¥H 16,000¬ü¤¸/¦~Àøµ{¶O¤W¥«,¬°Lucentis 24,000 ¬ü¤¸/¦~Àøµ{¶Oªº66%.
¦X²z¥«³õ¹w¦ô Eylea , 30»õ¬ü¤¸*66.6%=20»õ¬ü¤¸³Ì°ª¾P°â.-----a
--------------------------------------- 2012¦~ 1¤ë3¤é ,ªÑ»ù65 ¬ü¤¸/ªÑ/ªÑ»ù¥«È¬ù65»õ¬ü¤¸ -----b
ªÑ»ù¥«È/³Ì°ª¾P°â, b/a=65/20=3.25¿
4¤ë23¤é,ªÑ»ù140¬ü¤¸/ªÑ»ù¥«È¬ù140»õ¬ü¤¸
2013¦~ 5¤ë13¤é,ªÑ»ù266¬ü¤¸/ªÑ//¥«È¬ù266»õ¬ü¤¸ ,(¤½¥¬/Eylea 2012¦~ À禬8»õ¬ü¤¸) 9¤ë30¤é,ªÑ»ù308¬ü¤¸/ªÑ/¥«È¬ù30»õ¬ü¤¸ ,(¤½¥¬2013¦~Q3À禬)----¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸)
2014¦~ 7¤ë dupilumab 2b Á{§Éµ²ªG¥¿¦V 2014¦~10¤ë6¤éªÑ»ù343¬ü¤¸/ªÑ/¥«È¬ù343»õ¬ü¤¸ 11¤ë dupilumab ÀòBTD(¬ð¯}©ÊÀøªk)-----¤ÀªR®v¦ôdupilumab ¥¼¨Ó³Ì°ª¾P°â50»õ¬ü¤¸
12¤ë29¤éªÑ»ù427¬ü¤¸/ªÑ/¥«È¬ù427»õ¬ü¤¸
2015¦~8¤ë10¤é579¬ü¤¸/ªÑ/¥«È¬ù579»õ¬ü¤¸
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(REGN----Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35// 2012¡V24.00//8.70**B/A=36%**32.7 ¡]Eylea 2011,11¤ë FDA ®Öã¤W¥«) 2013¡V39.53//20.43**B/A=51%**50.96¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis))
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/20 ¤W¤È 08:47:42
²Ä 3336 ½g¦^À³
|
×¥¿-1
1.Temasek Holdings (Private) Limited 1,422,475 Jun 29, 2020 2.Sio Capital Management, LLC 1,376,954 Jun 29, 2020(1,294¤dªÑ 3¤ë©³,2020)
finance.yahoo.com/quote/ASLN/holders?p=ASLN
¨È·à±dADR(¬ù12,000 ¤dªÑ) ,²Ä¤G¤jªÑªFSio Capital Management, LLC ,«ùªÑ¤W©u¼W¥[ªñ¶È6.3%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/20 ¤W¤È 08:29:48
²Ä 3335 ½g¦^À³
|
1.Temasek Holdings (Private) Limited 1,422,475 Jun 29, 2020 2.Sio Capital Management, LLC 1,376,954 Jun 29, 2020
finance.yahoo.com/quote/ASLN/holders?p=ASLN
¨È·à±dADR(¬ù12,000 ¤dªÑ) ,²Ä¤G¤jªÑªFSio Capital Management, LLC ,«ùªÑ¤W©u¼W¥[ªñ100%.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gellelin10138869 |
µoªí®É¶¡:2020/8/20 ¤W¤È 07:49:22
²Ä 3334 ½g¦^À³
|
¹q¤l§ë²¼¤º®e¥X¨Ó¤F~ ½Ð°Ý¦U¦ì¤j¤j¡A¸Ó«ç»ò¿ï¾Ü¹ïªÑªF³Ì¦³§Q©O¡H («e´£¬O¤ä«ù¦b¥xÆWºM¾P¤½¶}µo¦æ¨ÃÂà´«ADR)
1~ ÀÀ²×¤î¥»¤½¥q¦b¥x¤½¶}µo¦æ®× ¡C (««×¨Mij)
2 ~ ÀÀ×q¥»¤½¥q¤½¥q³¹µ{®× (¯S§O ¨Mij)-conditional approval ©óºM¾P¤½ ¶}µo¦æ«á¤§±ø¥ó«¬¨Mij ¡C
3~ÀÀ«·s¦W¥Ø¥»¤½¥qÃB©w¸ê¥»®× (´¶³q¨Mij) -conditional approval ©ó ºM¾P¤½¶}µo¦æ«á¤§±ø¥ó«¬¨Mij ¡C
4 ~ ÀÀ´î¤Ö¥»¤½¥qÃB©w¸ê¥»®× (¯S§O
¨Mij)-conditional approval ©óºM¾P¤½ ¶}µo¦æ«á¥BÀò±o¶}°Ò¸s®q¤jªk°| ®Öã´î¸ê©R¥O«á¤§±ø¥ó«¬¨Mij ¡C
5~ÀÀ©óÀò±o¶}°Ò¸s®q¤jªk°|®Öã´î ¸ê©R¥O«á , ¥H°Æ¥»§Î¦¡¥¿¦¡¨ú¥N ¤Wz×q«á¤§¥»¤½¥q¤½¥q³¹µ{®× (¯S§O¨Mij) - c o n d i ti onal approval©ó ºM¾P¤½¶}µo¦æ«á¥BÀò±o¶}°Ò¸s®q ¤jªk°|®Öã´î¸ê©R¥O«á¤§±ø¥ó«¬¨Mij
6~ÀÀ½Ð¨D»OÆW¶°¤¤«OºÞµ²ºâ©Ò¨ó §U,±N¥»¤½¥qªÑªFÃÒ¨é±b¤á¤¤¨È ·à±d¤@K¤X´¶³qªÑªÑ¼Æ¥þ¼ÆÂà¦Ü ªÑªFµn¿ý±b¤U , ¥H§Q¨È·à±d¤@K ¤X¥xÆW°õ¦æ³æ¦ì¥H¤À¤äµn°O³B¤§ ¨¥÷ , ¨Ì·Ó¥»¤½¥q³¹µ{¤Î¬ÛÃö¥U ¦aªk¥O , «áÄò¥Nªí¥»¤½¥q¤Î¶}°Ò µn°O³B¶i¦æªÑªF¦W¥U¤§ºûÅ@¤ÎºÞ²z
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/20 ¤W¤È 07:19:12
²Ä 3333 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
Ë¼Æ²Ä 3 Ó¥æ©ö¤ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/19 ¤U¤È 03:13:45
²Ä 3332 ½g¦^À³
|
www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw
¤µ¤Ñ¥~¸ê¶R¶W495±i ¡Aªñ¤@¥b¦¨¥æ¶q¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/19 ¤W¤È 06:23:29
²Ä 3331 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
Ë¼Æ²Ä 4 Ó¥æ©ö¤ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/18 ¤U¤È 03:10:59
²Ä 3330 ½g¦^À³
|
www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw
¥~¸ê¤µ¤Ñ¶R¶W ¨È·à 268±i¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/18 ¤W¤È 08:47:53
²Ä 3329 ½g¦^À³
|
Kevzara Approval History
FDA Approved: Yes (First approved May 22, 2017) Brand name: Kevzara Generic name: sarilumab Dosage form: Injection Company: Sanofi and Regeneron Pharmaceuticals, Inc. Treatment for: Rheumatoid Arthritis
Kevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). www.drugs.com/history/kevzara.html
Kevzara¼f§å¾ú¥v
FDA§åã¡G¬O¡]2017¦~5¤ë22¤éº¦¸§åã¡^ «~µP¦WºÙ¡GKevzara ³q¥Î¦WºÙ¡Gsarilumab ¾¯«¬¡Gª`®g¾¯ ¤½¥q¦WºÙ¡GSanofi and Regeneron Pharmaceuticals¡AInc. ªvÀø¡GÃþ·ÀãÃö¸`ª¢
Kevzara¡]sarilumab¡^¬O¤@ºØ¥Õ¤¶¯À6¡]IL-6¡^¨üÅé«ú§Ü¾¯¡A¾A¥Î©óªvÀø¹ï¤@ºØ©Î¦hºØ¯e¯f½w¸Ñ©Ê§Ü·ÀãÃÄ¡]DMARDs¡^ªº¤ÏÀ³¤£¨¬©Î@¨ü¤£¨}ªº¤¤«×¦Ü««×¬¡°Ê©ÊÃþ·ÀãÃö¸`ª¢ªº¦¨¦~±wªÌ ¡C
investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2020-financial-and-operating
REGN, 2020 Q2°]³ø
¤W¥b¦~²ÖpÀ禬
1.EYLEA(a) 36»õ¬ü¤¸(2011¦~,11¤ë FDA ®Öã¤W¥«,ªvÀø ²´·ú¶À´³³¡¯fÅÜ...µ¥AMD.¦~¾P°â¦¨ªø²v0% 2.Dupilumab 18»õ¬ü¤¸(2017,3¤ë FDA ®Öã¤W¥«,ªvÀøAD/ý³Ý/COPD),¦~¾P°â¦¨ªø²v93% 5.Kevzara 1.3 »õ¬ü¤¸(2017,5¤ë FDA ®Öã¤W¥«¡AªvÀøRA:Ãþ·ÀãÃö¸`ª¢),¦~¾P°â¦¨ªø²v39%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/18 ¤W¤È 06:58:28
²Ä 3328 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
Ë¼Æ²Ä 5 Ó¥æ©ö¤ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/17 ¤U¤È 08:26:54
²Ä 3327 ½g¦^À³
|
110»õ¬ü¤¸¾P°â¡X¡X×¥¿1
±ÂÅv¦X¬ù=±ÂÅvª÷55»õ¬ü¤¸¡Ï¾P°â¤À¼í
§é²{È 75»õ¬ü¤¸¡A ¨ä¤¤ ¨È·à50»õ¬ü¤¸¡ACSL25»õ¬ü¤¸ (³Q¨ÖÁÊ»ùÈ) 50x29.5/22=670¤¸/ªÑ(¥x¹ô) 670x5/29.5=113¬ü¤¸/ªÑ
110»õ¬ü¤¸ªº¾P°â¹w´ú¡A ¦p©ñ¦b2013¦~8¤ëªºREGN Eylea 47»õ¬ü¤¸¡ÏDupilumab 50»õ¬ü¤¸ ,¨ä¥L13»õ¬ü¤¸
·í®É³Ì°ª¥«È560»õ¬ü¤¸¡C562.5¬ü¤¸/ªÑ
www.marketwatch.com/investing/stock/regn?mod=mw_quote_switch
ASLAN004 ©ñ¤W°ê»Ú¥h½æ75»õ¬ü¤¸¡Aµ´¹ï·m¤â¡I
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¥u¬O 2022¦~Dupilumab ¹w¦ôÀ禬 80»õ¬ü¤¸¡C
¨È·à±ÂÅv¦X¬ù n½Í110»õªº³Ì°ª¾P°â°ò¦¦³ÂIÃø«×¡C
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¦ý110x64%=70»õ ¬ü¤¸ªºASLAN004³Ì°ª¾P°â¡A¥Ø«e¬Ý¨Ó±N»´ÃP¹F¦¨¡I ±ÂÅv¦X¬ù=35»õ±ÂÅvª÷¡Ï¾P°â¤À¼í §é²{È50»õ¬ü¤¸ ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¨È·à¤À32»õ¬ü¤¸¡]AD21e¡Ï2b 4e¡Ïý³Ý/copd 7e)¡X¡X³Q¨ÖÁÊ»ùÈ CSL18»õ¬ü¤¸
32x29.5/22=429 ¤¸/ªÑ (¥x¹ô) 429x5/29.5 =72¬ü¤¸/ªÑ¤@¤@¤@ADR ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X
70e~110e ³Ì°ª¾P°âª÷ÃB ¡A±ÂÅv¦X¬ù
35e~55 e¬ü¤¸ ±ÂÅvª÷¡Ï¾P°â¤À¼í¡C¤@¤@¤@¥i³Q´Á«Ý¡C ¡X¡X¡X- ¥H¤W ¨Ì¾ÚASLAN004 ¥|¶g¤@°w/x416 ¶g¡AÁ`¾¯¶q1600mg ¥H¤U¡A¦~«×Àøµ{¶O¥Î20,000¬ü¤¸¡A¬°Dupilumab 31,200¬ü¤¸¥X¼t»ù®æ 64%
¡X¡X¡X- |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/17 ¤W¤È 07:23:45
²Ä 3326 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
Ë¼Æ²Ä 6 Ó¥æ©ö¤ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/15 ¤U¤È 03:45:43
²Ä 3325 ½g¦^À³
|
110»õ¾P°â
±ÂÅv¦X¬ù=±ÂÅvª÷55»õ¬ü¤¸¡Ï¾P°â¤À¼í
§é²{È 60»õ¬ü¤¸¡A ¨ä¤¤ ¨È·à40»õ¬ü¤¸¡ACSL20»õ¬ü¤¸ (³Q¨ÖÁÊ»ùÈ)
2022¦~Dupilumab ¹w¦ôÀ禬 80»õ¬ü¤¸¡C
¨È·à±ÂÅv¦X¬ù n½Í110»õªº³Ì°ª¾P°â°ò¦¦³ÂIÃø«×¡C
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X-
¦ý110x64%=70»õ ¬ü¤¸ªºASLAN004³Ì°ª¾P°â¡A¥Ø«e¬Ý¨Ó±N»´ÃP¹F¦¨¡I ±ÂÅv¦X¬ù=35»õ±ÂÅvª÷¡Ï¾P°â¤À¼í §é²{È50»õ¬ü¤¸ ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¨È·à¤À32»õ¬ü¤¸¡]AD21e¡Ï2b 4e¡Ïý³Ý/copd 7e)¡X¡X³Q¨ÖÁÊ»ùÈ CSL18»õ¬ü¤¸
32x29.5/22=429 ¤¸/ªÑ (¥x¹ô)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/15 ¤U¤È 02:29:44
²Ä 3324 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j¡A«ö¦¹±À¦ô¦X²zªº¨ÖÁÊ»ùÀ³¸Ó¬O¦h¤Ö |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/15 ¤U¤È 12:26:37
²Ä 3323 ½g¦^À³
|
¼ÒÀÀ2030¦~ ¡ADupilumab 88»õ¬ü¤¸¤ÎASLAN004 110»õ¬ü¤¸¾P°â ¡K¡K¡K¡K¥¼¨ü±±AD¥«³õ渗³z²v约30%¡K¡K¡K¡K ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Dupilumab ³Ì°ª¾P°â110»õ¬ü¤¸¡K¡K2029¦~ ¬ü°ê¦û75% AD¦û75% 40%Â÷¶}²v¡A¥§¡¨Ï¥Î¥b¦~¡AÂ÷¶}²v20% AD¦~Àøµ{费3.12¸U(¥X¼t»ù) 110¡Ñ75%x75%/3.12¸U¬ü¤¸/80%=25¸U¤H¦~
¥¼¨ü±±¨îAD¬ü°ê¦¨¦~¤H¦ôp160¸U¤H¡C °²³]¥¼¦¨¦~¥¼¨ü±±¨î为¦¨¦~¤H25%,40¸U¤H ¦Xp200¸U¤H¡C
25/200¸U¤H=12.5%______¬ü°ê¥¼¨ü±±AD¥«Ô·渗³z²v¡C
¦]¦¹ASLAN004¤W¥«¡A¥Î64%ªºDupilumab¦~Àøµ{费(2¸U¬ü¤¸/¦~)/¤@¥bªº¥´°w¦¸(¥|¶g¤@°w)¡C ¤Á¤J¥«场¡C¹F销°â110»õ¬ü¤¸¡C Â÷¶}²v10%
110¡Ñ75%¡Ñ75%/2/90%=34.4¸U¤H
34.4+25=59.4 59.4/200=30%¡K¡K¡K2029¦~¡A ¬ü°ê¥¼¨ü±±AD¡A¥«³õ¥i¯à渗³z²v¡C
2030¦~Dupilumab ¾P°â¥i¯à°¬°88»õ¬ü¤¸(±M§Q¨ì´Á¡A°â»ù¥´80%) ¦ÓASLAN004¥i¯à为110»õ¬ü¤¸¡C¦Xp¥þ²y198»õ¬ü¤¸¡C
¥¼¨ü«ö¥«³õ渗³z²v30%
¥H¤W¼ÒÀÀ¡A°Ñ¦Ò ASLAN004 ¥¼¨Ó¥HDupilumab*64%¦~Àøµ{¶O¤W¥«,¥i±æÂX¥RAD/ý³Ý¥«³õ
¦]¦¹2022¦~ ASLAN004 ñ±ÂÅv¦X¬ù,±N¥i¯àÀu©ó³Q¨ÖÁÊ»ùÈ.
------ ¥¼º¡¨¬¥«³õ,°»ù¬O¦³¥Îªº,¥i¤j´TÂX¥R¥«³õ.
2015 Lucentis ³Ì°ª¾P°â43»õ¬ü¤¸ 2019¦~ ¨âÃľP°â¦Xp119»õ¬ü¤¸
¨ì2019¦~¥«³õ¼W¥[119-43=76»õ¬ü¤¸
76/43=176% ¼W¥[²v.-----(¥¼º¡¨¬¥«³õ,°»ù¬O¦³¥Îªº)
2012: Eylea ¤W¥«²Ä¤@¦~¾P°â¬°Lucentis¤w¤W¥«6¦~ 36%. 2013: Eylea ¤W¥«²Ä¤G¦~¾P°â¬°Lucentis¤w¤W¥«7¦~ 51%. 2014: Eylea ¤W¥«²Ä¤T¦~¾P°â¬°Lucentis¤w¤W¥«8¦~ 65%. 2015: Eylea ¤W¥«²Ä¥|¦~¾P°â¬°Lucentis¤w¤W¥«9¦~ 120%.
2012 ¨âÃľP°â¦Xp32.7»õ¬ü¤¸ 2013 ¨âÃľP°â¦Xp50.96»õ¬ü¤¸ 2015 ¨âÃľP°â¦Xp74.8»õ¬ü¤¸ 2016 ¨âÃľP°â¦Xp88.38»õ¬ü¤¸ 2019 ¨âÃľP°â¦Xp119»õ¬ü¤¸
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70**B/A=36%**32.7 --------(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43**B/A=51%**50.96 ¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38**B/A=161%**88.38 2017¡V33.00//62.82**B/A=190%**95.82 2018¡V37.00//67.00**B/A=11%**104 2019¡V41(¦ô)//78.52**B/A=191%**119
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AMD¡X¡X°w¾¯ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/15 ¤W¤È 08:32:56
²Ä 3322 ½g¦^À³
|
«ùªÑÁ`¤H¼Æ3543¤H,¤ñ¤W¶g 3839¤H´î¤Ö 296¤H
¤@.1-50±i«ùªÑ¤W¶g19193±i/3665¤H ----¥»¶g«ùªÑ17565±i/3360¤H(§t112¤H¹sªÑ), ¤ñ¤W¶g´î¤Ö1628±i,´î¤Ö305¤H.
----¥»¶g50±i¥H¤W«ùªÑ«ùÄò¼W¥[,¼W¥[1628±i ¤G¡B.¥»¶g¥~¸ê¶R¶W¼W¥[:267±i
ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~08¤ë14¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 112 10,959 0.00 2 1,000-5,000 2,426 4,884,828 2.57 3 5,001-10,000 395 3,247,529 1.70 4 10,001-15,000 150 1,965,106 1.03 5 15,001-20,000 112 2,139,000 1.12 6 20,001-30,000 99 2,578,549 1.35 7 30,001-40,000 36 1,341,547 0.70 8 40,001-50,000 30 1,401,000 0.73 9 50,001-100,000 72 5,398,368 2.84 10 100,001-200,000 42 6,316,483 3.32 11 200,001-400,000 22 5,955,850 3.13 12 400,001-600,000 14 6,837,967 3.59 13 600,001-800,000 2 1,465,000 0.77 14 800,001-1,000,000 6 5,427,155 2.85 15 1,000,001¥H¤W 25 140,985,629 74.22 ¦X¡@p 3,543 189,954,970 100.00
ÃÒ¨é¥N¸¹¡G6497 ÃÒ¨é¦WºÙ¡G¨È·à±d-KY ¸ê®Æ¤é´Á¡G109¦~08¤ë07¤é §Ç «ùªÑ/³æ¦ì¼Æ¤À¯Å ¤H¡@¡@¼Æ ªÑ¡@¡@¼Æ/³æ¦ì¼Æ ¥e¶°«O®w¦s¼Æ¤ñ¨Ò (%) 1 1-999 110 11,106 0.00 2 1,000-5,000 2,644 5,366,317 2.82 3 5,001-10,000 448 3,699,523 1.94 4 10,001-15,000 162 2,104,372 1.10 5 15,001-20,000 130 2,456,000 1.29 6 20,001-30,000 102 2,682,549 1.41 7 30,001-40,000 37 1,371,652 0.72 8 40,001-50,000 32 1,504,000 0.79 9 50,001-100,000 67 4,944,368 2.60 10 100,001-200,000 39 5,757,483 3.03 11 200,001-400,000 20 5,327,849 2.80 12 400,001-600,000 14 6,911,967 3.63 13 600,001-800,000 3 2,195,000 1.15 14 800,001-1,000,000 6 5,397,155 2.84 15 1,000,001¥H¤W 25 140,225,629 73.82 ¦X¡@p 3,839 189,954,970 100.00
www.tdcc.com.tw/smWeb/QryStockAjax.do |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/14 ¤U¤È 01:55:01
²Ä 3321 ½g¦^À³
|
ASLAN004¦³¼ç¤O¦¨¬°¦P¯e¯f³Ì¨ÎÀøªk ¤@¡B IL-13R£\1 §í¨î¾¯ : ASLAN004¬O°ß¤@Âê©wIL-13R£\1ªº³æ®è§ÜÅé¡A¦³¼ç¤O¦¨¬°ªvÀø²§¦ì©Ê ¥Ö½§ª¢»P®ð³Ý¤§³Ì¨ÎÀøªk ¤G¡B¾÷Âà¡]M〇A¡^¤wÀòÃÒ¹ê : »PdupilumabÂê©w¬Û¦Pªº¸ô®|»P¨üÅé½Æ¦XÅé ¡]20¸U¤H¤wÅçµý¡A¥¼¨Ó³Ì°ª¦~¾P°â110»õ¬ü¤¸) ¤T¡BÂê©w¥«³õ°Ï¹j®ÄªG : ¨ãÀø®Ä¼W¶i¤§¼ç¤O¡B´î¤Ö¤£¨}¤ÏÀ³(µ²½¤ª¢) ¡B¨C¤ëµ¹ÃĤ@¦¸
p.7
aslanpharma.com/app/uploads/2020/05/20-05-19-ASLAN-CN.pdf 5¤ë26¤é ¤½¥q²¤¶¡A¤¤¤åª©¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/14 ¤U¤È 12:13:49
²Ä 3320 ½g¦^À³
|
¨Ì¤½¥q²¤¶ ASLAN004 MOA ¤w½T»{,
¦Pdupilumab ¥iªýÂ_ II«¬¨üÅé½Æ¦XÅ餧²Õ¦¨,¦Ó¦P®É¥iªýÂ_IL-4/IL-13 Âù¼Ð¹v°T¸¹¶Ç»¼. --------------------------------------------------
²Ä¥|©uASLAN004 ¸Ñª¼ªº3²Õ(200mg/400mg/600mg)¼Æ¾Ú, ¨C¶g¤@°w*8 ¶g
¥§¡ESAI°´T, ESAI-50, ESAI-75.------8¶g ¨¬¥H¹F³Ì¨Îª¬ªp
ESAI-90, IGA,0/1(¬O§_8¶g¯à¹F³Ì¨Î? ¥¼ª¾)
¥i°Ñ¦Ò¥H¤UDupilumab ¦U´ÁÁ{§É¼Æ¾Ú¡C ¨C¶g¤@°wªº³¡¥÷:
1. Dupilumab ¦´Á¥|Ó AD Á{§É 4¶g/12¶g , 2014/07/10
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
www.nejm.org/doi/10.1056/NEJMoa1314768
2. Dupilumab 2a/2b Á{§É ,2018/SEP
journals.lww.com/jaanp/Fulltext/2018/09000/Efficacy_and_safety_of_dupilumab_for_the_treatment.10.aspx
3.Dupilumab AD 2Ó¤T´ÁÁ{§É, 300mg/¨C¶g¤@°w/300mg/¨C¤G¶g¤@°w 2016/12/15
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis www.nejm.org/doi/full/10.1056/nejmoa1610020 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/14 ¤W¤È 11:32:12
²Ä 3319 ½g¦^À³
|
¥¼º¡¨¬¥«³õ,°»ù¬O¦³¥Îªº,¥i¤j´TÂX¥R¥«³õ.
2015 Lucentis ³Ì°ª¾P°â43»õ¬ü¤¸ 2019¦~ ¨âÃľP°â¦Xp119»õ¬ü¤¸
¨ì2019¦~¥«³õ¼W¥[119-43=76»õ¬ü¤¸
76/43=176% ¼W¥[²v.-----(¥¼º¡¨¬¥«³õ,°»ù¬O¦³¥Îªº)
2012: Eylea ¤W¥«²Ä¤@¦~¾P°â¬°Lucentis¤w¤W¥«6¦~ 36%. 2013: Eylea ¤W¥«²Ä¤G¦~¾P°â¬°Lucentis¤w¤W¥«7¦~ 51%. 2014: Eylea ¤W¥«²Ä¤T¦~¾P°â¬°Lucentis¤w¤W¥«8¦~ 65%. 2015: Eylea ¤W¥«²Ä¥|¦~¾P°â¬°Lucentis¤w¤W¥«9¦~ 120%.
2012 ¨âÃľP°â¦Xp32.7»õ¬ü¤¸ 2013 ¨âÃľP°â¦Xp50.96»õ¬ü¤¸ 2015 ¨âÃľP°â¦Xp74.8»õ¬ü¤¸ 2016 ¨âÃľP°â¦Xp88.38»õ¬ü¤¸ 2019 ¨âÃľP°â¦Xp119»õ¬ü¤¸
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) PK ¡X- A:Lucentis) //B:(Eylea)**B/A**¦XpA+B 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70**B/A=36%**32.7 --------(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43**B/A=51%**50.96 ¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00**B/A=65%**71 2015¡V34.00//40.8.00**B/A=120%**74.8 (Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38**B/A=161%**88.38 2017¡V33.00//62.82**B/A=190%**95.82 2018¡V37.00//67.00**B/A=11%**104 2019¡V41(¦ô)//78.52**B/A=191%**119
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AMD¡X¡X°w¾¯ Ävª§¥v¡]ªvÀø¡X²´·ú¶À¯Z³¡¯fÅÜ¡^ ¤@¡BLucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ¡A¨C¤ë¤@°w¡A¨C¦~24,000¬ü¤¸Àøµ{¶O¥Î
¤G¡BEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A¨C2¤ë¤@°w¡A¨C¦~16,000¬ü¤¸Àøµ{¶O¥Î¡C
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) ¡X- Lucentis//Eylea 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00 2015¡V34.00//40.8.00(Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38 2017¡V33.00//62.82 2018¡V37.00//67.00 2019¡V????//78.52
Lucentis¡]Ranibizumab¡^ ©MEylea¡]aflibercept¡^ ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C
¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/14 ¤W¤È 11:27:30
²Ä 3318 ½g¦^À³
|
¬Ý¨Ó¥u¦³¾a004I¤ô¤@¾Ô¤F¡A¦Ó¥B³Ì²×³Q¨ÖÁʬO³Ì§¹¬üªºµ²§½ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/14 ¤W¤È 07:54:30
²Ä 3317 ½g¦^À³
|
ªÚ»ÖL¨üÅé«ú§Ü¾¯¡A2006¦~¦³¤H°µ1bÁ{§É¡A«á¨Ó没·sÁ{§É¡C ASLAN004 ¤½¥q¤w¼È°±³æÃĬã¨s¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/14 ¤W¤È 07:20:55
²Ä 3316 ½g¦^À³
|
½Ð±Ð¤Ñ©R¤j¡A¥Ø«e¤½¥q尙¦³ªÚ»ÖL¨üÅé«ú§Ü¾¯¡A»PASLAN003 ¤w¨ú±o¬ü°ê FDA ©t¨àÃĸê®æ»{©w¡A¥Bªñ´Á§¹¦¨¬ÛÃö¸ÕÅç¡A¥¿¦bµû¦ô¸ÓÃÄ¥¼¨Óµo®ipµe¡C³o¨â¼ËÁÙ¦³¾÷·|¯B¥X¤ô±¡A¬°¤½¥q³Ð³y»ùȶܡH |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/14 ¤W¤È 05:34:21
²Ä 3315 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
˼ƲÄ7Ó¥æ©ö¤ê¡C
¬Q¤é¥~资¶R¶W203±i¡C
MOA! MOA! MOA! ¡K¡KASLAN004 «¤¤¤§·¥«¡ADupilumabªº64%§é¦~Àøµ{费¤§·½¡A¥|¶g¤@针区¹j¨â¶g¤@针¤§¨Ì¾Ú¡C
Âù¼Ð¹v(IL-4/IL-13)§í¨î/¥@¬É°ß¤@¦PDupilumab¡A20¸U¤H¤wÅçÃÒ¡C ADý³Ý2029ºÙ¤ý¡C
¼¯¥§Ä_¯]Âéó¹Ð(ASLAN004¡K¡K2022±ÂÅv/¨ÖÁʬҩy) ¤@¤é¯}쯥X¤j¦a(2025«÷¤W¥«) ·Ó¯}¤sªe¤d¸U朶(¼Æ¦Ê¸U¤H¨ü´f) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤U¤È 11:05:08
²Ä 3314 ½g¦^À³
|
ASLAN004³Ì°ª¾P°â70»õ¬ü¤¸¤§¦ôºâ
Dupilumab 110»õ¬ü¤¸x64%=70»õ¬ü¤¸
ASLAN004 ¦ô5¦~«á¤W¥«¡A±NÀHEylea ¦bAMD¦æ¾Pµ¦²¤, q»ùx64% /¥´°wÀW²v´î¤Ö50% ,§C°Æ§@¥Î ¤W¥«©MDupilumabÄvª§ ¡A¦ôp¦b2029¦~Dupilumab ¬ü°ê12¦~ªº±M§Q´Á¨ì´Á¡AASLAN004 ±N¦¨¬°AD/ý³Ý ÅQ¥D¡C
ASLAN004 q»ù 19968¬ü¤¸ : Dupilumab ¦~Àøµ{¶O¥Î 31,200¬ü¤¸/¡]¥X¼t»ù) x64%=19,968¬ü¤¸ ¥´°wÀW²v: ASLAN004 ¥|¶g¤@°w VS. Dupilumab ¤G¶g¤@°w
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- AMD¡X¡X°w¾¯ Ävª§¥v¡]ªvÀø¡X²´·ú¶À¯Z³¡¯fÅÜ¡^ ¤@¡BLucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ¡A¨C¤ë¤@°w¡A¨C¦~24,000¬ü¤¸Àøµ{¶O¥Î
¤G¡BEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A¨C2¤ë¤@°w¡A¨C¦~16,000¬ü¤¸Àøµ{¶O¥Î¡C
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) ¡X- Lucentis//Eylea 2006(¤W¥«//) 2009¡V20.35//¡]Eylea 11¤ë FDA ®Öã¤W¥«) 2012¡V24.00//8.70(Eylea²Ä¤@¦~¾P°â, ¦~«×¶O¥Î16,000¬ü¤¸¨C2Ӥ르¤@°w vs Lu centis 24000¬ü¤¸/¨C¤ë¤@°w) 2013¡V39.53//20.43¡]2013/10¤ë¡A¤ÀªR®v¦ô2018/Eylea 47»õ¬ü¤¸) 2014¡V43.00//28.00 2015¡V34.00//40.8.00(Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38 2017¡V33.00//62.82 2018¡V37.00//67.00 2019¡V????//78.52
Lucentis¡]Ranibizumab¡^ ©MEylea¡]aflibercept¡^ ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C
¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤U¤È 03:16:21
²Ä 3313 ½g¦^À³
|
ir.aslanpharma.com/financial-information/sec-filings ¦b¤½¥qºô¯¸¤W¡A¦V¬ü°êµý´Á§½³ø§i¡A°]³ø¡B«°T¬Ò¦³¡C
^¤å¥ÎGoogle ½Ķ
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X
¤µ¤Ñ¥~¸ê¶R¶W203±i¡C
www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/13 ¤U¤È 03:03:29
²Ä 3312 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j¡A¥¼¨Ó¤U¥««á¤½¥qªºÀç¹B®ø®§·|¦b¥xÆWºô¯¸¤Wµo§G¶Ü¡HÁÙ¬O¥u¦³¦b¬ü°êµo§G¡Aì¤åªº¬Ý¤£¤ÓÀ´ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/13 ¤U¤È 12:31:08
²Ä 3311 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤W¤È 11:38:27
²Ä 3310 ½g¦^À³
|
ASLAN004 §@¥Î¾÷Âà MOA ASLAN004 ¬O¤@ºØ¥þ¤HÃþ³æ®è§ÜÅé¡A¥¦¯à±M¤@©Ê¦aµ²¦X©ó¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)¨üÅé½Æ¦XÅé¤WªºIL-13R£\1¦¸³æ¦ì¡A¶i¦Ó§í¨î¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)ªº°T®§¶Ç»¼¡C
ASLAN004¥i ªýÂ_²ÄIIÃþ¨üÅéµ²¦X,¦Ó¦P®É§í¨îIL-4¤ÎIL-13¤§°T®§¶Ç»¼¡C
ASLAN004 ªýÂ_¤¶¥Õ¯À-13 £\1¨üÅé(IL-13R£\1)¥i§í¨îIL-4 ¤ÎIL-13²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥]¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥ÕE (IgE)¡C
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/8/13 ¤W¤È 11:19:56²Ä 3308 ½g¦^À³ MOA : MECHANISM OF ACTION ,§@¥Î¾÷Âà
12.1 §@¥Î¾÷Âà Dupilumab¬O¤@ºØIgG4¤HÃþ³æ®è§ÜÅé¡A¥¦¯à±M¤@©Ê¦aµ²¦X©ó¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)¨üÅé½Æ¦XÅé¤WªºIL-4R£\¦¸³æ¦ì¡A¶i¦Ó§í¨î¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)ªº°T®§¶Ç»¼¡C
Dupilumab¥iÂǥѻP²ÄIÃþ¨üÅéµ²¦X¦Ó§í¨îIL-4°T®§¶Ç»¼¡A¥H¤ÎÂǥѻP²ÄIIÃþ¨üÅéµ²¦X¦Ó¦P®É§í¨îIL-4¤ÎIL-13¤§°T®§¶Ç»¼¡C DupilumabªýÂ_¤¶¥Õ¯À-4 £\¨üÅé(IL-4R£\)¥i§í¨îIL-4 ¤ÎIL-13²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥]¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥ÕE (IgE)¡C
www.ktgh.com.tw/Public/tbDrug/201905241612517055.pdf
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
----------------------------------
ASLAN004 ASLAN004¬°Âê©wIL-13¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤§¥þ¤H·½³æ®è§ÜÅé¡A¦¹ÃĨã³Æ¦¨¬°¦P¯Å³Ì¨ÎÀøªk¤§¼ç¤O¡C ASLAN004¬ã¨s¶i«×¥Ø«e¬°Á{§É«e¸ÕÅç¡A³z¹LÂê©wIL-13R£\1¡AASLAN004¥i¦P®É±j®Ä§í¨îinterleukin 4 (¥çºÙ§@IL-4) ¤Îinterleukin 13 (¥çºÙ§@IL-13) ªº°T¸¹¶Ç»¼¡CIL-4»PIL-13¦b¤Þµo²§¦ì©Ê¥Ö½§ª¢¹L±ÓÁ{§É¯gª¬ªº¾÷¨î¤¤§êºtÃöÁ䨤¦â¡A¨Ò¦pµo¬õ»P¥Ö½§·kÄo¡A¥ç¥i¯à³y¦¨®ð³Ý¡B©I§lµu«P¡Bý»ï¤Î«y¹Â¡C
Dupilumab°w¹ïªº¯e¯f¬°ÄY«²§¦ì©Ê¥Ö½§ª¢¤Î®ð³Ý¡C¥Ñ©óASLAN004Âê©wªº§@¥Î¾÷Âà»Pdupilumab¬Û¦ü¡A§Ú̬۫HASLAN004±N¥i´`»P¨ä¬Û¦üªº¼f¬d¬yµ{¨Ã¦¨¬°¦P¯Åº¨£ªºIL-13R£\1§í¨î¾¯¡C³z¹LÂê©w¦b¤HÅé²ÓM¤Wªº¤À¥¬½d³ò¸ûIL-4¨üÅé¤pªºIL-13R£\1¡AASLAN004¥i±æ´£¨Ñ¾¯¶q¸û§C»P¥ÎÃÄÀW²v¸û§C¤§µ¹ÃĤ覡¡A³z¹L³o¨Ç¥Ö¤Uª`®gªº¥Dn¯S¦â´£¨Ñ¯f±w§ó°ªªº«K§Q©Ê¡C¦¹¥~¡AASLAN004ªºµ²¦X¿ï¾Ü©Ê¸ûdupilumab¨Î¡A¦]¦¹§Ú̬۫HASLAN004¤Þ°_ªº°Æ§@¥Î¸ûdupilumab»´·L¡C¨È·à±d¤w±Ò°ÊASLAN004°w¹ï²§¦ì©Ê¥Ö½§ª¢ªº¤@´ÁÁ{§É¸ÕÅç¡C2019¦~²Ä¤G©u¤w°w¹ï°·±d§ÓÄ@¨ü¸ÕªÌ§¹¦¨³æ¤@¾¯¶q»¼¼W¸ÕÅç(SAD)Á{§É¸ÕÅç¡C¦b2019¦~10¤ë¡A§Ú̱ҰʤF¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢±wªÌªº¦h¾¯¶q»¼¼WÃĪ«¡]MAD¡^Á{§É¸ÕÅç¡C§Ú̹wp±N¦b2020¦~¤U¥b¦~µo§G´Á¤¤¼Æ¾Ú¡A¨Ã¹wp©ó2021¦~¤W¥b¦~§¹¦¨¸ÕÅç¡C
¨È·à±d¥¼¨Ó¥ç¥i¯à±NASLAN004°w¹ï¨ä¥Lµoª¢©Ê¾AÀ³¯g¶i¦æ¬ã¨s¡A¨Ò¦pºC©Êªý¶ë©ÊªÍ¯f (COPD)¡C¥»¤½¥q¦b2014¦~¤¤ë¦ÛCSL¨ú±oASLAN004¤§¥þ²y±ÂÅv¡C aslanpharma.com/zh/drug/aslan004/
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤W¤È 11:27:32
²Ä 3309 ½g¦^À³
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/8/12 ¤W¤È 08:12:11²Ä 3290 ½g¦^À³ 资°T¤£¹ïºÙ:
¤@¯ëÀù¯gMOA(§@¥Î¾÷Âà)¤§½T»{¡A须n2bÁ{§ÉÅçÃÒ©M¹ï·Ó组¥Dn«ü¼Ð¤ñ¸û PÈ<0.05¡C ----------------------------------------------- ¤¤-««×AD¼Ð¹v¡A¥Ñ©ó«D¼Ð¹v¹ï·Ó组ªº预«á«ü¼ÐESAI¥±`°´T·±20%¥ª¥k¡A¦Ó¼Ð¹vªºESAI¥§¡°´T¡ADupilumab¦b70%¥ª¥k¡A¬°¹ï·Ó组3.5¿¡A¦]¦¹nµý©úMOA·§©À©ÊÁ{§É¡A´£«e¨ì1b 50¤H¥H内¡C <0.05
¨È·àASLAN004¡AM0A«á¬q©Mdupilumab¬Û¦P¡Aªý断II«¬¨üÅéªý组¦¨¡A¦P®É¥i§í¨îÂù¼Ð¹vIL-4/IL-13°T¸¹¶Ç»¼¡C
¦]¦¹´£«e¦b1A¡A°·±d¤H42¤HªºÁ{§É¡A¥i´úªº§¹¥þ§í¨î¤U´å¤¶½èpSTAT6,¨Óµý©ú¤wªý断II«¬¨üÅé组¦¨¡C¦Ó½T»{MOA¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤W¤È 11:19:56
²Ä 3308 ½g¦^À³
|
MOA : MECHANISM OF ACTION ,§@¥Î¾÷Âà
12.1 §@¥Î¾÷Âà Dupilumab¬O¤@ºØIgG4¤HÃþ³æ®è§ÜÅé¡A¥¦¯à±M¤@©Ê¦aµ²¦X©ó¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)¨üÅé½Æ¦XÅé¤WªºIL-4R£\¦¸³æ¦ì¡A¶i¦Ó§í¨î¤¶¥Õ¯À-4 (IL-4)¤Î¤¶¥Õ¯À-13 (IL-13)ªº°T®§¶Ç»¼¡C
Dupilumab¥iÂǥѻP²ÄIÃþ¨üÅéµ²¦X¦Ó§í¨îIL-4°T®§¶Ç»¼¡A¥H¤ÎÂǥѻP²ÄIIÃþ¨üÅéµ²¦X¦Ó¦P®É§í¨îIL-4¤ÎIL-13¤§°T®§¶Ç»¼¡C DupilumabªýÂ_¤¶¥Õ¯À-4 £\¨üÅé(IL-4R£\)¥i§í¨îIL-4 ¤ÎIL-13²ÓM¿E¯À©Ò»¤µo¤§¤ÏÀ³¡A¥]¬AÄÀ©ñ«Pµoª¢²ÓM¿E¯À (proinflammatory cytokines)¡BÁͤƯÀ (chemokines)¤Î§K¬Ì²y³J¥ÕE (IgE)¡C
www.ktgh.com.tw/Public/tbDrug/201905241612517055.pdf
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/13 ¤W¤È 11:11:56
²Ä 3307 ½g¦^À³
|
®z®zªº½Ð±Ð¤Ñ©R¤j¡AMOA¬O¤°»ò·N«ä¡A¨º¬O¤@Ó¸g¹L°ê»Úªº¬YÓ»{ÃÒ¡A©Î¬O¤½¥q¬ã¨s¹êÅçµo²{½T»{ªº¤@ºØÀø®Ä¡A©Î²{¶H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤W¤È 09:29:18
²Ä 3306 ½g¦^À³
|
¦P¼ËÅÞ¿èASLAN004 ¦bAD ,¥|¶g¤@°wªº¦¨¥\²v,¦³¼ç¤O¦bÂù¼Ð¹v§í¨î¤U.
400mg/200mg/200mg /200mg ,IGA,0/1 ,p<0.001ªº¾÷·|°ª. ¦Ó«D¶ÈLebrikizumab IGA,0/1 <0.05, >0.01
1.Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
(¤G).250 mg Q4W(¥|¶g¤@°w),°_©l¶q500mg EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3%
*p<0.05, **p<0.01, and ***p<0.001 versus placebo www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤W¤È 08:16:46
²Ä 3305 ½g¦^À³
|
§Ü¤¶¥Õ¯À-4 ¤Î§Ü¤¶¥Õ¯À-13 ¥Íª«»s¾¯¥Î©óÄY««¬®ð³Ý MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
Lebrikizumab ±µ¦XIL-13 B.CÁ³±Û,©MIL-13 ¨üÅé¥i¥¿±`±µ¦X,¦ýµLªk¦A±µ©MIL-4¨üÅé,¦ÓªýÂ_IL-13°T¸¹¶Ç»¼.
ASLAN004 ±µ¦X¦bIL-13 ¨üÅé ,¼Æ¶qÀ³¤Ö©ó&±µªñLebrikizumab ±µ¦XIL-13 .
©Ò¥H·íLebrikizumab ,¶È§í¨îIL-4&³¡¥÷IL-13,¥H 37.5mg/¥|¶g¤@°w,¦³¤@Ó¤T´ÁÁ{§É p<0.01
µ´¹ï¥i¹w´úASLAN004 §í¨îÂù¼Ð¹vIL-4/IL-13 ,ý³Ý, 30mg/¥|¶g¤@°w*48¶g/12°w ¦¨¥\¾÷²v°ª. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤W¤È 07:53:52
²Ä 3304 ½g¦^À³
|
§Ü¤¶¥Õ¯À-4 ¤Î§Ü¤¶¥Õ¯À-13 ¥Íª«»s¾¯¥Î©óÄY««¬®ð³Ý MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M
Lebrikizumab ¨âÓ¤T´Áý³ÝÁ{§É¡A¦³¤@ÓPȹLÃö¡A¥t¤@ÓPȤ£¹LÃö¡C
¨CÓÁ{§É¡ALeb¬Ò¦³37.5mg&125mg,°_©l¶q250mg¨C¥|¶g¤@°w¡A48¶g¡C ¨âÓ¾¯¶q¥Dn预«á«ü¼ÐµL¤j®t²§¡C
37.5¡Ñ48+250=2050mg
Dupilumab 200mg¡Ñ11+400mg=2600mg(24¶g¡A2¶g¤@针¡A°_©l¶q400mg)
Lebrikizumab µLªk§¹¥þ§í¨îIL-4±µ¦XIL-4¨ü¾¹¡A¦A±µ¦XIL-13¨ü¾¹¡A¦Ó¦¨ªºII«¬¨ü¾¹¡CµLªk§¹¥þ§í¨îIL-4°T¸¹¶Ç»¼¡C©Ò¥HÀø®ÄµLªk¦Pdupilumab.
ASLAN004ý³Ý2a¥i¯à³]p
¥|¶g¤@针¡A120mg¡Ñ24/48¶g ¥|¶g¤@针, 30mgx24/48¶g |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/13 ¤W¤È 05:56:59
²Ä 3303 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
˼ƲÄ8Ó¥æ©ö¤ê¡C
MOA!MOA!MOA! «¤¤¤§·¥«¡ADupilumabªº64%§é¦~Àøµ{费¤§·½¡A¥|¶g¤@针区¹j¨â¶g¤@针¡C Âù¼Ð¹v(IL-4/IL-13)§í¨î¡A¥@¬É°ß¤@¦PDupilumab ADý³Ý2029ºÙ¤ý
¼¯¥§Ä_¯]Âéó¹Ð(2022±ÂÅv/¨ÖÁʬҩy) ¤@¤é¯}쯥X¤j¦a(2025«÷¤W¥«) ·Ó¯}¤sªe¤d¸U朶(¼Æ¦Ê¸U¤H¨ü´f)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤U¤È 04:26:49
²Ä 3302 ½g¦^À³
|
2013¦~Q3,¥«³õ¤ÀªR®v¡A¦ôEy1ea¡A¦b2018¦~±N销40»õ¬ü¤¸¡C
2018¦~¹ê»Ú销°â67»õ¬ü¤¸¡A REGNªÑ»ù¡A2011-11¤ë30¦h¬ü¤¸/ªÑ°_º¦¡A¨ì2015¦~2¤ë°ªÂI500¦h¬ü¤¸¨CªÑ¡C
Eylea-¦A¥Í¤¸©M«ô¦ÕÂåÃÄ«O°· ¥ÑCarly Helfand | 2013¦~10¤ë2¤é¤W¤È7:20 ¤À¨ÉFacebook Twitter LinkedIn¹q¤l¶l¥ó¥´¦L Eylea¡]aflibercept¡^ ¦A¥Í¤¸»sÃÄ©M«ô¦ÕÂåÃÄ«O°· µo¥¬¤é´Á¡G2011¦~11¤ë¡]¬ü°ê¡A¦A¥Í¤¸¡^¡F 2012¦~11¤ë¡]¼Ú·ù¡A«ô¦Õ¡^ ²Ä¤@¦~¾P°âÃB¡G8.38»õ¬ü¤¸¡]2012¦~¡A¦A¥Í¤¸¡^¡F 1400¸U¼Ú¤¸¡]2012¦~³¡¤À¡A«ô¦Õ¡^ 2013¦~¤W¥b¦~¾P°âÃB¡G6.437»õ¬ü¤¸¡]Regeneron¡^¡F 1.22»õ¼Ú¤¸¡]«ô¦Õ¡^ 2018¦~¤ÀªR®v¦ôp¡G47»õ¬ü¤¸
Eylea©ó2011¦~11¤ë¤W¥«®É¦³«Ü¦h«nªº¨Æ±¡¡Cº¥ý¡A¥¦»Ýnªº²´³¡ª`®g¾¯¼Æ¶q¤Ö©óù¤ó¡]$ RHHBY¡^Lucentis¡A«áªÌ¬O°ß¤@ÀòãªvÀø»P¦~ÄÖ¬ÛÃöªºÀã©Ê¶À´³ÅÜ©Ê¡]AMD¡^ªºÄvª§¹ï¤â¡C»PLucentis¨C¤ë¤@¦¸ªºª`®g¬Û¤ñ¡A¨C¥|©P¤@¦¸¤T¦¸ªì©l¾¯¶q«á¡Aµ¹ÃĤè®×§ï¬°¨C¤K¶g¤@¦¸ª`®g¡C
¨ä¦¸¡A¥¦ªº»ù®æ§C©óù¤ó¡]Roche¡^ÃĪ«¡C Regeneron¡]REGN¡^±NEyleaªº»ù®æ©w¬°¨C¾¯1,850¬ü¤¸¡ALucentis¬°2,000¬ü¤¸¡CÁöµM¨C¦¸ª`®gªº®t²§¨Ã¤£¤j¡A¦ý¥Ñ©óEyleaªºµ¹ÃÄÀW²v¸û§C¡A¦]¦¹¦b¤@¦~ªºªvÀø¹Lµ{¤¤¸`¬Ù¤F«Ü¦h¿ú¡AEyleaªºÁ`¾¯¶q¬°16,000¬ü¤¸¡A¤ñLucentisªº24,000¬ü¤¸¤Ö¤F8,000¬ü¤¸¡C
¦ý¬O¡AEylea¹ïLucentis¨Ã¤£¬O«Ü¦h¤HÃöª`ªº¾Ô°«¡C Eylea¤W¥«®Éªº³Ì¤jÄvª§¬Où¤óªº¥t¤@ºØ²£«~¡G§ÜÀùÃÄAvastin¡AÂå¥Í¶}¥X¤F¤p¾¯¶qªº³B¤èÃÄ¡A¥HLucentisªº¤@¤p³¡¤À»ù®æªvÀøAMD¡C¾Ú¤@¨Ç¦ôp¡AAvastin¨C¦¸ª`®g¤j¬ùªá¶O50¬ü¤¸¡A±±¨î¤F¤T¤À¤§¤GªºAMD¥«³õ¡C
¦ý¬OAvastin¨Ã¨S¦³ªý¤îEylea¡C 2012¦~7¤ë¡A¦bEylea¦b¬ü°ê¤W¥«ªº¤j¬ù7Ó¤ë«á¡A¦b¬ü°ê¾P°â¸ÓÃĪ«¨Ã¥Ñ«ô¦Õt³d¥@¬É¨ä¥L¦a°ÏªºRegeneron¤½¥q²Ä¤T¦¸´£°ª¤F¨ä¾P°â¹w´Á¡Cº®u°õ¦æ©xۯǼw¡P¬IµÜ¥±¡]Leonard Schleifer¡^·í®É»¡¡G¡§¦pªG¹F¨ì§Ú̪º·s¹w´ú¡A§Ú̱N¦¨¬°¥Íª«§Þ³N¦æ·~¾ú¥v¤W³Ì¦nªº²£«~¤§¤@¡C¡¨
¦Ó¥B¡A³oºØ·m²´ªº¬r«~Ä~Äò±q¨º¸Ì»]»]¤é¤W¡A¬°¦A¥Í¤¸©M«ô¦Õ±a¨Ó¤F¥¨ÃB¦¬¯q¡C«ô¦Õ¦b¼Ú·ù©M¤é¥»Àò±o¤F2012¦~©³ªº§åã¡A¨Ã¦b¤µ¦~5¤ëÀò±o¤F^°ê¦¨¥»®Ä¯qºÞ²zªÌ°ê®a°·±d»PÅ@²z¨ô¶V¬ã¨s©Ò¡]NICE¡^ªº¤ä«ù¡C³o¨Ç§åã¨Ï2012¦~ªº¾P°âÃB¹F¨ì¤F¬ù1900¸U¼Ú¤¸¡C¦ý¬O¨ì2013¦~²Ä¤@©u«×¡AEylea¤S¬°«ô¦Õ¤½¥q¥æ¥I¤F4,900¸U¼Ú¤¸¡A¨ì6¤ë30¤é¤S¼W¥[¤F7,300¸U¼Ú¤¸¡A¤W¥b¦~Á`p¬°1.22»õ¼Ú¤¸¡A¬ù¦X1.65»õ¬ü¤¸¡C
¹ï©ó¸û¤pªºRegeneron¡A¾P°â¼Wªø¬Æ¦Ü§ó¬°¥iÆ[¡C³o®aÁ`³¡¦ì©ó¯Ã¬ù¦{¶ð¨½´°ªº¤½¥q¦b2012¦~±qEylea¨º¸ÌÀò±o¤F8.379»õ¬ü¤¸ªº²b¾P°âÃB¡A¤j¤j¶W¹L¤F¹w´Á¡A¨ÃÀ°§U¨ä°ªºÞÀò±o¤F1.4»õ¬ü¤¸ªº¦~«×Á~¹S¡C 2013¦~¤W¥b¦~¡A¸Ó¤½¥q¦A¦¸¥H6.437»õ¬ü¤¸ªº»ù®æ¶W¹L¤F¹w´Á¡A¤ñ¥h¦~¤W¥b¦~ªº3.175»õ¬ü¤¸¼Wªø¤Fªñ103¢H¡C Eylea¥i¯à«Ü§Ö´N·|¦³¾÷·|Åú¹Lucentisªº§ó¦h¥«³õ¥÷ÃB¡C¤K¤ë¡A«ô¦Õ«Å¥¬¤F¸ÓÃĪ«¥Î©óªvÀø¿}§¿¯f©Ê¶À´³¤ô¸~ªº¿n·¥ªº«á´Á¬ã¨s¼Æ¾Ú¡A¸Ó¯f¼vÅT¤F¬ù620¸U¥iªvÀø¤H¸s¡C«ô¦Õ©MRegeneron³£¥´ºâ´N¸Ó¾AÀ³¯g´M¨D§åã¡C´X¶g«á¡AEylea¦]µøºô½¤¤¤¥¡ÀR¯ßªý¶ë¦Ó¦b¶À´³ÅܩʱwªÌ¤¤Àò±o¤F¼Ú¬wªº»{¥i¡A¨Ï¨ä»PLucentis®i¶}¤F¥t¤@³õ¥¿±¥æ¾W¡]¥Ñ¿ÕµØ¦b¼Ú¬w¾P°â¡^¡C
Eylea - Regeneron and Bayer HealthCare by Carly Helfand | Oct 2, 2013 7:20am ¤À¨ÉFacebook Twitter LinkedIn Email Print Eylea (aflibercept) Regeneron Pharmaceuticals and Bayer HealthCare Launch Date: November 2011 (U.S., Regeneron); November 2012 (EU, Bayer) First-Year Sales: $838 million (2012, Regeneron); £á14 million (partial 2012, Bayer) First-Half 2013 Sales: $643.7 million (Regeneron); £á122 million (Bayer) Analyst Estimate for 2018: $4.7 billion
Eylea had a couple of big things going for it when it arrived on the scene in November 2011. First, it required fewer eye injections than Roche¡¦s ($RHHBY) Lucentis, the only competitor approved to treat wet age-related macular degeneration (AMD). After three initial doses once every four weeks, the dosing schedule switched to just one injection every 8 weeks, compared with Lucentis¡¦ once-monthly injections.
Second, it cost less than the Roche drug. Regeneron ($REGN) priced Eylea at $1,850 per dose, compared with $2,000 for Lucentis. While the per-injection difference wasn¡¦t all that much, savings built up over a full year¡¦s treatment thanks to Eylea¡¦s less-frequent dosing schedule, with Eylea totaling $16,000--$8,000 less than the $24,000 for Lucentis.
Eylea vs. Lucentis wasn¡¦t the battle many had their eyes on, however. Eylea¡¦s big competition at launch time was another Roche product: the cancer drug Avastin, which doctors prescribed off-label in small doses to treat AMD at a fraction of Lucentis¡¦ price. Running about $50 per injection, Avastin controlled more than two-thirds of the AMD market, according to some estimates.
But Avastin didn¡¦t hold Eylea back. In July 2012, around 7 months after Eylea¡¦s U.S. launch, Regeneron--which markets the drug in the U.S., with Bayer handling the rest of the world--raised its sales forecast for the third time. If we hit our new forecast, we will be one of the best launches in the history of the biotechnology industry, CEO Leonard Schleifer said at the time.
And the sight-saving drug continued to steamroll from there, bringing in big bucks for both Regeneron and Bayer. Bayer scored late-2012 approvals in the EU and Japan, and in May of this year, it followed up with backing from the National Institute for Health and Care Excellence (NICE), the U.K.¡¦s cost-effectiveness gatekeeper. Those approvals helped 2012 sales reach about £á19 million. But by the first quarter of 2013, Eylea had delivered another £á49 million for Bayer, adding another £á73 million by June 30 for a first-half total of £á122 million, or about $165 million.
Sales growth has been even more impressive for the much smaller Regeneron. The Tarrytown, NY-based company reaped $837.9 million in net sales from Eylea in 2012, well surpassing estimates and helping its top execs qualify for $140 million in compensation for the year. It surpassed expectations yet again with $643.7 million in the first half of 2013, up nearly 103% from last year¡¦s first-half total of $317.5 million.
Eylea may soon have the opportunity to encroach on more of Lucentis¡¦ market share. In August, Bayer announced positive late-stage study data for the drug in treating diabetic macular edema, a disease that affects a treatable population of about 6.2 million. Both Bayer and Regeneron intend to seek approval for that indication. A few weeks later, Eylea won European approval in patients with macular degeneration due to central retinal vein occlusion, setting it up for another head-to-head battle with Lucentis (marketed by Novartis in Europe).
For more: ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/8/10 ¤W¤È 08:16:05²Ä 21 ½g¦^À³ ¥¼¨ÓASLAN004 ¤W¥«Àøµ{»ù®æ¡A±N¥Hdupilumab Àøµ{»ùx64%¡AÂX®i&¥Ê¤ÀAD/ý³Ý¥«³õ.
¥¼¨ü±±¨î¬ü°êAD¤H¤f 230¸U¤H¡ADUPILUMAB 110»õ¡A¬ü°ê±N¶È»Ýº¯³z²v14%.
·í»ù®æ°§C¡A¥«³õº¯³z²v 14%/64%=22%, ¦]«OÀI¤½¥q¹wºâ¦½s¦C¡A¥«³õº¯³z²v±N¤j´T¼W¥[¡C
¦pEylea ±ßLucentis 5¦~¤W¥«¡Aµ²ªG±N2019¥«³õÂX¤j110»õ¬ü¤¸¥H¤W¡A¤ñ²Ä¤@¤W¥«lucentis ³Ì°ª¾P°â43»õ¬ü¤¸¤@°ª2.5¿¥H¤W
¡X¡X¡X¡X¡X¡X¡X
Eylea ±ßLucentis 5¦~¥b¤W¥«¡A¥Î¤¤¡B§C»ùq»ùµ¦²¤¶i¤JÉ]³õ¡A¦]¦ÓÂX¤j¥«Ô·¡AEylea ¤W¥«²Ä¥|¦~¡A¶W¹LLucentis ¥Ø«e¶W¹L¤@¿¾P°âÃB¡C.
AMD¡X¡X/²´·ú°w¾¯ Lucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ©MEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C
¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) ¡X Lucentis//Eylea 2006(¤W¥«) 2009¡V20.35// 2012¡V24.00//8.70(Eylea²Ä¤@¦~¾P°â) 2013¡V39.53//20.43 2014¡V43.00//28.00 2015¡V34.00//40.8.00(Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38 2017¡V33.00//62.82 2018¡V37.00//67.00 2019¡V????//78.52 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤U¤È 01:30:00
²Ä 3301 ½g¦^À³
|
·s¥[©Y²K61¤H¬V·s«aªÍª¢ ¹O4Ӥ뺨£§C©ó100¨Ò
A-A+ 2020-08-11 19:00¤¤¥¡ªÀ ·s¥[©Y11¤éºî¦X¥~¹q³ø¾É
·s¥[©Y½Ã¥Í³¡¤µ¤Ñ³q³ø¡A¹Ò¤º·s¼W61¤H½T¶E·P¬VªZº~ªÍª¢¡A¥þ°ê²Öp½T¶EÁ`¼Æ¹F5¸U5353¨Ò¡C³o¤]¬O¬P°ê¦Û4¤ëªì¥H¨Ó¡Aº¦¸³æ¤é·s¼W½T¶E¤H¼Æ§C©ó100¨Ò¡C
2019«aª¬¯f¬r¯e¯f¡]COVID-19¡A«UºÙªZº~ªÍª¢¡^¬Ì±¡«ùÄò¸vh¥þ²y¡C·s¥[©Y½Ã¥Í³¡¤U¤È«ü¥X¡A·s¼W½T¶E¯f¨Òµ´¤j¦h¼Æ¤´¬O¦í¦b¥~³Ò±JªÙªº²¾¤u¡F¥t¥~¡A·s¼W2°_ªÀ°Ï¯f¨Ò³£¬O·s¥[©Y¤½¥Á¡A·s¼Wªº3°_¹Ò¥~²¾¤J¯f¨Ò³£¦b¤J¹Ò«á´N±µ¨ì¡u©~®a³qª¾¡v¡A¨Ã¶i¦æ¹jÂ÷¡C
·s¥[©Y¥ý«eÃzµo²¾¤u±JªÙ¤j³W¼Ò¸s»E·P¬V¡A·í§½¤j¶qÀË´ú¦í¦b±JªÙªº²¾¤u¡A¦]¦¹4¤ëªì¥H¨Ó¡A¨C¤Ñ·s¼W½T¶E¯f¨Ò´X¥G³£ºû«ù¼Æ¦Ê¨Ò¡AÁÙ´¿¤@«×³sÄò4¤Ñ¯}¤d¡C
ªñ¨Ó·s¥[©Y¬Ì±¡ÁÍáAÀHµÛ¬P¬F©²°w¹ï±JªÙ²¾¤uªºÀË´ú¶i¤J§ÀÁn¡A5¤é³æ¤é½T¶E¤H¼Æ¤Söt¦Ü908¤H¡A½Ã¥Í³¡¹ï¦¹ªí¥Ü¡A¨ä¤¤¤j¦h¼Æ¬O¦í¦b±JªÙªº²¾¤u¡A¥L̦í¦b·P¬V²v¬Û¹ï¸û°ªªº±JªÙ¡C
¤£¹L¡A8¤é°_¡A·s¥[©Y³sÄò3¤éªº³æ¤é·s¼W½T¶E¤H¼Æ³£ºû«ù100¦h¤H¡C¤µ¤Ñ·s¼W61¤H½T¶E¡A¬O4¤ë6¤é¥H¨Ó¡Aº¦¸³æ¤é·s¼W½T¶E¤H¼Æ¦A«×°¦Ü100¤H¥H¤U¡C
½Ã¥Í³¡¬Q¤Ñªí¥Ü¡A¤w§¹¦¨©Ò¦³±JªÙ²¾¤uªº¿zÀË¡A¥Ø«eÁÙ¦³¬ù2¸U3300¦W²¾¤u¥¿¦b¹jÂ÷¡C
¦¹¥~¡A½Ã¥Í³¡«ü¥X¡A¹L¥h2¶g¥H¨Ó¡A·s¼WªÀ°Ï¯f¨Òéwºû«ù¦b¥§¡¨C¤Ñ·s¼W2°_¡F¦P´Á¶¡¡A·P¬V·½¤£©úªºªÀ°Ï¯f¨Ò¤]éwºû«ù¦b¥§¡¨C¤Ñ¤@¨Ò¡C
®Ú¾Ú·s¥[©Y½Ã¥Í³¡¼Æ¾Ú¡A¬Q¤Ñ¤S¦³694¤H±d´_¥X°|©ÎÂ÷¶}ªÀ°Ï¹jÂ÷³]¬I¡A¥Ø«e²Öp¤w¦³4¸U9609¤H²¬Â¡¡A¬ù¥eÁ`½T¶E¤H¼Æªº89.6%¡C¥þ°ê¬V¬Ì¯f¬G¤H¼Æ¨´¤µ¤´ºû«ù27¤H¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤U¤È 01:07:05
²Ä 3300 ½g¦^À³
|
¤@¤ÁÀH½t!
¦U¦Û¥Î¥\¡I¦U¦Û²`¬ã¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤U¤È 01:00:47
²Ä 3299 ½g¦^À³
|
doc.twse.com.tw/pdf/2020_6497_20200904F01_20200812_125815.pdf
¤½¶}¸ê°T¯¸ 8¤ë10¤é
ªÑªF·|³qª¾®Ñ¦³¼g©ú
n³q¹LªºÄ³®× |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2020/8/12 ¤U¤È 01:00:42
²Ä 3298 ½g¦^À³
|
¤Ñ©R¤j¡A§Ú«Øij§A¥i¥H¶}¤@ÓLINEªº¸s²Õ¥i¥H§ó¤è«K¦³¿³½ì°Ñ»Pªº§ë¸ê¤H§ó¤è«K°Q½×©M±µ¦¬®ø®§¡A¦pªG³o¤@¾Ô¯uªº¯à°÷¦¨¥\¤j®a¤]¦³¾÷·|¥i¥H¸I± |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2020/8/12 ¤U¤È 12:55:26
²Ä 3297 ½g¦^À³
|
¤Ñ©R¤j¡G½Ð°Ý¤@¤U¨È·à±d¤w©ó8/25²×¤îÂd¶R¤F¡A¬°¦óÁÙn9/4¤é¶}ªÑªF·|¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 11:58:43
²Ä 3296 ½g¦^À³
|
°]°T ¤£³ø ¦X¤@FB825 ¶È°µ12¤H¤¤««×AD¡A±ÂÅv5.3 »õ¬ü¤¸¡A¬O¦ó©~¤ß?
°]°T¤£³ø ¨È·àÂà´«²Ä¤@¤W¥«¦a¨ì¬ü°ê¯Ç´µ¹F§J¡A¬O¦ó©~¤ß¡H
°]°T¤£³ø ASLAN004 ¦P ¾÷ÂàDupilumab 2020¦~/¤W¥b¦~¤w¾P°â19»õ¬ü¤¸¡A¨ä¤½¥qªÑ²¼¤W¥b¦~¤jº¦300»õ¬ü¤¸¡C DUPILUMAB ¥¼¨Ó¾P°â110»õ¬ü¤¸¡C ¬O¦ó©~¤ß?
¬O¤£À´? ÁÙ¬O¤£ª¾?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 11:07:41
²Ä 3295 ½g¦^À³
|
ASLAN004 1b 18+6(3 ²Õ)¤H ,´Á¤¤¤ÀªR²Ä¥|©u¸Ñª¼¤½¥¬,
²Ä¥|©u¼W¸ê,©ú¦~°µ2b §¹1b ³Ì¨Î¾¯¶q12+6 ¤HAD ,----2021/03/31°µ§¹1b
--------------------------------------- AD °ê»Ú±ÂÅv¦b1b,
FB825,°µ§¹12¤H 1b AD,´N±ÂÅv¦¨¥\!
FB825 ,2a, 90¤H,IV ,¹wp2021¦~7¤ë15¤é°µ§¹. 2b¦ó®É°_°Ê? ¦ô¤ñASLAN004 ºC6Ó¤ë.
www.berich.com.tw/dp/TalkTalk/Talk_Detail.asp?ii=204490&CNpg=1#reply_a Study Design Study Type ƒÊ : Interventional (Clinical Trial) Estimated Enrollment ƒÊ : 90 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Arm A: FB825 Arm B: Placebo Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults With Atopic Dermatitis Actual Study Start Date ƒÊ : March 10, 2020 Estimated Primary Completion Date ƒÊ : May 30, 2021 Estimated Study Completion Date ƒÊ : July 15, 2021
------------------------------------------- ¬ü°ê 1b ¤¤««× AD Á{§É ªÑ²¼, §ë¸ê´A¤O!
---------------------------------------------------- ASLAN004 24¦W,¤¤««× AD ·§©À©ÊÁ{§É¼Æ¾Úªº±N¤½¥¬¡C(²Ä¥|©u)
¦P¯e¯f³Ì¨ÎASLAN004,
¬O§_¦³ AnaptysBio ,4-5Ó¤ë¡A ¤jº¦ 24»õ¬ü¤¸ªº¾÷·|? ¤@¦¸¤ÏÀ³ ?
AnaptysBio ,IL33 ªvÀø¤¤««×AD ²§¦ì©Ê¥Ö½§ª¢¼Ð¹vµo¥¬12¦W·§©À©ÊÁ{§É¥¿¦V¼Æ¾Ú¡C
ªÑ»ù2017¦~10¤ë«Å¥¬«e30¬ü¤¸¡A³sº¦4-5Ó¤ë¡Aº¦¥|¿¡A³Ì°ª128¬ü¤¸¡A±q¥«È4»õ¬ü¤¸¡Aº¦¨ì32»õ¬ü¤¸¡C ------------------------------------
¥i±¤«e2Ó¤ë¡A2019¦~11¤ë8¤é¤½¥¬2b/300¤HADÁ{§É¸Ñª¼¥¼¹LÃö¡C ªÑ»ù¦^15¬ü¤¸¡A³Ñ¥|»õ¬ü¤¸¡C www.marketwatch.com/investing/stock/anab
www.google.com.tw/amp/s/www.fool.com/amp/investing/2017/10/10/heres-why-anaptysbio-inc-is-rocketing-higher-today.aspx
³o´N¬OAnaptysBio Inc.¤µ¤Ñ¸³tµo®iªºì¦] ¤¤¶¡¶¥¬qªº·§©ÀÅçÃҼƾڹ蘆¤ÑªºAnaptysBioªÑ²¼²£¥Í¤F²§±`±j¯Pªº¼vÅT¡C
Cory Renauer¡]TMFang4apples¡^ 2017¦~10¤ë10¤é¡A¤W¤È11:38 µo¥Í¤F¤°»ò AnaptysBio Inc.¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GANAB¡^¬O¤@®aÁ{§É¶¥¬qªº¥Íª«§Þ³N¤½¥q¡A¥¿¦b¶}µo·s«¬§Üª¢ÃÄ¡A¸Ó¤½¥q³ø§i¤F¨äÀã¯lÔ¿ïÃĪ«ªºÁ{§É¸ÕÅçÀò±o¤F¿n·¥ªº¼Æ¾Ú«á¡A¡C¾¨ºÞ³o¥u¬O¤@¶µ¦³12¦W±wªÌªº·§©ÀÅçÃÒ¬ã¨s¡A¦ýºI¦Ü¶g¤G¬üªF®É¶¡¤W¤È10:15¡A¸ÓªÑ¤Wº¦¤F¬ù70.7¢H¡C
©Ò¥H©O ¤µ¤Ñªº¿³¾Ä¨Ó¦Û©ó¤@ӫܤjªº·t¥Ü¡A§Y¸Ó¤½¥q¤@¬yªºIL-33§í»s¾¯¦³±æ¦¨¬°¹L±Ó©Ê¥Öª¢¡]³Ì±`¨£ªºÀã¯lÃþ«¬¡^±wªÌªº¶W«K±¶ªvÀø¿ï¾Ü¡C¦b±µ¨ü³æ¾¯ANB020«áªº57¤Ñ¶¡¹j¤¤¡A 12¦W±wªÌ¤¤¦³10¦WÀò±o¤F50¢H©Î§ó°ªªº§ïµ½¡C¤ÏÀ³¦ü¥G¤]«Ü§Ö¡A¦b15¤Ñªºµû¦ô¤¤¡A12¨Ò±wªÌ¤¤¦³9¨Ò§ïµ½¤F50¢H¡C
¼y¯¬¦b¹êÅç«Ç¸Ìªº¤T¦ì¬ì¾Ç®a¡C ¹Ï¹³¨Ó·½¡GGETTY¹Ï¹³¡C
¦b²Ä¤G¶¥¬qªº·§©ÀÅçÃҼƾڪº¤ä«ù¤U¡A³q±`±z¤£·|¦b¤@©]¤§¶¡¬Ý¨ì¤½¥qªº¥«È¼Wªø¶W¹L5»õ¬ü¤¸¡C Celgene©MTesaro¤w±qAnaptysBioÀò±o¤F§ÜPD1Ô¿ïÃĪ«ªº³\¥i¡A¦ý³o¬O¸Ó¤½¥q¥þ¸ê¾Ö¦³ªº·sÔ¿ïÃĪ«¤¤ªº²Ä¤@Ó¡Aªí©ú¥¦½T¹ê¦b«n®É¨è¦³¥X¤â¡C¾Ú¦ôp¡A¬ü°ê¦¨¦~¤H¤f¤¤¦³3¢H±w¦³¬YºØ§Î¦¡ªºÀã¯l¡A³o·N¨ýµÛ¦pªGÄ~Äòµ¹¤H¯d¤U²`¨èªº¦L¶H¡AANB020¾Ö¦³¥¨¤jªºµo®i¼ç¤O¡C
¦b±µ¨ü³æ¾¯ANB020µ¹Ãī᪺140¤Ñ¤º¡AAnaptysBio±NÄ~Äòµû¦ô³o12¦W±wªÌ¡C¦b2018¦~¤W¥b¦~¡A§Ú̧Ʊæ¦Ü¤Ö¦³200¦WÀã¯l±wªÌ±µ¨ü¦h¾¯ªvÀø¥H±Ò°Ê¤@¶µ§ó¤jªº¬ã¨s¡C
¸Ó¤½¥qÁÙ¥¿¦b¬°±w¦³ÄY«ªá¥Í¹L±Ó¯gªº¦¨¦~¤H¶}µoANB020¡A¥t¤@®a¥þ¸ê»È®h¯fÔ¿ïÃĪ«ANB019À³¸Ó¦b¦~©³¤§«e§¹¦¨¨äºÓÁ{§É¶¥¬q¸ÕÅç¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 10:44:07
²Ä 3294 ½g¦^À³
|
¦pªG¬Ý¤£À´MOA!
µLªk½T»{,¨È·à¤½¥q»¡¤w½T»{MOA,¬O§_¥¿½T? µLªk½T»{,¥¼¨Ó¦U¶µÁ{§É«ü¼Ð±N¬Ûªñ? µLªk½T»{,¾P°âq»ùµ¦²¤64%dupilumab ,¬O§_¥i¦æ? µLªk½T»{,¥¼¨Ó¦A±ÂÅvªº»ùȤΧé²{È?
1.ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¤@¡BII«¬¨üÅé(TYPE II RECEPTER): ¡X¡X¹L±Ó©Êµoª¢¤ÏÀ³ ¸ô®|:
¤»Ó¥D¨¤: °tÅé : (1)IL-4(¤¶¥Õ¯À4¸¹) ,(2)IL-13 (¤¶¥Õ¯À13¸¹) ¨ü¾¹ : (3)IL-4R£\ , (4)IL-13 R£\1 (5)II«¬¨üÅé (TYPE II RECEPTER): (²Õ¦¨ A : IL4 ±µ¦XIL-4R£\ ¦A±µ¦X IL-13 R£\1) (²Õ¦¨ B : IL13 ±µ¦XIL-13R£\1 ¦A±µ¦X IL-4 R£\)
(6)pSTAT6
1. IL-4¤ÎIL-13 ¬Ò¥i ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³ , ¦³¥H¤UA¡BB¨â±ø¸ô®|
A: ¥ÑIL-4 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé) (3). II «¬¨üÅé±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
B: ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé) (3). II «¬¨üÅé ±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¤G丶Dupilumab¤ÎASLAN004 ¬Ò¥i¦P®ÉªýÂ_IL4¤ÎIL13 °T®§¶Ç¾É¸ô®|
Dupilumab µ²¦XIL-4R£\ & ASLAN004 µ²¦XIL-13 R£\1¤§¾÷Âà(MOA) ¬Ò¥i¦P®ÉªýÂ_ II«¬¨üÅ餧²Õ¦¨¦ÓÁקKÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6)¤§¬¡¤Æ¡A¤]ÁקK¹L±Ó©Êµoª¢¤ÏÀ³. ¨Ï±oA&B ¸ô®|¤¤¤£²£¥Í(2)~(5)¸ô®|¡C
¤T¡BLebrikizumab & Tralokinumab M〇A , ¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 10:29:17
²Ä 3293 ½g¦^À³
|
¬Û«HAD°ê»Ú±ÂÅv¦æ±¡! ¶W¹L5Ó°ê»Ú1b AD±ÂÅv¦æ±¡¡C ¬Û«HDupilumab ¹ê»Ú¾P°â!¤w¾P50»õ¬ü¤¸! ¬Û«HDupilumab MOA!
°¨«á¬¶¡AµL¯q§ë¸ê!
°]°T¤ô·Ç¡Aì¨Ó¦p¦¹?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G±áÄf10141758 |
µoªí®É¶¡:2020/8/12 ¤W¤È 09:59:42
²Ä 3292 ½g¦^À³
|
www.wealth.com.tw/home/articles/26937 éw·à¬O¶BÄF¶°¹Î¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 09:11:29
²Ä 3291 ½g¦^À³
|
ASLAN004 MOA ½T»{& °ê»Ú±ÂÅv-----¤½§i
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ
§Ç¸¹ 1 µo¨¥¤é´Á 108/03/29 µo¨¥®É¶¡ 17:14:34 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ ¸³¨Æªøº[°õ¦æªø µo¨¥¤H¹q¸Ü 0227583333 ¥D¦® ¨È·à±d-KY«Å¥¬§¹¦¨²§¦ì©Ê¥Ö½§ª¢·sÃÄASLAN004²Ä¤@³¡¤À³æ¤@ ¾¯¶q»¼¼W¸ÕÅç ²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 108/03/29 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/03/29 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ:¨È·à±d-KY§¹¦¨ASLAN004²Ä¤@³¡¤À¤§³æ¤@¾¯¶q»¼¼W¸ÕÅç(SAD)¡A¦¹³¡¤À«Y¥HÀR ¯ßª`®g¤§¤è¦¡¹ï°·±d¨ü¸ÕªÌ¶i¦æ¦P¯Åº¨£ªvÀø©Ê§ÜÅéASLAN004¤§ÃĪ«´ú¸Õ¡C ³o¶µ²Ä¤@´Á³æ¤@¾¯¶q»¼¼W¸ÕÅç¦b·s¥[©Y¤@³BÁ{§É¸ÕÅ礤¤ß¶i¦æ¡A¨äÅã¥ÜASLAN004¥HÀR¯ß ª`®g¤§µ¹ÃĤ覡¦b©Ò¦³¾¯¶q¤U¬Ò®i²{¨}¦n¤§¦w¥þ©Ê»P@¨ü©Ê¡A¸ÕÅ礤¥¼¦³¥X²{¤£¨}¨Æ¥ó ¦Ó¾ÉPªvÀø¤¤Â_ªº±¡ªpµo¥Í¡C°w¹ï¤U´å¤¶½è©Ò¶i¦æ¤§¤ÀªRÅã¥Ü¦bµ¹ÃĪº¤@¤p®É¤º¡A¥]¬A ¦b¹L±Ó©Êµoª¢¤ÏÀ³¤¤§êºt«n¨¤¦â¤§¤¶½è¡§ÁC»Ä¤ÆSTAT6 (pSTAT6)¡¨§Y¨ü¨ì§¹¥þ§í¨î¡C ¦¹§í¨î®ÄªG¥i«ùÄòªø¹F29¤Ñ¡AÅã¥Ü¨C¤ëµ¹ÃĤ@¦¸¥i±æ¬°¥i¦æªºµ¹ÃĤ覡¡C ¥Ø«e¥¿¦b¶i¦æ¤¤ªº²Ä¤G³¡¤À³æ¤@¾¯¶q»¼¼W¸ÕÅç±N°w¹ï¥Ö¤Uª`®g¤§µ¹ÃĤ覡¶i¦æÁ{§É´ú ¸Õ¡C¨È·à±d-KY±N©ó3¤ë27¤é§¹¦¨³Ì«á¤@¦ì¨ü¸ÕªÌ¤§ÃĪ«´ú¸Õ¡A¨Ã©ó¤¤ë¥÷¨ú±o²Ä¤G³¡¤À ¸ÕÅ礧¼Æ¾Úµ²ªG¡C¨È·à±d-KY¹wp¦b2019¦~¤U¥b¦~®i¶}°w¹ï¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢±w ªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GASLAN004 ¤G¡B¥Î³~¡GASLAN004¬°¥þ¤H·½³æ®è§ÜÅé¡AÂê©wIL-13¨üÅé£\1¦¸³æ¦ì (IL-13R£\1)¡C ASLAN004¹wp¾A¥Î©ó²§¦ì©Ê¥Ö½§ª¢»P®ð³Ý¡CASLAN004-001Á{§É¸ÕÅ礧°Ñ»PªÌ¬°¦ÛÄ@°Ñ¥[ ¤§°·±d¨ü¸ÕªÌ¡C
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¡B·sÃĬdÅçµn°O¨Ñ
§Ç¸¹ 1 µo¨¥¤é´Á 108/06/04 µo¨¥®É¶¡ 19:35:48 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ ¸³¨Æªøº[°õ¦æªø µo¨¥¤H¹q¸Ü 0227583333 ¥D¦® ¨È·à±d-KY«Å¥¬§¹¦¨ASLAN004²§¦ì©Ê¥Ö½§ª¢¤@´ÁÁ{§É¸ÕÅç ²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 108/06/04 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/06/04 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¨È·à±d¶¶§Q§¹¦¨ASLAN004³æ¤@¾¯¶q»¼¼W¸ÕÅç(SAD) ¨Ã¤½¥¬ASLAN004¥H¥Ö¤Uª`®gµ¹ÃÄ ¤è¦¡¤§²Ä¤G³¡¤À¸ÕÅç¼Æ¾Ú¡C¦¹¸ÕÅç°w¹ï°·±d¨ü¸ÕªÌ¶i¦æ¦P¯Åº¨£ªvÀø©Ê§ÜÅé ASLAN004¤§ÃĪ«´ú¸Õ¡A³æ¤@¾¯¶q»¼¼W¸ÕÅ礧³Ì«áµ²ªGÅã¥ÜASLAN004@¨ü©Ê¨}¦n¡A ¥i§¹¥þ§í¨î¤U´å¤¶½è¡A¥ÎÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C ¨È·à±d-KY©ó2019¦~3¤ë¤½¥¬²Ä¤@³¡¤À¸ÕÅçASLAN004¥HÀR¯ßª`®g¤è¦¡µ¹ÃĤ§¼Æ¾Úµ²ªG¡C ²Ä¤G³¡¤À¸ÕÅç¼Æ¾ÚÅã¥ÜASLAN004¥H¥Ö¤Uª`®gµ¹ÃĦb©Ò¦³¾¯¶q¤U¬Ò®i²{¨}¦n@¨ü©Ê¡A ¨ÃµL¥X²{¥ô¦óÄY«¤£¨}¨Æ¥ó¦Ó¾ÉPªvÀø¤¤Â_ªº±¡ªpµo¥Í¡A¶È¦³¤@¦W¨ü¸ÕªÌ¥X²{ »´·Lª`®g³¡¦ì·kÄo¡A¦ý¯gª¬¦b24¤p®É¤º§Y¸Ñ°£¡C°w¹ï¤U´å¤¶½è©Ò¶i¦æ¤§¤ÀªRÅã¥Ü¡A ¦bµ¹ÃĪº¤@¤p®É¤º¡A¥]¬A¦b¹L±Ó©Êµoª¢¤ÏÀ³¤¤§êºt«n¨¤¦â¤§¤¶½è ¡§ÁC»Ä¤ÆSTAT6 (pSTAT6)¡¨§Y¨ü¨ì§¹¥þ§í¨î¡A¥B¤@ÃĪ«°Ê¤O¦±½u¹Ï (pharmacokinetic profile)Åã¥ÜASLAN004ªºµ¹ÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C ¯S§Oȱoª`·Nªº¬O¡A¸ÕÅç¼Æ¾Ú«ü¥XASLAN004§¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«× (trough level)¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq¯Å¡C ³o¶µ¼Æ¾Ú¦b¨È·à±d-KY©ó2019¦~5¤ë31¤é«Å¥¬»PCSL×q¦X¬ù¨ú±oASLAN004¥þ²y¬ãµo¡B »s³y»P°Ó«~¤ÆÅv§Q«á¤½¥¬¡A¨È·à±d-KY¤U¤@¨B±N©ó2019¦~¤U¥b¦~±Ò°Ê°w¹ï¤¤«×¦Ü««× ²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C 6.¦]À³±¹¬I:µL
¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ
§Ç¸¹ 1 µo¨¥¤é´Á 108/05/31 µo¨¥®É¶¡ 14:30:34 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ ¸³¨Æªøº[°õ¦æªø µo¨¥¤H¹q¸Ü 0227583333 ¥D¦® ¨È·à±d-KY¦VCSL¨ú±oASLAN004¥þ²y°Ó«~¤Æ©Ò¦³Åv ²Å¦X±ø´Ú ¡@²Ä 10 ´Ú ¨Æ¹êµo¥Í¤é 108/05/31 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/05/31 2.«´¬ù©Î©Ó¿Õ¬Û¹ï¤H:CSL Limited 3.»P¤½¥qÃö«Y:µL 4.«´¬ù©Î©Ó¿Õ°_¨´¤é´Á¡]©Î¸Ñ°£¤é´Á¡^:108/05/31 5.¥Dn¤º®e¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497) »PCSL (CSL Limited)×q±ÂÅv¦X¬ù¡A ¨ú±oASLAN004©ó©Ò¦³¾AÀ³¯g¤§¥þ²y¶}µo¡B»s³y»P°Ó«~¤ÆÅv§Q¡A×q¦X¬ù ±N¨ú¥NÂù¤èì¥ý©ó2014¦~5¤ëñq¤§¦X¬ù¡C 6.¨î±ø´Ú¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ¨ÌÂù¤èñq¤§«O±K¦X¬ù¡AÂù¤è¹ï©ó¨ãÅ騽µ{¸O´Ú¤ÎÅv§Qª÷¬Ò¨ã¦³«O±K¸q°È¡A¸Ó¦X¬ù ¹ï©ó¥¼¨ÓÀ禬°^Äm¡A¨Ì¤½¶}¸ê°TÆ[´ú¯¸¨C¤ëÀ禬¤§¤½§i°T®§¤Î·|p®v¬d®Ö©Î®Ö¾\¤§¦U ´Á°]°È³ø§i¤½§i°T®§¬°¥D¡C 7.¹ï¤½¥q°]°È¡B·~°È¤§¼vÅT¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ¨È·à±d-KY±N©óASLAN004¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥ICSLºµ§´Ú¶µ3,000¸U¬üª÷¡CCSL±N¥i¦¬¨ú ³Ì°ª¹F9,500¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F6.55»õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB ¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü10%¤§Åv§Qª÷¡C ®Ú¾Úì¦X¬ù¤º®e¡A¨È·à±d-KYÀ³ºÉ¬ãµoASLAN004¦Ü·§©À©ÊÅçÃÒ(proof-of-concept) §¹¦¨¤§¸q°È¨Ã´M§ä°õ¦æ¤T´ÁÁ{§É¸ÕÅç¤Î°Ó«~¤Æ¤§¦X§@¹Ù¦ñ¡C CSL±N¥i¦¬¨ú¥]¬AÂà¥X±ÂÅv¦X¬ù¦b¤º©Ò¦³ ASLAN004 ¦¬¤J¤§ 40%¦Ü50%¡C 8.¨ãÅé¥Øªº¡]¸Ñ°£ªÌ¤£¾A¥Î¡^: ÂX¤j¹ï²£«~¤§°Ó·~±±¨îÅv§Q¨Ã«O¯d§ó¦h²£«~²Õ¦X»ùÈ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 08:12:11
²Ä 3290 ½g¦^À³
|
资°T¤£¹ïºÙ:
¤@¯ëÀù¯gMOA½T»{¡A须n2bÁ{§ÉÅçÃÒ©M¹ï·Ó组¥Dn«ü¼Ð¤ñ¸û PÈ<0.05¡C
¤¤-««×AD¼Ð¹v¡A¥Ñ©ó«D¼Ð¹v¹ï·Ó组ªº预«á«ü¼ÐESAI¥±`°´T·±20%¥ª¥k¡A¦Ó¼Ð¹vªºESAI¥§¡°´T¡ADupilumab¦b70%¥ª¥k¡A¬°¹ï·Ó组3.5¿¡A¦]¦¹nµý©úMOA·§©À©ÊÁ{§É¡A´£«e¨ì1b 50¤H¥H内¡C
¨È·àASLAN004¡AM0A«á¬q©Mdupilumab¬Û¦P¡Aªý断II«¬¨üÅéªý组¦¨¡A¦P®É¥i§í¨îÂù¼Ð¹vIL-4/IL-13°T¸¹¶Ç»¼¡C
¦]¦¹´£«e¦b1A¡A°·±d¤H42¤HªºÁ{§É¡A¥i´úªº§¹¥þ§í¨î¤U´å¤¶½èpSTAT6,¨Óµý©ú¤wªý断II«¬¨üÅé组¦¨¡C¦Ó½T»{MOA¡C
2019/05/31²Ä¤@¦¸°ê»Ú±ÂÅv¦¨¥\¡C 谮¦b°ªÂI¾P°â31.2»õ¬ü¤¸¡C(¨ÌDupilumab预´Á50»õ¬ü¤¸¾P°â°ªÂIx64%(q»ù§é¦©)
¨È狮±d©MCSL¦@¦P¶}µo¡A¦U±oÀò§Q ¡K¡K±ÂÅvª÷7.8»õ¬ü¤¸+¾P°â¤À¼í¡K¡K¡K §é现ȦU±o10»õ¬ü¤¸¡C¦Xp20»õ¬ü¤¸¡C
随Dupilumab ¾P°â°ªÂI´£°ª¨ì110»õ¬ü¤¸¡C ASLAN004销°â°ªÂI¡A¦ô110¡Ñ64%=70»õ¬ü¤¸¡C ¨È·à³Q¨ÖÁÊ»ùÈ´£°ª¨ìAD21»õ¬ü¤¸+4e¬ü¤¸2b+7e¬ü¤¸ý³Ý/COPD¡C
资°T¤£¹ïºÙ¡A»ùÈ«D¤Z¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 06:40:00
²Ä 3289 ½g¦^À³
|
¾÷Âà¤wÀò½T»{¡A¨È·à¼çÈ21-25-32»õ¬ü¤¸¡C
°ê»Ú¤w±ÂÅv¤§¨Ì¾Ú:M0A¤§½T»{¡C
©MDupilumab¦PMOA¡A¦P®É§í¨îIL-4/IL-13Âù¼Ð¹v¡A 20¸U¤H¤wÅçÃÒ¡C ¤w销°â52»õ¬ü¤¸¡C
¤@¡B¨È·à±d¤½¥q²¤¶ 2020,05,26 ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ASLAN004¦³¼ç¤O¦¨¬°¦P¯e¯f³Ì¨ÎÀøªk
1. IL-13R£\1 §í¨î¾¯: ASLAN004¬O°ß¤@Âê©wIL-13R£\1ªº³æ®è§ÜÅé¡A¦³¼ç¤O¦¨¬°ªvÀø²§¦ì©Ê ¥Ö½§ª¢»P®ð³Ý¤§³Ì¨ÎÀøªk
2.¾÷Âà¤wÀòÃÒ¹ê :»PdupilumabÂê©w¬Û¦Pªº¸ô®|»P¨üÅé½Æ¦XÅé(·¥Àø®ÄÀ³¬Û·í)
3.Âê©w¥«³õ°Ï¹j®ÄªG:¨ãÀø®Ä¼W¶i¤§¼ç¤O¡B´î¤Ö¤£¨}¤ÏÀ³(µ²½¤ª¢) ¡B¨C¤ëµ¹ÃĤ@¦¸(«¤jªºÄvª§Àu¶Õ) §¹¦¨³æ¤@¾¯¶q»¼¼W¸ÕÅç. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/12 ¤W¤È 05:48:11
²Ä 3288 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
˼ƲÄ9Ó¥æ©ö¤ê¡C
MOA!MOA!MOA! «¤¤¤§·¥« Âù¼Ð¹v§í¨î ADý³ÝºÙ¤ý
¼¯¥§Ä_¯]Âéó¹Ð ¤@¤é¯}쯥X¤j¦a ·Ó¯}¤sªe¤d¸U朶
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/11 ¤W¤È 07:32:31
²Ä 3287 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
˼ƲÄ10¥æ©ö¤ê¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/10 ¤W¤È 08:30:02
²Ä 3286 ½g¦^À³
|
¥¼¨ÓASLAN004 ¤W¥«Àøµ{»ù®æ¡A±N¥Hdupilumab Àøµ{»ùx64%¡AÂX®i&¥Ê¤ÀAD/ý³Ý¥«³õ.
¥¼¨ü±±¨î¬ü°êAD¤H¤f 230¸U¤H¡ADUPILUMAB 110»õ¡A¬ü°ê±N¶È»Ýº¯³z²v14%.
·í»ù®æ°§C¡A¥«³õº¯³z²v 14%/64%=22%, ¦]«OÀI¤½¥q¹wºâ¦½s¦C¡A¥«³õº¯³z²v±N¤j´T¼W¥[¡C
¦pEylea ±ßLucentis 5¦~¤W¥«¡Aµ²ªG±N2019¥«³õÂX¤j110»õ¬ü¤¸¥H¤W¡A¤ñ²Ä¤@¤W¥«lucentis ³Ì°ª¾P°â43»õ¬ü¤¸¤@°ª2.5¿¥H¤W
¡X¡X¡X¡X¡X¡X¡X
Eylea ±ßLucentis 5¦~¥b¤W¥«¡A¥Î¤¤¡B§C»ùq»ùµ¦²¤¶i¤JÉ]³õ¡A¦]¦ÓÂX¤j¥«Ô·¡AEylea ¤W¥«²Ä¥|¦~¡A¶W¹LLucentis ¥Ø«e¶W¹L¤@¿¾P°âÃB¡C.
AMD¡X¡X/²´·ú°w¾¯ Lucentis¡]Ranibizumab¡^¡X¡X2006¦~6¤ë¡AFDA®Öã¤W¥«,ù¤ó(¬ü°ê¾P°â)/¿ÕµØ(¨ä¥L¦a°Ï¾P°â) ©MEylea¡]aflibercept¡^¡X¡X-2011¦~11¤ë,FDA®Öã¤W¥«¡ARegeneron Pharmaceuticals(¬ü°ê¾P°â)/«ô¦Õ(¨ä¥L¦a°Ï¾P°â,§Q¼í§¡¤À)¡A ¬O¥Ø«e¼sªx¥Î©ó²´¬ì¯e¯fªºÀøªk¡AªvÀø¥]¬A·s¥Í¦åºÞ¡]Àã©Ê¡^¦~ÄÖ¬ÛÃö©Ê¶À´³ÅÜ©Ê¡Bµøºô½¤ÀR¯ßªý¶ë«á¶À´³¤ô¸~¡B¿}§¿¯f©Ê¶À´³¤ô¸~¡]DME¡^©MDME¦ñ¦³¿}§¿¯f©Êµøºô½¤¯fÅÜ¡C
¨âªÌ§¡¬°§Ü¦åºÞ¤º¥Ö¥Íªø¦]¤l¡]VEGF¡^Àøªk¡C2018¦~¡A³o¨â´ÚÃĪ«ªº¥þ²y¾P°âÃB±µªñ110»õ¬ü¤¸¡A¶È¦b¬ü°êªº¾P°âÃB´N¶W¹L¤F58»õ¬ü¤¸¡C Lucentis¦b¬ü°êªº±M§Q±N©ó2020¦~¨ì´Á¡A¦ý¹w´ú2021¦~¾P°âÃB¤´±N¹F¨ì41»õ¬ü¤¸¡C 2015¦~²Ä¤@Ó¥é¥ÍÃÄ¡A¦L«×¤W¥« 75%»ù®æ¡C Eyleaªº¤@¶µÃöÁä±M§Q¦b¬ü°ê±N©ó2023¦~¨ì´Á¡A¦b¼Ú¬w¨ì2025¦~¤~¨ì´Á¡A¹wp2021¦~¾P°âÃB±N¹F¨ì70»õ¬ü¤¸¡C
¥þ²y¾P°âª÷ÃB¡]»õ¬üª÷) ¡X Lucentis//Eylea 2006(¤W¥«) 2009¡V20.35// 2012¡V24.00//8.70(Eylea²Ä¤@¦~¾P°â) 2013¡V39.53//20.43 2014¡V43.00//28.00 2015¡V34.00//40.8.00(Lucentis ¡¥s ¥é¥ÍÃĦL«×¤W¥«//Eylea ¤W¥«²Ä¥|¦~,¦~¾P°â¶W¹LLucentis)) 2016¡V33.00//55.38 2017¡V33.00//62.82 2018¡V37.00//67.00 2019¡V????//78.52
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1¶ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/8/10 ¤W¤È 07:57:27²Ä 20 ½g¦^À³ Dupilumab2020¦~¡A«e¥b¦~À禬¦Xp19»õ¬ü¤¸¡C ¤µ¦~¤U¥b¦~¡A¦ô±N¦³21-22»õ¬ü¤¸ªºÀ禬¤ô·Ç¡C 2020¦~À禬¦ô40-41»õ¬ü¤¸¡C 2019¦~À禬23»õ¬ü¤¸¡C 2021¦~À禬¦ô60»õ¬ü¤¸¡C ¡K¡K¥¼¨Ó³Ì°ª110»õ¬ü¤¸销°â
ASLAN004 1.¥@¬É¤W°ß¤@©MDupilumab¡A¥i¦P®É§í¨îIL-4¤ÎIL-13Âù¼Ð¹v°T¸¹¶Ç»¼ªº³æ¤@¼Ð¹v·sÃÄ¡C
MOA¦PDupilumab,¥iªýÂ_II«¬¨üÅ餧²Õ¦¨¡C
. IL-4¤ÎIL-13 ¬Ò¥i ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³ , ¦³¥H¤UA¡BB¨â±ø¸ô®|
A: ¥ÑIL-4 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-4 ±µ¦X IL-4R£\ = IL4& IL-4R£\ (2). IL4& IL-4R£\ ¦A±µ¦X IL-13 R£\1=II «¬¨üÅé (²Õ¦¨II«¬ ¨üÅé) (3). II «¬¨üÅé±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
B: ¥ÑIL-13 ³y¦¨¹L±Ó©Êµoª¢¤ÏÀ³¸ô®|
¸ô®|(1). IL-13 ±µ¦X IL-13R£\1 = IL13& IL-13R£\1 (2). IL13 & IL-13R£\1 ¦A±µ¦X IL-4 R£\= II«¬ ¨üÅé (²Õ¦¨II «¬¨üÅé) (3). II «¬¨üÅé ±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼ (4). ¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (pSTAT6) (signal transducer and activator of transcription 6, pSTAT6) ¶Ç¾É¸ô®|, (5) ¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
2.AD/ý³Ý³Ì¨ÎÀøªk¼ç¤O 预´Á¥|¶g¤@针¡A区¹jDupilumab¤G¶g¤@针¡C
§C©óDupilumaÀøµ{¾¯¶q40%-60%ªº谮¤O¡C
§C°Æ§@¥Î¡AµLDupilumab结½¤ª¢25%-50%¡C
Àø®Ä¦³¾÷·|Àu©óDupilumab¼Ð·ÇÀøªk¡C
3.¥¼¨Ó¦ô2025¦~¤W¥«¡A 2030-2031¦~¡A³Ì°ª销°â¦ô Dupilumab110»õ¬ü¤¸¡Ñ80%¡Ñ80%=70»õ¬ü¤¸ªº销°â¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2020/8/10 ¤W¤È 07:18:52
²Ä 3285 ½g¦^À³
|
8¤ë24¤é¡A¨È·à±d6497¡A¥xÆWÂd¥x³Ì«á¥æ©ö¤é¡C
˼Æ11¤Ñ¡C
¤W¶g¥~资¤j¶R¶W¡Aªñ2000±i¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2020/8/9 ¤U¤È 01:43:49
²Ä 3284 ½g¦^À³
|
¥Ó½Ð®Ñ¸Ì 4. ¦s°U¤H±b¤á©Ò¦b¤§¬ü°ê¨é°Ó¦WºÙ: 5. ¬ü°êÃÒ¨é°Ó±b¸¹: 6. ¬ü°êÃÒ¨é°Ó©ó¬ü°ê¶°¤¤«OºÞ«H°U¤½¥q(DTC)°Ñ¥[¤H¥N¸¹: 7. ½Æ©e°U±b¤á¦WºÙ (¦p¾A¥Î): 8. ½Æ©e°U±b¸¹ (¦p»P5.¬ü°êÃÒ¨é°Ó±b¸¹¤£¦P®É¶ñ¼g):
½Ð°Ý¦³ª©¤jª¾¹D³o´X¶µ¦pªG¬O¥Î½Æ©e°U±b¤á«ç»ò¶ñ? |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 3301 ~ 3400 «h¦^ÂÐ >> |
|